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CONTEXT 
Infertility is the inability to have a child and is a complex 
condition that can take many forms. Approximately 12% of 
women aged 15–44 experience infertility and 
approximately 9% of men aged 19–44 report some type of 
infertility.  
The cost of undergoing infertility treatments such as 
assisted reproductive technology (ART) can be a 
prohibitive factor for couples and individuals faced with 
infertility.1  
AT A GLANCE 
The version of California Assembly Bill (AB) 767 
analyzed by CHBRP would require coverage of 
infertility treatments, including in vitro fertilization 
(IVF), and mature oocyte cryopreservation (OC). 
1. CHBRP estimates that, in 2020, of the 24.5 
million Californians enrolled in state-regulated 
health insurance, 14.6 million of them will 
have insurance subject to AB 767.  
2. Benefit coverage. Benefit coverage for 
infertility treatments, including IVF, would 
increase from 4.3% premandate to 100% 
postmandate. Benefit coverage of planned OC 
would increase from 0% premandate to 100% 
postmandate. AB 767 would likely exceed 
EHBs.  
3. Utilization. Utilization of infertility services 
would increase between 9% for diagnostic 
tests and 350% for IVF with intracytoplasmic 
sperm injection (ICSI). Utilization of planned 
OC is expected to increase from 0% to 
between 2% and 5%.  
4. Expenditures. AB 767 would increase total 
net annual expenditures by $627,288,000 or 
0.39% due to a $537,777,000 increase in total 
health insurance premiums, adjusted by 
decrease in enrollee expenses for covered 
and/or noncovered benefits. 
a. Enrollees with uncovered expenses at 
baseline would receive on the whole a 
$133,897,000 reduction in their out-of-
pocket spending for covered and 
noncovered expenses.  
b. Per member per month premiums 
would increase between $2.76 for 
enrollees in CalPERS HMOs (an 
increase of 0.47%) and $3.72 in the 
DMHC-regulated small group market 
(an increase of 0.68%). 
5. Medical effectiveness.  
a. There is a preponderance of evidence 
that IVF is an effective treatment for 
infertility.  
 
AT A GLANCE, CONT.  
b. There is a preponderance of evidence 
that IVF is associated with certain 
maternal harms.  
c. There is clear and convincing 
evidence that IVF can lead to multiple 
gestation and preterm delivery. 
However, these outcomes can be 
mitigated by single embryo transfers.  
d. CHRBP found a preponderance of 
evidence that IVF mandates are 
associated with lower numbers of 
embryos transferred per cycle, lead to 
fewer births per cycle, and a reduction 
in overall harms of IVF. 
6. Public health. The number of pregnancies 
resulting from infertility treatments in the first 
year postmandate will increase the number of 
pregnancies by 6,000 (from 7,000 to 13,000) 
and the number of live births by 5,000 (from 
6,000 to 11,000). 
7. Long-term impacts. For each cohort of 
females electing to undergo mature OC for the 
prevention of age-related infertility in a given 
year, CHBRP estimates the long-term 
marginal impact of AB 767 would yield about 
685 more live births among these women over 
a 20 year period. 
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BILL SUMMARY  
Current law requires most group health plans and policies 
to offer coverage for infertility services, excluding in vitro 
fertilization. AB 767 would require group health plans and 
policies, excluding the individual market and Medi-Cal, to 
provide coverage for infertility treatments, including in vitro 
fertilization (IVF), and mature oocyte cryopreservation 
(OC).  
AB 767 defines infertility as the presence of a 
demonstrated condition recognized by a licensed 
physician and surgeon as a cause of infertility. “Treatment 
of infertility” includes procedures consistent with 
established medical practices in the treatment of infertility 
by licensed physicians and surgeons, including, but not 
limited to, diagnosis, diagnostic tests, medication, surgery, 
gamete intrafallopian transfer, and in vitro fertilization.  
Mature OC is a form of fertility preservation. While fertility 
preservation usually refers to the preservation of fertility in 
advance of medical procedures that can lead to iatrogenic 
infertility (medically caused infertility), such as treatment 
for cancer or during sex transition, AB 767 could expand 
coverage of mature OC to a woman seeking to preserve 
her fertility for age-related reasons or to women seeking to 
preserve their fertility if they experience other medical 
conditions, such as endometriosis. 
Figure A notes how many Californians have health 
insurance that would be subject to AB 767. 
Figure A. Health Insurance in CA and AB 767  
 
Source: California Health Benefits Review Program, 2019. 
Notes: *Medicare beneficiaries, enrollees in self-insured products, etc. 
IMPACTS 
Revision 
The initially released version of these Key Findings (April 
18) referenced an incorrect figure (see the updated full 
report for more).  This version has been updated using the 
correct total expenditures impact figure, 0.39%. 
Benefit Coverage, Utilization, and Cost  
To capture the full cost of coverage of infertility services 
for each year, CHBRP included the cost of pregnancies 
and births resulting from infertility services in year 1 into 
year 1 cost estimates. 
No utilization data are available for planned OC in 
MarketScan claims data. There are no studies that 
estimate utilization of OC for non-iatrogenic or planned 
use, thus the approach to CHBRP’s estimation of 
utilization change postmandate due to AB 767’s coverage 
of mature OC included an estimate of potential increase in 
utilization per CHBRP’s content expert. The estimates of 
utilization change do not include planned fertility 
preservation, however CHBRP offers an estimate of 
potential cost increase if a modest proportion of females of 
reproductive age opt to use the service in the Planned 
Oocyte Cryopreservation section. 
Benefit Coverage 
Currently, 4.3% of enrollees with health insurance that 
would be subject to AB 767 in DMHC-regulated plans or 
CDI-regulated policies have coverage for infertility 
treatments, including in vitro fertilization. No enrollees 
currently have coverage for mature OC as defined by AB 
767. Benefit coverage for infertility treatments and planned 
OC would increase to 100% postmandate.   
Utilization 
In California, there are approximately 53,000 users of 
female diagnostic tests at baseline and about the same 
number of users of medications for infertility (i.e., only 
medications and no other service). IUI baseline utilization 
is about 9,000 users annually. IVF services alone (i.e., 
without ICSI) is estimated to have about 2,000 users and 
ICSI, which is done with IVF, is 2,000 users annually. For 
males, at baseline there are 25,000 users of diagnostic 
tests and 11,000 users of any male treatment. 
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Pent-up demand is assumed to occur given the financial 
burden currently cited by couples hoping to use infertility 
services but are unable to because of cost barriers. It is 
assumed that utilization in the first and second year would 
be 10% greater. Pent-up demand for infertility services 
likely dissipates over time and utilization reaches a steady 
state after a few years postmandate.  
Expenditures 
AB 767 would increase total net annual expenditures by 
$627,288,000 or 0.39% for enrollees with DMHC-
regulated group plans and CDI-regulated group policies. 
This is due to a $537,777,000 increase in total health 
insurance premiums paid by employers and enrollees for 
newly covered benefits, adjusted by an increase in 
enrollee expenses for covered expenses and a decrease 
in enrollee expenses for noncovered benefits. 
CHBRP estimates that enrollees with uncovered expenses 
at baseline would receive on the whole a $133,897,000 
reduction in their out-of-pocket spending for covered and 
noncovered expenses associated with AB 767’s coverage 
of infertility services.  
Per member per month (PMPM) premiums would increase 
between $2.76 among CalPERS HMOs (an increase of 
0.47%) and $3.72 in the DMHC-regulated small-group 
market (an increase of 0.68%). Total expenditures would 
increase between 0.33% in the CDI-regulated large-group 
market and 0.64% in the DMHC-regulated small-group 
market.  
 
Figure B. Expenditure Impacts of AB 767 
 
Source: California Health Benefits Review Program, 2019.  
Planned Oocyte Cryopreservation 
CHBRP did not find any source of data on baseline 
utilization for planned OC or likely changes postmandate. 
CHBRP estimates that if 2% of women aged 25–37 years 
used planned OC services, the total expenditures would 
increase by $319,683,000. If a higher share of women 
aged 25–37 used planned OC (5%), total expenditures 
would increase by $799,197,000. This assumes the 
average cost for OC is $10,078. 
Medi-Cal 
AB 767 does not apply to Medi-Cal enrollees and 
therefore there is no measurable impact.  
CalPERS 
CalPERS employer expenditures are projected to increase 
by $14,539,000 for coverage of infertility treatments. Total 
premiums would increase by $2.76 PMPM (0.47%) and 
total expenditures would increase by $3.38 PMPM 
(0.53%).  
Number of Uninsured in California 
Because the change in average premiums does not 
exceed 1% for any market segment for coverage of 
infertility treatments, CHBRP would expect no measurable 
change in the number of uninsured persons due to the 
enactment of AB 767. 
However, should 5% of female enrollees aged 25–37 use 
mature OC services as a form of fertility preservation, 
premiums would increase by more than 1% for enrollees 
in group and CalPERS HMO plans (premium increases for 
private employers for group insurance increase 1.24% and 
CalPERS HMO 1.31%). It is unclear how the increase in 
premiums translates into uninsurance since not all of the 
increase is transferred to the enrollee.  
Medical Effectiveness 
CHBRP found a preponderance of evidence that IVF is an 
effective treatment for infertility, resulting in increased 
pregnancy rates and live birth rates. There is also a 
preponderance of evidence that planned OC is an 
effective treatment for infertility, resulting in pregnancies 
and live births.  
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CHBRP found a preponderance of evidence that IVF is 
associated with certain maternal harms, including ovarian 
hyperstimulation syndrome and thromboembolism. There 
is also clear and convincing evidence that IVF can lead to 
multiple gestation and preterm delivery. However, it is 
important to note that multiple gestation is associated with 
higher numbers of embryos transferred per cycle, and that 
preterm delivery is associated with multiple gestation — 
these outcomes can be mitigated by single embryo 
transfers.  
CHRBP found a preponderance of evidence that IVF 
mandates are associated with lower numbers of embryos 
transferred per cycle. There is also a preponderance of 
evidence that IVF mandates lead to fewer births per cycle 
(due to the decreased number of embryos transferred per 
cycle), and a reduction in overall harms of IVF (i.e., lower 
rates of multiple gestation, preterm deliveries, and low-
birthweight births). 
Public Health 
CHBRP estimates that the number of pregnancies 
resulting from infertility treatments in the first year 
postmandate will increase the number of pregnancies by 
6,000 (from 7,000 to 13,000) and the number of live births 
by 5,000 (from 6,000 to 11,000).These estimates are 
supported by a preponderance of evidence that infertility 
treatments, including IVF, are medically effective and that 
health insurance benefit mandates are effective in 
increasing utilization of treatments for infertility, including 
IVF. 
Although CHBRP found evidence that engaging in 
infertility treatments may result in short-term psychosocial 
harms, evidence-based literature also indicates that the 
inability to have wanted children is itself associated with 
stress, anxiety, depression, and quality of life deficits that 
are likely to decrease upon the achievement of a 
successful pregnancy through treatment. Therefore, it 
stands to reason that mental health and quality of life 
would improve for the additional 5,000 persons and 
couples who would have a live birth resulting from 
infertility treatments postmandate. 
Disparities 
Barriers in fertility treatment access related to sexual 
orientation are reduced with the change in language 
defining infertility to be more inclusive, however barriers 
remain as the bill does not cover donor materials (sperm 
or eggs) or gestational carriers (surrogates) that are 
required for same-sex couples. Cost-related barriers to 
infertility treatment would be significantly reduced for 
those covered by the bill, however cost sharing could still 
represent a significant cost barrier. 
Long-Term Impacts 
In the short-term, the aggregate pregnancy and birth rate 
is expected to increase postmandate due to increased 
utilization of infertility services. In the longer term, it is 
possible that the coverage of infertility services results in 
encouraging couples to undergo infertility treatment earlier 
than they would normally and where pregnancy might be 
achieved naturally.  
For each cohort of females electing to undergo mature OC 
for the prevention of age-related infertility in a given year, 
CHBRP estimates the long-term marginal impact of AB 
767 would yield about 685 more live births among these 
women over a 20-year period.  
Although AB 767 would decrease the financial burden of 
planned OC services in the short term, AB 767 would not 
cover future storage costs, which can range from range 
from $100 to $1,500 per year (average $300/year). These 
additional uncovered costs may have an impact on the 
demand for these services, but the magnitude of this 
effect is unknown. 
Essential Health Benefits and the 
Affordable Care Act 
AB 767 would require coverage for a new state benefit 
mandate that appears to exceed the definition of EHBs in 
California. A state that requires QHPs to offer benefits in 
excess of the EHBs must make payments to defray the 
cost of those additionally mandated benefits, either by 
paying the purchaser directly or by paying the QHP. 
CHBRP estimates that the state would potentially be 
required to defray the following amounts due to AB 767:  
• $6.43 PMPM for each QHP enrollee in a small-
group DMHC-regulated plans; and 
• $7.10 PMPM for each QHP enrollee in a small-
group CDI-regulated policy. 
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CHBRP estimates that this translates to a state-
responsibility of $51,823,000 total, which includes:  
• $50,801,000 in payments to DMCH-regulated 
small group plans; and 
• $1,023,000 in payments to CDI-regulated small 
group policies. 
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REVISION HISTORY 
Date Description of Revisions 
May 10, 2019 
In the initially released version of this report (April 18), one summary table, Table 
6, correctly indicated a 0.39% impact.  However, the other summary tables, 
Table 1 & 9, were in error, indicating a 0.49% impact. All tables and text in this 
version have been updated to indicate the correct 0.39% impact. 
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The California Health Benefits Review Program (CHBRP) was established in 2002. As per its authorizing 
statute, CHBRP provides the California Legislature with independent analysis of the medical, financial, 
and public health impacts of proposed health insurance benefit-related legislation. The state funds 
CHBRP through an annual assessment on health plans and insurers in California.  
An analytic staff based at the University of California, Berkeley, supports a task force of faculty and 
research staff from multiple University of California campuses to complete each CHBRP analysis. A 
strict conflict-of-interest policy ensures that the analyses are undertaken without bias. A certified, 
independent actuary helps to estimate the financial impact. Content experts with comprehensive 
subject-matter expertise are consulted to provide essential background and input on the analytic 
approach for each report.  
More detailed information on CHBRP’s analysis methodology, authorizing statute, as well as all 
CHBRP reports and other publications are available at www.chbrp.org. 
Analysis of California Assembly Bill 767 
Current as of April 18, 2019 www.chbrp.org ix 
TABLE OF CONTENTS 
 
List of Tables and Figures ............................................................................................................................. x 
Policy Context ............................................................................................................................................... 1 
Bill-Specific Analysis of AB 767, Infertility ................................................................................................. 1 
Interaction With Existing Requirements .................................................................................................... 2 
Analytic Approach and Key Assumptions.................................................................................................. 5 
Background on Infertility ................................................................................................................................ 8 
Definitions of Infertility ............................................................................................................................... 8 
Causes and Risk Factors of Infertility ........................................................................................................ 9 
Evaluation and Treatment of Infertility ..................................................................................................... 10 
Treatment-Associated Financial Burden ................................................................................................. 13 
Prevalence of Infertility and Impaired Fecundity in the United States ..................................................... 14 
Disparities and Social Determinants of Health in Infertility ...................................................................... 15 
Societal Impact of Infertility in the United States ..................................................................................... 19 
Medical Effectiveness ................................................................................................................................. 20 
Research Approach and Methods ........................................................................................................... 20 
Methodological Considerations ............................................................................................................... 21 
Outcomes Assessed ................................................................................................................................ 21 
Study Findings ......................................................................................................................................... 22 
Benefit Coverage, Utilization, and Cost Impacts......................................................................................... 32 
Approach and Assumptions .................................................................................................................... 32 
Baseline and Postmandate Benefit Coverage ........................................................................................ 34 
Baseline and Postmandate Utilization ..................................................................................................... 35 
Baseline and Postmandate Per-Unit Cost ............................................................................................... 36 
Baseline and Postmandate Expenditures ............................................................................................... 36 
Other Considerations for Policymakers ................................................................................................... 38 
Public Health Impacts ................................................................................................................................. 44 
Estimated Public Health Outcomes ......................................................................................................... 44 
Impact on Disparities ............................................................................................................................... 47 
Long-Term Impacts ..................................................................................................................................... 51 
Long-Term Utilization and Cost Impacts ................................................................................................. 51 
Long-Term Public Health Impacts ........................................................................................................... 51 
Appendix A Text of Bill Analyzed ...........................................................................................................A-1 
Appendix B Literature Review Methods ................................................................................................B-1 
Appendix C Cost Impact Analysis: Data Sources, Caveats, and Assumptions .................................... C-1 
 
References 
California Health Benefits Review Program Committees and Staff  
Analysis of California Assembly Bill 767 
Current as of April 18, 2019 www.chbrp.org x 
LIST OF TABLES AND FIGURES 
Table 1. AB 767 Impacts on Benefit Coverage, Utilization, and Cost, 2020 ................................................ xi 
Table 2. Common Infertility Treatment Options by Category ..................................................................... 11 
Table 3. Prevalence of Infertility and Impaired Fecundity Among Women Aged 15–44 Years by Age 
Group National Survey of Family Growth Cycles 2002, 2006-2010, 2011-2015 ........................................ 14 
Table 4. Estimated State Responsibility for Portion of Mandate that Is in Excess of EHBs, California, 
2020 ............................................................................................................................................................ 38 
Table 5. Baseline Per Member Per Month Premiums and Total Expenditures by Market Segment, 
California, 2020 ........................................................................................................................................... 40 
Table 6. Postmandate Per Member Per Month Premiums and Total Expenditures by Market Segment, 
California, 2020 ........................................................................................................................................... 42 
Table 7. States with Infertility Mandates to Cover IVF and Limits Placed by those Mandates ................ C-4 
Table 8. Pregnancy related outcomes of infertility treatment, by treatment category .............................. C-5 
Table 9. AB 767 Impacts on Benefit Coverage, Utilization, and Cost, 2021 ............................................ C-7 
 
Figure 1. Effectiveness of IVF as a Treatment for Infertility ....................................................................... 23 
Figure 2. Effectiveness of Planned Oocyte Cryopreservation for Fertility Preservation ............................ 25 
Figure 3. Maternal Harms of IVF and Planned Oocyte Cryopreservation ................................................. 28 
Figure 4. Harms of IVF and Planned Oocyte Cryopreservation due to Multiple Gestation and Preterm 
Delivery ....................................................................................................................................................... 29 
 
 
 Current as of April 18, 2019 www.chbrp.org xi 
Table 1. AB 767 Impacts on Benefit Coverage, Utilization, and Cost, 2020 
  Baseline Postmandate Increase/ 
Decrease 
Percentage 
Change 
Benefit coverage 
 Total enrollees with health 
insurance subject to state 
benefit mandates (a) 24,490,000 24,490,000 0 0% 
 Total enrollees with health 
insurance subject to AB 767 14,613,000 14,613,000 0 0% 
 Percentage of enrollees with 
coverage for infertility 
services, including IVF  4.3% 100% 96% 2247% 
 Number of enrollees with 
coverage for infertility 
services, including IVF  622,600 14,613,000 96% 2247% 
 Percentage of enrollees with 
coverage for mature oocyte 
cryopreservation  0% 100% 100% 100% 
 Number of enrollees with 
coverage for mature oocyte 
cryopreservation  0 14,613,000 100% 100% 
Utilization and unit cost 
 Female - Number of enrollees using:  
   Diagnostic tests  53,000  58,000 5,000 9% 
   Medications only 14,000 17,000 3,000 21% 
   IVF 2,000 7,000 5,000 250% 
   ICSI-IVF 2,000 9,000 7,000 350% 
   IUI 9,000 10,000 1,000 11% 
 Male - Number of enrollees using: 
   Diagnostic tests 25,000 27,000 2,000 8% 
   Treatment 11,000 12,000 1,000 9% 
 Average per unit cost 
   Diagnostic tests  $458 $458 $0 0% 
   Medications only $5,486 $5,486 $0 0% 
   IVF $15,331 $15,331 $0 0% 
   ICSI-IVF $28,773 $28,773 $0 0% 
   IUI $6,593 $6,593 $0 0% 
   Male diagnostic tests $81 $81 $0 0% 
   Male treatment $635 $635 $0 0% 
 Pregnancy      
 # of pregnancies due to 
infertility services (all types)  7,000   13,000  6,000 86% 
 # of live birth deliveries due to 
infertility services (single, twin, 
multiples)  6,000   11,000  5,000 83% 
 Average annual cost of 
pregnancy and delivery from 
infertility services (single, twin, 
multiples) $37,000 $39,000 2,000 5% 
Expenditures 
Premiums by payer 
 Current as of April 18, 2019 www.chbrp.org xii 
 Private employers for group 
insurance $86,438,375,000 $86,877,812,000 $439,437,000 0.51% 
 CalPERS HMO employer 
expenditures (b) (c) $3,098,551,000 $3,113,090,000 $14,539,000 0.47% 
 Medi-Cal Managed Care Plan 
expenditures $28,492,273,000 $28,492,273,000 $0 0% 
 Enrollees with individually 
purchased insurance $12,045,324,000 $12,045,324,000 $0 0% 
 Enrollees with group 
insurance, CalPERS HMOs, 
Covered California, and Medi-
Cal Managed Care (c) 
$14,476,394,000 $14,560,195,000 $83,801,000 0.58% 
Enrollee expenses 
 For covered benefits 
(deductibles, copayments, 
etc.) (d) 
$14,750,880,000 $14,974,288,000 $223,408,000 1.51% 
 For noncovered benefits (e) $133,897,000 
 $0 
-$133,897,000 -100.00% 
Total expenditures $159,435,694,000 $160,062,982,000 $627,288,000 0.39% 
Source: California Health Benefits Review Program, 2019. 
Notes: For estimates of the impact of mature oocyte cryopreservation coverage, refer to the Benefit, Cost, and Utilization section.  
(a) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in employer-
sponsored health insurance. This group includes commercial enrollees (including those associated with Covered California or 
CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.2  
(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents.  
(c) Enrollee premium expenditures include contributions by employees to employer-sponsored health insurance, health insurance 
purchased through Covered California, and contributions to Medi-Cal Managed Care. 
(d) Enrollee out-of-pocket expenses for covered benefits for IVF and ICSI services (not including associated pregnancies) is 
$42,829,000, at baseline and $168,182,000 postmandate, resulting in an increase of 293%; for all other infertility services, out-of-
pocket expenses at baseline is $14,708,051,000 and $14,806,106,000 postmandate, a 0.67% increase. 
(e) Includes only expenses paid directly by enrollees (or other sources) to providers for services related to the mandated benefit that 
are not currently covered by insurance. This only includes those expenses that would be newly covered postmandate. Other 
components of expenditures in this table include all health care services covered by insurance.  
Key: CalPERS  = California Public Employees’ Retirement System; CDI = California Department of Insurance; DMHC = Department 
of Managed Health Care; HMO = Health Maintenance Organizations; ICSI = intracytoplasmic sperm injection; IUI = intrauterine 
insemination; IVF = in vitro fertilization 
 
                                                     
2 For more detail, see Estimates of Sources of Health Insurance in California, available at 
http://chbrp.com/analysis_methodology/cost_impact_analysis.php.   
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POLICY CONTEXT 
The California Assembly Committee on Health has requested that the California Health Benefits Review 
Program (CHBRP)3 conduct an evidence-based assessment of the medical, financial, and public health 
impacts of AB 767 (Wicks), Infertility. AB 767 was amended on April 9, 2019, and the new language is 
incorporated below.  
Bill-Specific Analysis of AB 767, Infertility 
Bill Language Summary 
AB 767 would require group health plans and policies, excluding individual market plans and policies and 
Medi-Cal, to provide coverage for infertility treatments, including in vitro fertilization (IVF), and mature 
oocyte cryopreservation (OC). The full text of AB 767 as amended can be found in Appendix A.  
Current law requires most group health plans and policies to offer coverage for infertility services, 
excluding IVF.  
Definition of infertility 
Current law4 defines infertility as: 
(1) “the presence of a demonstrated condition recognized by a licensed physician and surgeon as a 
cause of infertility, or 
(2) the inability to conceive a pregnancy or to carry a pregnancy to a live birth after a year or more of 
regular sexual relations without contraception.” 
AB 767 amends the definition of infertility by removing the second clause.  
Treatment for infertility  
Current law defines “treatment for infertility” as procedures consistent with established medical practices 
in the treatment of infertility by licensed physicians and surgeons, including, but not limited to, diagnosis, 
diagnostic tests, medication, surgery, and gamete intrafallopian transfer. AB 767 adds IVF to the list of 
treatments.  
Mature oocyte cryopreservation  
AB 767 requires plans and policies to also cover mature OC, which the bill defines as procedures 
consistent with established medical practices, including laboratory medical procedures, involving 
induction, egg retrieval, and freezing of the egg. Mature OC is used for fertility preservation purposes. AB 
767 as introduced defines “preventive fertility care treatment” as procedures consistent with established 
medical practices in the treatment of fertility care, which is rendered by a licensed physician and surgeon, 
to prevent the inability to conceive a child. However, this definition was removed from the version of AB 
767 amended on April 9, 2019.  
                                                     
3 CHBRP’s authorizing statute is available at http://chbrp.org/faqs.php. 
4 H&SC Section 1374.55 and IC Section 10119.6. 
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Discrimination clause 
Current law includes a non-discrimination clause that states “coverage for the treatment of infertility shall 
be offered, and if purchased, provided without discrimination on the basis of age, ancestry, color, 
disability, domestic partner status, gender, gender expression, gender identity, genetic information, 
marital status, national origin, race, religion, sex, or sexual orientation.” This clause remains unchanged in 
AB 767.  
Religious exemption  
Current law states that any employer that is a religious organization is not required to offer coverage for 
forms of infertility treatment in a manner inconsistent with the religious organization’s religious and ethical 
principles. AB 767 eliminates this exemption.  
Relevant Populations 
If enacted, AB 767 would affect the health insurance of approximately 14,613,000 enrollees (37% of all 
Californians). This represents 60% percent of the 24.5 million Californians who will have health insurance 
regulated by the state that may be subject to any state health benefit mandate law — health insurance 
regulated by the California Department of Managed Health Care (DMHC) or the California Department of 
Insurance (CDI). If enacted, the law would affect the health insurance of enrollees in DMHC-regulated 
large- and small-group plans and CDI-regulated large- and small-group policies. AB 767 does not apply to 
the health insurance of enrollees in the individual market or Medi-Cal. 
Among the 14.6 million Californians with insurance impacted by AB 767, there are approximately 3.43 
million women of reproductive age, ages 15 to 44.5 As described in the Background section, there is no 
upper age bound for men, although reproductive capacity declines beginning around age 60. There are 
4.89 million men ages 18 to 60. More information about the populations likely to use infertility treatments 
and mature OC is included in the Background section.  
Interaction With Existing Requirements 
Health benefit mandates may interact and align with the following state and federal mandates or 
provisions. 
California Policy Landscape 
California law and regulations 
Current California law requires most group CDI-regulated policies and most DMHC-regulated plans to 
offer coverage for infertility treatment, except IVF. “Mandate to offer” means all health care service plans 
and health insurers selling health insurance subject to the mandate are required to offer coverage for the 
benefit for purchase. The health plan or insurer may comply with the mandate either (1) by including the 
benefit as standard in its health insurance products, or (2) by offering coverage for the benefit separately 
at an additional cost (e.g., a rider). “Mandate to cover” means that all health insurance subject to the law 
must cover the benefit. 
                                                     
5 While women above age 44 may use infertility treatments and be able to conceive, ages 15 to 44 is a commonly 
used range when discussing women of reproductive age. (ACOG, 2014b) 
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CHBRP reviewed the state’s Independent Medical Review (IMR) determinations for inclusion of infertility 
services. Of note, three IMRs in the last 10 years overturned the decision of the health plan for enrollees 
requesting coverage of consultations for infertility services. Seven health plans’ decisions were upheld in 
instances where enrollees requested coverage of infertility treatments either due to insufficient medical 
evidence or advanced maternal age and the likelihood of success.  
Similar requirements in other states 
Currently, 14 states have laws that require insurance companies to cover infertility treatment and two 
states — California and Texas — have laws that require insurance companies to offer coverage for 
infertility treatment. States that require coverage of infertility treatment are: Arkansas, Connecticut, 
Hawaii, Illinois, Louisiana, Maryland, Massachusetts, Montana, New Jersey, New York, Ohio, Rhode 
Island, and West Virginia, and most recently Delaware, which passed legislation in 2018 (NCSL, 2018). In 
2019, New York amended its existing mandate through a budget measure in the 2020 state budget that 
mandates certain large-group insurance plans cover IVF, and requires all private insurance companies to 
cover medically necessary egg freezing. The Connecticut, New Jersey, and Rhode Island mandates are 
closest to the proposed AB 767 legislation, with the exception of planned OC, which is not included those 
states’ mandates. 
While most states with laws requiring insurance companies to offer or provide coverage for infertility 
treatment include coverage for IVF, California and Louisiana have laws that specifically exclude coverage 
for the procedure. 
Other examples of unique state laws are Louisiana and New York’s previous law, which prohibit the 
exclusion of coverage for a medical condition otherwise covered solely because the condition results in 
infertility; Minnesota, which specifies that medical assistance will not provide coverage for fertility drugs 
when specifically used to enhance fertility; and Utah, which requires insurers providing coverage for 
maternity benefits to also provide an indemnity benefit for adoption or infertility treatments. 
Limits on infertility coverage in other states that mandate coverage include applying dollar lifetime caps, 
and limiting the number of treatment cycles covered.  
• Connecticut allows four cycles of ovulation induction, a lifetime maximum coverage of three 
cycles of intrauterine insemination, and a lifetime maximum coverage of two cycles of IVF, GIFT, 
ZIFT or low tubal ovum transfer, with not more than two embryo implantations per cycle.  
• Hawaii requires that only one cycle of IVF be covered.  
• Illinois mandates that each patient is covered for up to four egg retrievals. However, if a live birth 
occurs, two additional egg retrievals will be covered, with a lifetime maximum of six retrievals 
covered. 
• New York covers up to three IVF cycles. 
• Rhode Island limits coverage to a lifetime cap of $100,000. 
Federal Policy Landscape 
Affordable Care Act 
A number of Affordable Care Act (ACA) provisions have the potential to or do interact with state benefit 
mandates. Below is an analysis of how AB 767 may interact with requirements of the ACA as presently 
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exists in federal law, including the requirement for certain health insurance to cover essential health 
benefits (EHBs).6 
Any changes at the federal level may impact the analysis or implementation of this bill, were it to pass into 
law. However, CHBRP analyzes bills in the current environment given current law and regulations.  
Essential Health Benefits 
State health insurance marketplaces, such as Covered California, are responsible for certifying and 
selling qualified health plans (QHPs) in the small-group and individual markets. QHPs are required to 
meet a minimum standard of benefits as defined by the ACA as essential health benefits (EHBs). In 
California, EHBs are related to the benefit coverage available in the Kaiser Foundation Health Plan Small 
Group Health Maintenance Organization (HMO) 30 plan, the state’s benchmark plan for federal EHBs.7,8 
States may require QHPs to offer benefits that exceed EHBs.9 However, a state that chooses to do so 
must make payments to defray the cost of those additionally mandated benefits, either by paying the 
purchaser directly or by paying the QHP.10,11 State rules related to provider types, cost-sharing, or 
reimbursement methods would not meet the definition of state benefit mandates that could exceed 
EHBs.12  
AB 767 and EHBs 
AB 767 could be interpreted to exceed the EHBs for the following reasons: 
 AB 767 would apply to small-group QHPs in Covered California.  
 The state’s benchmark plan (Kaiser Foundation Health Plan Small Group HMO 30) excludes 
coverage for infertility treatments. Thus, this service would not appear to be considered an 
essential health benefit for the state of California. 
                                                     
6 The ACA requires nongrandfathered small-group and individual market health insurance — including but not limited 
to QHPs sold in Covered California — to cover 10 specified categories of EHBs. Resources on EHBs and other ACA 
impacts are available on the CHBRP website: http://www.chbrp.org/other_publications/index.php. 
7 The U.S. Department of Health and Human Services (HHS) has allowed each state to define its own EHBs for 2014 
and 2015 by selecting one of a set of specified benchmark plan options. CCIIO, Information on Essential Health 
Benefits Benchmark Plans. Available at: https://www.cms.gov/cciio/resources/data-resources/ehb.html.  
8 H&SC Section 1367.005; IC Section 10112.27. 
9 ACA Section 1311(d)(3). 
10 State benefit mandates enacted on or before December 31, 2011, may be included in a state’s EHBs, according to 
the U.S. Department of Health and Human Services (HHS). Patient Protection and Affordable Care Act: Standards 
Related to Essential Health Benefits, Actuarial Value, and Accreditation. Final Rule. Federal Register, Vol. 78, No. 37. 
February 25, 2013. Available at: www.gpo.gov\fdsys\pkg\FR-2013-02-25\pdf\2013-04084.pdf. 
11 However, as laid out in the Final Rule on EHBs HHS released in February 2013, state benefit mandates enacted 
on or before December 31, 2011, would be included in the state’s EHBs and there would be no requirement that the 
state defray the costs of those state mandated benefits. For state benefit mandates enacted after December 31, 
2011, that are identified as exceeding EHBs, the state would be required to defray the cost. 
12 Essential Health Benefits. Final Rule. A state’s health insurance marketplace would be responsible for determining 
when a state benefit mandate exceeds EHBs, and QHP issuers would be responsible for calculating the cost that 
must be defrayed. 
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 The federal definition of a state benefit mandate that can exceed EHBs is “specific to the care, 
treatment, and services that a state requires issuers to offer to its enrollees.”13 AB 767 would 
appear to meet this federal definition. 
As outlined above, AB 767 would require coverage for a new state benefit mandate that appears to 
exceed the definition of EHBs in California.  
Analytic Approach and Key Assumptions 
Definition of Infertility for Analysis of AB 767 
There are multiple definitions of infertility (see details below):  
 The current infertility treatment mandate includes a definition of infertility;  
 AB 767’s definition of infertility; 
 The medical policies for DMHC-regulated plans and CDI-regulated policies include definitions of 
infertility;  
 The National Survey on Family Growth (NSFG) defines infertility; and  
 The American Society of Reproductive Medicine (ASRM) defines infertility.14 
Current infertility treatment mandate. As stated previously, the current infertility treatment mandate 
defines infertility as either: “(1) the presence of a demonstrated condition recognized by a licensed 
physician and surgeon as a cause of infertility, or (2) the inability to conceive a pregnancy or to carry a 
pregnancy to a live birth after a year or more of regular sexual relations without contraception.” AB 767 
removes the second clause of this definition.  
Medical policies. The medical policies of DMHC-regulated plans and CDI-regulated insurers are not 
identical in how they define infertility, but the medical policies generally define infertility for heterosexual 
couples as the inability to achieve conception after having frequent, unprotected intercourse for at least a 
year, or for 6 months for a woman over the age of 35. For a single woman, infertility is defined as the 
inability to achieve conception after having 6 to 12 cycles of artificial insemination, generally within a 1-
year period. Sometimes, the language for the definition of infertility for a single woman includes the words 
“medically supervised” artificial insemination.  
American Society for Reproductive Medicine. The ASRM defines infertility as a disease. The definition 
of infertility is “the failure to achieve a successful pregnancy after 12 months or more of appropriate, timed 
unprotected intercourse or therapeutic donor insemination” (ASRM, 2013). 
National Survey on Family Growth. The NSFG defines fecundity as the ability of a woman or couple to 
have a child (Chandra et al., 2013), and then defines “impaired fecundity,” which encompasses their 
definition of infertility.  
                                                     
13 Essential Health Benefits Final Rule. Federal Register, Vol. 87, No. 27. February 25, 2013. Available at: 
www.gpo.gov/fdsys/pkg/FR-2013-02-25/pdf/2013-04084.pdf. 
14 There are likely further definitions of infertility beyond those listed here. These definitions are addressed in this 
report because they directly relate to AB 767 and/or the data and literature discussed in the report.  
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DHMC-regulated plans and CDI-regulated policies are subject to the Health and Safety Code and 
Insurance Code, respectively, which includes one definition of infertility, and DMHC-regulated plans and 
CDI-regulated insurers include other definitions of infertility in their medical policies, which generally align 
with the ASRM definition. However, because much of the information and data presented in the 
Background on Infertility section of this report and the literature reviewed in the Medical Effectiveness 
section of this report rely on the NSFG, the definitions used by the NSFG inform much of this report. The 
NSFG definitions of impaired fecundity and infertility are discussed in more depth in the Background on 
Infertility section.  
Definition for men and women in same-sex relationships. The National Institute for Health and 
Clinical Excellence (NICE) recently released updated clinical guidelines on assessment and treatment for 
people with fertility problems. Included in the guidelines are definitions for when men and women in 
same-sex relationships not having vaginal intercourse should be eligible for assessment and possible 
treatment for infertility. Specifically, the clinical guidelines state that “for same-sex couples, failure to 
conceive after 6 cycles of [artificial insemination] within the 12 past months should be the indication for 
further assessment” (NICE, 2013). 
 
 
 
By removing the medical component from the definition of infertility, the diagnosis of infertility is left solely 
to the provider. This may result in more enrollees receiving a diagnosis of “infertility” earlier than they 
would have previously or when they would not have received a diagnosis at all, and enrollees would 
potentially use higher-intensity treatments sooner than they would have previously, as well.   
Mature Oocyte Cryopreservation for the Analysis of AB 767 
Mature OC is a form of fertility preservation, as defined above. While fertility preservation usually refers to 
the preservation of fertility in advance of medical procedures that can lead to iatrogenic infertility 
(medically caused infertility), such as treatment for cancer or during sex transition, the lack of definition of 
fertility preservation in AB 767 as amended could result in a much broader interpretation. The lack of a 
definition for fertility preservation, in combination with the non-discrimination clause included in current 
law, could expand coverage of mature OC to a woman seeking to preserve her fertility for age-related 
reasons or to women seeking to preserve their fertility if they experience other medical conditions, such 
as endometriosis. CHBRP’s analysis of AB 767 analyzes only the impacts of expanding OC services to 
women not seeking these services for iatrogenic reasons. This report refers to non-iatrogenic fertility 
preservation as “planned oocyte cryopreservation,” in accordance with guidance from the ASRM (2018).   
Information about fertility preservation related to iatrogenic infertility and projected impacts of coverage of 
fertility preservation services is included in CHBRP’s April 2019 analysis of SB 600 Fertility 
Preservation.15  
Religious Exemption  
CHBRP does not provide legal analysis and is unable to analyze the impacts of the removal of the 
religious exemption.  
                                                     
15 CHBRP reports are available at http://chbrp.org/completed_analyses/index.php.  
When using “infertility” throughout this report, CHBRP refers to AB 767’s definition of infertility, “the 
presence of a demonstrated condition recognized by a licensed physician and surgeon as a cause 
of infertility,” unless otherwise specified.  
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Other Key Assumptions 
 CHBRP assumes all non-experimental infertility treatments and planned OC would need to be 
covered for a plan to be in compliance with AB 767. More information about non-experimental 
infertility treatments is included in the Background on Infertility section.  
 CHBRP assumes AB 767 does not require coverage of donor materials (oocytes or semen), 
surrogacy services, or storage of frozen materials unless included as part of the infertility 
treatment (such as during IVF), as this is not stated in the bill language.  
 AB 767 does not provide a definition of “demonstrated condition.” CHBRP assumes this to 
encompass a diagnosis of infertility and apply to couples in same-sex relationships and single 
women. Single men are not included as a “demonstrated condition” because a surrogate would 
be required to “treat infertility” and both surrogacy and semen cryopreservation are not included 
as a covered service within AB 767.  
 Gamete intrafallopian transfer (GIFT) and zygote intrafallopian transfer (ZIFT), while specified as 
required treatments for infertility, are no longer performed. These procedures have been replaced 
by IVF. Therefore, CHBRP does not incorporate utilization of GIFT and ZIFT into the cost impact 
projections and does not discuss these procedures in the Background, Medical Effectiveness, or 
Public Health sections.  
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BACKGROUND ON INFERTILITY 
Infertility is the inability to have a child and is a complex condition that can take many forms. In order for a 
live baby to be born without medical intervention, several conditions must be met: 
 An egg (oocyte) must be released from an ovary; 
 Sperm must join with (fertilize) the egg; 
 A fertilized egg must be able to move through the fallopian tube toward the uterus; 
 The fertilized egg must attach (implant) to the lining of the uterus to begin pregnancy; and 
 The fertilized egg must develop to an embryo and then fetus in the uterus and be gestated 
(carried) until live birth occurs.  
Infertility may result from a problem with any one of these steps, or a combination of several steps. 
Persons attempting to have a child may experience primary infertility (physical difficulties having a first 
child) or secondary infertility (having had at least one child, but experiencing difficulty having another), 
either of which may be related to the inability to become pregnant or successfully carry a pregnancy to 
term. 
There are important differences between male and female reproductive biology that impact infertility. 
Women are born with a finite number of eggs (oocytes) that mature with the onset of menarche (median 
age 12 years) and decrease in number and quality until the onset of menopause, beyond which women 
are not able to naturally bear children; this is generally referred to as the female reproductive range. 
National datasets of in vitro fertilization (IVF) use show that less than 1% of women initiating IVF at age 
44 or older will have a live birth; however, women up to the age of menopause, average age 51 in the US, 
may experience fertility treatment success using donor materials (ACOG, 2014b). In contrast, males 
become able to produce sperm during puberty (median age 12 years) and, according to the American 
Society for Reproductive Medicine (ASRM), retain optimal reproductive capabilities until 60 years of 
age.16  
Definitions of Infertility 
As described in the Policy Context section, there are many definitions of infertility that vary in specificity 
depending on the population or context to which they are applied.  
In most clinical contexts, infertility is defined as the inability to become pregnant after 12 months of trying 
to conceive without contraceptives. Some clinical definitions specify a shorter timeframe (6 months) for 
women aged 35 years and older or separately define infertility for single women wishing to become 
pregnant (ASRM, 2013). In demographic contexts, infertility is often broadly defined as the inability to 
become or remain pregnant among reproductive-aged women. In some public health or social justice 
contexts, infertility is considered to meet the legal definition of a disability or disease, since the inability to 
have children is an impairment of a basic human function (ASRM, 2013). In other instances, infertility is 
only described among persons currently attempting to become pregnant or only among heterosexual 
                                                     
16 Men produce sperm throughout their lives, and it is thought that there is no maximum age at which it is not possible 
for a male to father a child. 
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married and cohabitating persons, thereby excluding single women, same-sex couples, persons who may 
be infertile but have stopped trying to become pregnant, or persons who experienced infertility in the past.  
In the context of AB 767, infertility is defined as “the presence of a demonstrated condition recognized by 
a licensed physician and surgeon as a cause of infertility.” In taking a condition-related approach, this 
definition recognizes infertility in enrollees regardless of their conception-related intentions and for whom 
timeframe restrictions are not meaningful, such as single women, same-sex couples, and persons who 
are surgically sterile for non-contraceptive reasons.17  
Causes and Risk Factors of Infertility 
Medical Causes 
There are numerous medical causes of infertility, and an individual can have more than one cause of 
infertility. Within a couple, one or both partners can have a cause of infertility. In the United States, results 
from a prospective cohort study of almost 400 women presenting at eight infertility practices showed that 
58% of infertility cases were attributable to female factors, 7% were attributable to male factors, 31% were 
attributable to both male and female factors, and 4% were not directly attributable to either partner (Smith 
et al., 2011). 
Treatments for infertility can target the cause of infertility, and many treatments, including IVF, are options 
for a number of different causes of infertility. Infertility in persons with iatrogenic causes (i.e., cancer 
treatments and sex transition) are addressed in another 2019 CHBRP analysis (SB 600) and will not 
directly be addressed here. 
Common causes of infertility among females are:  
• Ovarian factors (ovulatory and/or oocyte disorders): Issues with the eggs or release of eggs. 
Ovulation disorders include infrequent ovulation (oligoovulation) and absent ovulation 
(anovulation). Polycystic ovarian disorder (PCOS) is the most common cause; other causes 
include primary ovarian insufficiency (previously called premature ovarian failure or premature 
menopause), other hormonal disorders, other chronic conditions, and oocyte aging. Oocyte aging 
(i.e., age-related infertility) is an expected decline in the quality and quantity of oocytes (eggs) as 
a woman ages. This begins when a woman is 30–35, and is significant by age 40. 
• Tubal factors (fallopian tube abnormalities): Blocked fallopian tubes inhibit transport of oocytes 
and sperm though the fallopian tube. Tubal abnormalities are often caused by pelvic inflammatory 
disease, which results from infections such as Chlamydia or gonorrhea. Endometriosis is also a 
cause of blocked fallopian tubes. 
• Uterine factors: Can cause problems with pregnancy implantation and ability to carry a 
pregnancy to a term live birth. These include uterine leiomyomata (fibroids), which are benign 
smooth muscle tumors within the uterus that develop over time, and congenital (present from 
birth) uterine anomalies. 
                                                     
17 This CHBRP analysis draws on many informational sources regarding infertility and related treatments that rely on 
differing definitions of infertility; therefore, the term “infertility” is used broadly throughout this report to refer to the 
inability to conceive or carry a pregnancy. Distinctions in definitions due to data sources are described and cited 
when necessary. 
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• Endometriosis: A chronic condition in which endometrium (the lining of the uterus) implants 
inappropriately outside the uterus. This can block the fallopian tubes or uterus cavity, and 
damage the ovaries, which can lead to impaired fertilization and implantation outcomes. 
• Immune factors: Antiphospholipid syndrome (APS) leads to the immune system rejecting early 
pregnancy or to placental damage, resulting in recurrent pregnancy loss. 
• Genetic causes: The most common genetic cause of female infertility is Turner syndrome (45,X), 
which is the absence or abnormality of one of the two X chromosomes that women have, and 
leads to ovarian failure in most women with this syndrome. Genetic causes in the fertilized egg, 
embryo, and fetus can also lead to miscarriage. 
• Unexplained infertility: A diagnosis of exclusion, when testing for the above conditions is 
negative and no specific cause of infertility can be found. Fertility treatments are still possible 
even when female factor infertility cannot be explained. 
Common causes of infertility among males are: 
• Sperm-related factors: 
o Sperm motility and morphology disorders: Defective sperm production, impaired sperm 
motility, and low count lead to a lack of sperm available to reach and fertilize the egg. 
There are multiple causes of sperm dysfunction or inadequate production. These include 
congenital (present at birth, such as missing or undescended testes), trauma to the 
testicles, varicoceles, genetic causes (chromosomal disorders, such as Klinefelter 
syndrome), infections (such as mumps), medications and/or toxin exposure, chronic 
health conditions (including cancer and treatments for cancer, renal failure, celiac 
disease, and sickle cell disease), and other causes of hormonal dysfunction. 
o Sperm transport issues: Includes abnormalities of the epididymis and the vas deferens 
(including absence of the vas deferens, as in cystic fibrosis), and defective ejaculation or 
ejaculatory ducts. These disorders can be congenital (present at birth) or caused by 
trauma or infection.  
• Unexplained infertility: When semen analyses are normal, but pregnancy cannot be achieved 
with a woman who had normal infertility testing, unexplained infertility (idiopathic infertility) is 
considered the cause. Fertility treatments are still possible even when male factor infertility 
cannot be explained. 
Relationship Status  
Persons in same-sex relationships or who are not in a relationship also are unable to achieve pregnancy 
without additional intervention as they lack either the male or female components necessary for 
fertilization and pregnancy. These persons could have the above medical causes of infertility as well.  
 
Evaluation and Treatment of Infertility  
Diagnostic Evaluation 
Diagnostic evaluation for infertility is clinically recommended for couples that have not become pregnant 
after a year of unprotected intercourse, or 6 months of unprotected intercourse for women over 35 years 
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of age. Single women or women who are in same-sex relationships who are planning on attempting 
insemination might also benefit from a diagnostic evaluation.  
Diagnostic evaluation typically starts with a thorough medical examination as well as a discussion of 
sexual, reproductive, and family history. Depending on the results of this preliminary evaluation, females 
are assessed for ovulatory function, ovarian reserve, uterine abnormalities, tubal patency (fallopian tube 
functioning), or peritoneal factors (endometriosis or pelvic adhesions) (ASRM, 2015a). After preliminary 
evaluation, males are evaluated using a semen analysis, endocrine evaluation, post-ejaculation 
urinalysis, or ultrasonography of the scrotum or genital tract to identify structural abnormalities (ASRM, 
2015b). A diagnostic evaluation can effectively identify the source of the infertility problem in 70% of 
cases. In the 30% where infertility cannot be identified, a protocol for treatment of unspecified infertility is 
recommended (ASRM, 2015a). 
In the 2006–2010 cycle of the National Survey of Family Growth (NSFG), 7.3% of women and 5.3% of 
men aged 25–44 years reported that either they or their partners had ever undergone tests to diagnose 
infertility (Chandra et al., 2014; NSFG, 2017). 
Treatments for Infertility 
As described in Table 2, there are a number of treatment options for women and men seeking medical 
help to achieve a pregnancy, including medical advice, medications, surgery, artificial insemination, and 
assisted reproductive technology (ART), which includes IVF.  
In the 2006–2010 cycle of the NSFG, 12.5% of women aged 25–44 years reported ever having any 
medical help to get pregnant (including treatment among their partners). Among the same cohort of 
women, 9.4% received advice, 5.8% reported using ovulation drugs, 1.3% had surgery or treatment of 
blocked fallopian tubes, 1.7% had artificial insemination, and 0.7% had ever used any form of assisted 
reproductive technologies (Chandra et al., 2014). 
Table 2. Common Infertility Treatment Options by Category 
Treatment Description 
Advice Medical advice usually includes information about how to 
measure biological readiness (such as ovulation) and time 
sexual intercourse to optimize the chances of conception in 
a given month.  
Medications Medications are usually used in instances of abnormal 
ovarian function. In general, medications are used to time 
or stimulate the release of oocytes (ovulation) or stimulate 
greater egg production.18   
Surgery  With the advent of IVF, surgery is becoming a less 
common infertility treatment option. 
                                                     
18 Common medications (generic then common brand names) include: clomiphene citrate (Clomid), Serophene); 
metformin (Glucophage, Glumetza); follicle-stimulating hormone (FSH) (Bravelle, Follistim, Gonal-F); human 
chorionic gonadotropin (hCG) (Pregnyl, Profasi, Novarel, Ovidrel); human menopausal gonadotropin (hMG) 
(Menopur, Repronex); dopamine agonists; gonadotropin-releasing hormone (GnRH) (Factrel, Lutrepulse); GnRH 
agonists (Lupron, Zoladex, Synarel); GnRH antagonists (Ganirelix, Cetrotide); aromatase inhibitors (letrozole, 
anastrozole, exemestane); letrozole, and dexamethasone (Decadron). 
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Treatment Description 
Tubal repair Surgery on the fallopian tubes is generally performed to 
treat blockages that may prevent the transfer of oocytes or 
sperm, such as in the instance of tubal scarring or desire 
for a tubal ligation reversal. 
Uterine fibroid removal Surgery to remove fibroids from the uterus that could 
interfere with fertility. 
Endometriosis excision or ablation Procedure to remove or destroy deposits of endometrial 
tissue where they do not belong in the genital tract and 
abdomen, and that can interfere with fertility. 
Vasectomy or tubal ligation reversal Men with prior vasectomies or women with prior tubal 
ligations may have a surgery to reattach the vas deferens 
or fallopian tubes and thereby allow the sperm and eggs to 
travel without impediment to allow fertilization. 
Artificial Insemination The deliberate introduction of semen into the uterus (also 
known as intrauterine insemination [IUI]) is another method 
for treating infertility, in the case of male factor or 
unexplained infertility. IUI is also a potential option for 
single women or same-sex couples wishing to conceive. 
ICI (intracervical insemination) is another lesser-used 
approach to artificial insemination that is an option in 
certain situations in which sperm is placed inside the 
vagina against the cervix.  
Assisted Reproductive Technologies 
(ART) 
ART is defined as any procedure in which both the oocyte 
(egg) and sperm are handled. 
In vitro fertilization (IVF) IVF is a multicomponent process in which mature eggs 
(oocytes) are retrieved from the ovaries and then combined 
(fertilized) with sperm in a culture dish in a laboratory. The 
resulting embryos are then transferred into the uterus. This 
is the most common form of ART. (a) 
Intracytoplasmic sperm injection (ICSI) 
as part of IVF 
An assistive IVF procedure wherein a single sperm is 
injected into a mature egg (as compared with allowing 
sperm to fertilize eggs on their own in a culture dish) as 
part of IVF. ICSI is often used for couples with male factor 
infertility. 
Source: Centers for Disease Control and Prevention, 2019. 
Note: This table only presents information on commonly used treatments for infertility and, therefore, should not be 
used as a comprehensive source. (a) Less commonly used forms of ART include zygote intrafallopian tube transfer 
(ZIFT) and gamete intrafallopian tube transfer (GIFT). 
Treatment considerations for same-sex couples and single persons 
For two women in a relationship or single women, donor sperm will be needed, and in some cases IUI or 
IVF. For two men in a relationship or men who are single, donor eggs and a gestational carrier 
(surrogate) with IVF will be needed (Greenfeld and Seli, 2016). As stated in the Policy Context section, 
the use of donor materials and gestational carriers are not explicitly included in AB 767 and therefore 
CHBRP has assumed they are not required to be covered.  
Analysis of California Assembly Bill 767 
Current as of April 18, 2019 www.chbrp.org 13 
Preventive Infertility Treatments 
In addition to detection and treatment of infertility, AB 767 mandates coverage for mature oocyte 
cryopreservation (OC) — a procedure in which viable, unfertilized eggs (oocytes) are frozen and 
preserved for future fertilization and implantation via IVF — which is generally performed in two instances: 
1) Prior to a medical treatment known to cause infertility, such as chemotherapy for cancer (also 
known as iatrogenic infertility); or  
2) As an elective procedure, known as “planned oocyte cryopreservation,” in which women choose 
to have their eggs frozen to increase the likelihood of having viable eggs in the event they 
experience difficulty conceiving when they are ready to become pregnant (Hirshfeld-Cytron et al., 
2012).  
Since fertility preservation for iatrogenic infertility is the focus of another 2019 CHBRP analysis (SB 600), 
discussion of mature OC in this analysis will refer only to persons utilizing planned OC. For information 
about iatrogenic infertility incidence and related fertility preservation utilization, see CHBRP’s April 2019 
analysis of SB 600 at www.CHBRP.org. 
According to the ASRM, planned OC is potentially beneficial for women facing non-immediate threats to 
their fertility. These threats may include conditions such as endometriosis, polycystic ovarian syndrome, 
or age-related fertility loss (ASRM, 2018). National estimates of planned OC use are not available, but 
individual studies indicate that awareness and use of planned OC has increased and the average age of 
initiation has decreased in the past decade (Argyle et al., 2016; Goldman et al., 2014; Mucowski et al., 
2014). 
Treatment-Associated Financial Burden 
As compared with other developed countries, the cost of undergoing ART is highest in the United States. 
Chambers et al. (2009) assessed the cost of ART in 2003 for 10 highly developed countries, taking into 
account differences in regulatory structure and the relative value of currency. A 2009 study showed that 
the cost of one standard cycle of IVF was $12,513 (2006 USD) in the United States compared to $3,956 
in Japan, and the cost of one live birth with IVF was $41,132 in the US compared to $24,329 in Japan. 
Similarly, one cycle of IVF in the United States accounted for up to 50% of a couple’s annual disposable 
income as compared with 6% in Australia (Chambers et al., 2009). Due to these high costs, Chambers et 
al. (2009) estimated that only 24% of the demand for ART in 2003 was being met in the United States, 
whereas Australia and Scandinavia demonstrated almost no unmet demand.  
More recent data from a cohort of couples recruited from eight community and academic endocrinology 
clinics in California indicates that out-of-pocket costs are significant and may impact overall utilization of 
infertility treatments. Based on cost diaries, Wu et al. (2014) estimated that the median out-of-pocket cost 
of infertility treatments ranges from $912 for medications alone, up to $19,234 for one cycle of IVF, with 
each additional cycle of IVF costing $6,995. Further analysis of the same cohort found that, on average, 
couples undergo 3.7 cycles of IVF, which means that an average couple utilizing IVF might accrue up to 
$40,219 in out-of-pocket treatment costs for infertility treatment. Costs were even higher for couples 
utilizing donor eggs (Katz et al., 2011). In addition to oocyte retrieval and IVF, persons undergoing 
planned OC generally also need to pay out of pocket for frozen storage costs, which range from $100 to 
$1,500 per year (average $300/year) (Mesen et al., 2015). Treatments for infertility are also complex and 
time-consuming, with one study estimating that a single cycle of IVF could account for 15.6 work-day 
equivalents, mostly in administrative time (Wu et al., 2013). 
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For current, California-specific estimates of treatment costs, demand, and utilization, please see Table 1 
and the Benefit Coverage, Utilization, and Cost Impacts section.  
Prevalence of Infertility and Impaired Fecundity in the United States 
This section presents prevalence estimates of infertility and impaired fecundity from the CDC’s National 
Survey of Family Growth (NSFG).19 As defined by the NSFG, “infertility” is a subset of the broader term 
“impaired fecundity.” Whereas impaired fecundity is the difficulty conceiving or carrying a 
pregnancy to term among women of any relationship status or sexual orientation within a 3-year period, 
infertility is specific to difficulty conceiving within a 1-year period among women who have been 
continuously married to, or cohabitating with, an opposite-sex partner (Chandra et al., 2013). In contrast, 
AB 767 is broadly inclusive of all persons experiencing infertility, regardless of timeframe, marital status, 
or cause and, therefore, more closely aligns with the NSFG’s definition of impaired fecundity.20 
Females 
Results from the 2011–2015 cycle of the NSFG (Table 3) indicate that just over 12% of all women aged 
15–44 years in the United States have impaired fecundity and almost 7% of married or cohabitating 
women are infertile (NSFG, 2017).  
As described by Table 3, prevalence and age-related trends of infertility have remained fairly consistent 
across the past three cycles of the NSFG (encompassing 13 years of data), with overall slightly lower 
rates reported for both outcomes in the 2006–2010 cycle. However, a report of all NSFG cycles from 
1982 to 2010 indicates that the prevalence of impaired fecundity significantly increased from 8.4% in 
1982 to 11.8% in 2002, driven primarily by an increase in the number of women for whom it is physically 
difficult or dangerous to have a baby. In contrast, the prevalence of infertility among married and 
cohabitating women has steadily decreased, from 8.5% in 1982 to an all-time low of 6% in the 2006–2010 
NSFG cycle (Chandra et al., 2013). 
Table 3. Prevalence of Infertility and Impaired Fecundity Among Women Aged 15–44 Years by Age 
Group National Survey of Family Growth Cycles 2002, 2006-2010, 2011-2015 
 Infertility (a) (%) Impaired Fecundity (%) 
 2002 2006-
2010 
2011-
2015 
2002 2006-
2010 
2011-
2015 
Overall 7.4 6.0 6.7 11.8 10.9 12.1 
Age Group (years)       
15–29  6.3 5.0 5.8 8.4 8.9 9.0 
30–34  8.1 4.6 6.3 14.1 12.2 14.0 
35–39  5.7 7.8 6.5 12.1 13.9 15.2 
40–44 9.4 6.2 8.0 17.9 12.5 16.2 
                                                     
19 The NSFG consists of nationally representative data gathered from in-person interviews with males and females 
aged 15–44 years, administered by trained interviewers. Only one person per household was interviewed.  
20 Persons who are surgically sterile for non-contraceptive reasons (e.g., cancer treatment) but still have a potentially 
viable uterus are not included in the NSFG’s estimates of impaired fecundity but may be eligible to receive infertility 
treatment under the proposed mandate. 
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Source: National Survey of Family Growth (2017) 
Note: Estimates of infertility and impaired fecundity may reflect the fertility status of a respondent’s partner as well their own. (a) 
NSFG estimates infertility only among married or cohabiting women and their opposite sex partners aged 15–44 years. 
Males 
Currently, there is no national registry that systematically collects information about males and the true 
prevalence of infertility among males in the United States is unknown. Although the NSFG estimates 
several measures of impaired fertility among married or cohabitating males aged 15–44 years21 it should 
be noted that there are no completely analogous measures of infertility or impaired fecundity for males as 
compared with females and male participation in the NSFG is low (Chandra et al., 2013; Mehta et al., 
2016). At the time of this report, estimates of impaired fertility from the 2011–2015 NSFG were not yet 
available; however, 9.4% of men aged 15–44 years reported some type of impaired fertility in the 2006–
2011 NSFG; of those, a little over half (5.2%) of men were subfertile and just under half (4.2%) were non-
surgically sterile (Chandra et al., 2013).  
A more recent survey conducted in Great Britain found that 10.1% of males aged 16–75 years surveyed 
between 2010 and 2012 had experienced infertility22 at some point in their lives. Among this cohort of 
men, increased prevalence of infertility was associated with increased socioeconomic status, later 
cohabitation with a partner, and — among men with children — becoming parents at an older age (Datta 
et al., 2016). 
Disparities23 and Social Determinants of Health24 in Infertility 
Per statute, CHBRP includes discussion of disparities and social determinants of health (SDoH) as it 
relates to infertility. Disparities are differences between groups that are modifiable. CHBRP found 
literature identifying disparities by race/ethnicity, marital status/sexual orientation, and socioeconomic 
status.  
Disparities 
Race or ethnicity 
According to a pooled analysis of race and ethnicity data over three cycles of the NSFG (2002, 2006–
2010, and 2011–2013), overall infertility and impaired fecundity rates are highest among Hispanic and 
non-Hispanic black women; however, utilization of infertility treatments is highest among non-Hispanic 
white women (Chandra et al., 2013; Craig et al., 2019). In the 2006–2010 NSFG, the most recent cycle 
for which race and ethnicity data are available, non-Hispanic white women reported almost twice the 
                                                     
21 Male NSFG respondents are limited to the same age range as the women respondents (15–44 years); however, 
according to the American Society for Reproductive Medicine (ASRM), males retain optimal reproductive capabilities 
until 60 years of age and do not have a maximum age at which it is not possible to father a child. 
22 Defined by unsuccessfully attempting pregnancy for a year or longer. 
23 Several competing definitions of “health disparities” exist. CHBRP relies on the following definition: 
Health disparity is defined as the differences, whether unjust or not, in health status or outcomes within a population. 
Wyatt et al., 2016. 
24 CHBRP defines social determinants of health as conditions in which people are born, grow, live, work, learn, and 
age. These social determinants of health (economic factors, social factors, education, physical environment) are 
shaped by the distribution of money, power, and resources and impacted by policy (adapted from Healthy People 
2020, 2015; CDC, 2014). See CHBRP’s SDoH white paper for further information: 
http://chbrp.com/analysis_methodology/public_health_impact_analysis.php. 
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utilization rate of medical help to get pregnant (15%) as compared with non-Hispanic black women (8.0%) 
or Hispanic women (7.6%) (Chandra et al., 2014).  
Furthermore, in a cumulative analysis of several NSFG cycles, Janitz et al. (2018) observed that non-
Hispanic black women respondents were significantly less likely to undergo infertility testing, seek medical 
advice for infertility, or utilize infertility treatments as compared with non-Hispanic white women after 
adjusting for age and income. Although Hispanic women reported less use of infertility treatments as 
compared with non-Hispanic women, these differences were not statistically significant; however, 
Hispanic women were significantly more likely to seek medical advice or infertility testing (Janitz et al., 
2018). In addition to being less likely to seek medical help for infertility overall, Chin et al. (2015) observed 
that, on average, black women who do utilize medical help for infertility wait twice as long to seek care 
after an infertility diagnosis as compared with white women (i.e., 2 years versus 1 year). 
Studies of data from the Society for Assisted Reproductive Technology (SART) Clinic Outcome Reporting 
System (CORS) database suggest that when black, Hispanic, and Asian women access ART for infertility 
treatment, they experience less success as compared with non-Hispanic white women. In a systematic 
review of studies using SART CORS data from 1999-2007, Wellons et al. (2012) found that black, Asian, 
and Hispanic women had significantly lower live birth rates resulting from ART as compared with white 
women; and black and Hispanic women were significantly less likely than white women to opt for a single 
embryo transfers meaning that they may have had increased risk of multiple pregnancies (likely due to 
the higher costs associated with multiple single-embryo cycles compared to a single multiple-embryo 
transfer cycle), which have been associated with poor maternal and perinatal outcomes (see Harms 
discussion in the Public Health Impacts section). In addition, individual studies describing ART outcome 
disparities by racial or ethnic groups have shown that black women are significantly more likely to 
experience miscarriages after ART and Asian women are less likely to conceive a pregnancy from ART 
as compared with white women, which may, in part, be driving the lower birth rates observed among 
these groups overall (Fujimoto et al., 2010; Purcell et al., 2007; Quinn and Fujimoto, 2016; Seifer et al., 
2008).  
It has been suggested that increased rates of obesity, tubal factor infertility associated with endometriosis 
or infections, and fibroid-related uterine factor infertility observed among minority women may contribute 
to the previously discussed disparity in treatment outcomes, but cannot explain the full magnitude of the 
difference (Humphries et al., 2016; Insogna and Ginsburg, 2018). 
Marital status and sexual orientation 
As described previously, single persons and same-sex couples need to utilize infertility treatments, 
including donor materials, in order to have biological children. Although estimates vary widely, use of 
fertility treatments among same-sex couples and single persons is increasing. According to the NSFG, 
almost half of all births (49%) between 2011 and 2015 were to single or unmarried women, as compared 
with 38% in 2002 (NSFG, 2017). Similarly, retrospective studies of gay and lesbian couples have 
documented increases in fertility treatment use since the early 2000s ranging from 21% among lesbians 
seeking artificial insemination with donor sperm to a 21-fold increase among gay and single men 
undergoing ART (Carpinello et al., 2016; Grover et al., 2013). Despite these increases, advocates and 
professional groups, such as the ASRM, recognize that same-sex couples and single persons face 
disproportionate barriers to infertility treatment as compared with opposite-sex couples.  
Same-sex couples and single persons are sometimes subject to definitional barriers that mediate their 
utilization of infertility treatments. Single or same-sex oriented persons may themselves be fertile or 
fecund but are not able to conceive a child with their spouses or partners; however, lacking a biologically 
compatible partner is not always recognized as cause of infertility in most clinical contexts or in major 
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demographic surveys, like the NSFG, which may impact how insurance coverage is applied to these 
populations (Daar et al., 2015; Daar, 2008; National LGBT Health Education Center, 2019). 
Same-sex couples and single persons need to use donor materials, including gestational carriers 
(surrogates), which pose an additional cost burden beyond the previously discussed expense of standard 
infertility treatments. At a minimum, female same-sex couples and single women attempting to conceive 
need to undergo artificial insemination with donor sperm whereas male same-sex couples and single men 
typically need to engage a gestational carrier (surrogate) and use donor eggs via IVF (with ICSI) to have 
biological children. The average cost of insemination with donor sperm is estimated at around $5,000 and 
the cost of IVF with donor eggs has been estimated to be around $38,000 for a live birth; gestational 
carrier (surrogacy) arrangements are very costly, ranging from $80,000 to $140,000 depending on 
medical and legal expenses (Katz et al., 2011; National LGBT Health Education Center, 2019). Note that 
use of donor materials is not exclusive to same-sex couples and single persons, but it is always required 
for these populations. 
Finally, same-sex couples and single persons may experience informational deficits regarding to 
reproduction procedures. CHBRP identified two studies that reviewed a representational sample of ART 
clinic websites in the United States, of which only about half (45.5%–53%) contained content specific to 
LGBT or single-person reproduction. Western clinic websites had the second highest rate of LGBT-
specific content (66%) after the Northeast (72%) (Jin and Dasgupta, 2016; Wu et al., 2017). 
Socioeconomic status 
Greil et al. (2011) analyzed data from 2,162 respondents to the National Survey on Fertility Barriers 
(NSFB) and found that having higher income, greater educational attainment, and private insurance were 
all independently associated with higher odds of medical service use for infertility. Among women 
recruited from high- and low-resource infertility clinics in California, Ho et al. (2017) observed that lower 
income and educational levels were significantly associated with longer durations of untreated infertility. 
With each level of education attained (e.g., high school diploma vs. some college) patients presented for 
infertility care approximately 3.5 months earlier; as compared with patients who did not attend college, 
patients with a college education presented 8.4 months earlier on average. A similar pattern was 
observed with respect to income in the same study wherein patients with an annual income greater than 
$100,000 sought infertility care approximately 6 months earlier than patients with incomes below 
$100,000 (Ho et al., 2017). 
CHBRP also found evidence suggesting that socioeconomic factors mediate documented disparities in 
use of infertility treatments by race and ethnicity. Missmer et al. (2011) surveyed over 1,300 women 
receiving infertility treatments about barriers to treatment and found that African American women were 8 
times more likely than white or Asian American women to report difficulty getting treatment for infertility 
due to income and Hispanic women were about 6 times more likely to report income-related barriers. In 
addition, African American and Hispanic women were significantly more likely to have difficulty taking time 
off for appointments, a significant component of successful infertility treatment.  
Disparities in infertility treatment outcomes by socioeconomic status have also been documented. Among 
approximately 800 women recruited from eight fertility clinics in California, women with college educations 
had almost twice the odds of achieving a pregnancy as compared with women without a degree after 
controlling for age, demographic factors, and fertility factors. Similarly, women with an annual income 
greater than $60,000 had 3 to 5 times the odds of achieving a pregnancy compared to women with 
incomes less than $60,000 (Smith et al., 2011). 
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Social Determinants of Health (SDoH) 
SDoH include factors outside of the traditional medical care system that influence health status and 
health outcomes (e.g., income, education, geography). With respect to AB 767, CHBRP found literature 
regarding the impact of cultural beliefs and discrimination on the prevalence of infertility treatment use 
and outcomes.  
Discrimination 
CHBRP found evidence suggesting that discrimination may contribute to disparities in infertility treatment. 
A study of over 1,300 women receiving infertility treatments at a university-based fertility center found 
that, compared to whites, African American and Hispanic women felt it was more difficult to obtain 
infertility treatment, and this difficulty was a direct result of their race or ethnicity (Missmer et al., 2011). 
Infertility-associated discrimination is also present on a system level. Gurmankin et al. (2005) surveyed 
nearly 369 assisted reproductive technology (ART) clinics across the country to assess the opinions of 
clinic directors on access-to-service issues in comparison to their clinic policy. They found that 53% and 
48% of clinic directors would be very likely to turn away single men pursuing parenthood and male same-
sex couples planning to engage a surrogate, respectively. In contrast, clinic directors were less likely to 
express intent to deny services to single women (20%) and female same-sex couples pursuing 
insemination with donor sperm (17%).  
Cultural beliefs 
Missmer et al. (2011) surveyed over 1,300 women receiving infertility treatments and reported numerous 
cultural differences in access to infertility care. Compared with whites, African American and Hispanic 
women reported more difficulty finding a physician they felt comfortable with and that their race or 
ethnicity made it more difficult to obtain treatment. Similarly, Catholic women were 9 times more likely 
than Protestant women to report that difficulty obtaining treatment was specifically due to their religion 
(Missmer et al., 2011). Moreover, among 2,162 women participating in the National Survey of Family 
Barriers, Greil et al. (2011) observed that compared to white women, black, Hispanic, and Asian women 
were more likely to express ethical concerns about infertility treatments, such as artificial insemination 
(with partner or donor sperm), which was associated with significantly lower odds of seeking treatment for 
infertility (OR, 0.77;p<0.0001). Black and Hispanic respondents also had lower scores with respect to the 
perceived importance of motherhood as compared with white respondents, which was associated with 
significantly greater odds of receiving tests or treatment for infertility.  
Community-related social stigma may also be a reason racial and ethnic minority populations seek out 
infertility treatments less often than non-Hispanic whites do. Greil et al. (2011) analyzed data from the 
NSFB and found that black and Hispanic women reported infertility-related stigma more frequently than 
whites and Asians and were less likely to seek treatment as a result of encouragement from a partner or 
family member. Similarly, in a survey of women receiving infertility treatments, Missmer et al. (2011) 
found that African American women were up to 4 times more likely than white women to be concerned 
with failing to conceive naturally and the social stigma of infertility. Compared to white women, Asian 
American women were 7 times as likely to be concerned with social stigma of infertility; women of 
Chinese descent were nearly 60 times as likely to name social stigma as a significant worry or concern in 
seeking infertility treatment. 
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Societal Impact of Infertility in the United States 
As described previously, infertility is a common condition and the presence of infertility in the U.S. creates 
a societal impact. In dollar terms, the societal impact can be indirect (lost wages, etc.) as well as direct 
(medical care, etc.). CHBRP did not identify data that displays the broad societal impact of infertility, 
specifically. However, research shows that, on an individual basis, treatment for infertility in the United 
States is very costly in terms of time and personal finances (Katz et al., 2011; Wu et al., 2013; Wu et al., 
2014). To that end, see the Benefit Coverage, Utilization, and Cost Impacts section for estimates of cost 
impacts on payers, including enrollees, and the Long-Term Impacts section on economic loss for 
estimates on indirect costs to enrollees. Such figures represent a subset of the total societal impact 
related to infertility. 
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MEDICAL EFFECTIVENESS 
As discussed in the Policy Context section, AB 767 would modify the current infertility treatment mandate, 
which requires most group market DMHC-regulated plans and CDI-regulated policies to offer coverage for 
infertility treatment, excluding in vitro fertilization (IVF), as an optional rider. AB 767 would instead 
mandate that plans and policies, except for individual market plans and policies and Medi-Cal, provide 
coverage for infertility treatment, including IVF, and mature oocyte cryopreservation (OC). Additional 
information on infertility causes, diagnostic work-up, preventive options, and treatments is included in the 
Background section.  
Research Approach and Methods 
As presented in the Background section, infertility diagnosis and treatment encompasses a wide range of 
tests, treatments, and medications. It is not feasible for CHBRP to review the literature on the 
effectiveness of the numerous diagnostic and treatment options for all causes of infertility to which AB 
767 applies within the 60-day timeframe allotted for this analysis. In light of the wide range of conditions 
that cause infertility, the types of treatments to which AB 767 would apply, and the fact that AB 767 
addresses the provision of coverage of infertility benefits, the medical effectiveness review summarizes 
these findings from evidence:25 (1) the impact of health insurance coverage (specifically mandates to 
cover) for infertility treatments and (2) the medical effectiveness of the two treatments newly mandated 
under the bill language (IVF and mature OC).  
Studies of infertility treatments and impacts of infertility insurance coverage were identified through 
searches of PubMed, the Cochrane Library, Web of Science, EconLit, and Business Source Complete, 
the Cumulative Index of Nursing and Allied Health Literature, and PsycINFO. Websites maintained by the 
following organizations that produce and/or index meta-analyses and systematic reviews were also 
searched: the Agency for Healthcare Research and Quality (AHRQ), the International Network of 
Agencies for Health Technology Assessment (INAHTA), the National Health Service (NHS) Centre for 
Reviews and Dissemination, the National Institute for Health and Clinical Excellence (NICE), and the 
Scottish Intercollegiate Guideline Network. The search was limited to abstracts of studies published in 
English.  
The search related to the effectiveness and harms of IVF and planned OC (“planned oocyte 
cryopreservation”) was limited to studies published from 2000 to present. Due to the amount of literature 
published related to IVF, CHBRP focused on previously published systematic reviews to inform the 
medical effectiveness analysis. In assessing harms related to IVF and planned OC, CHBRP relied 
primarily on previously published systematic reviews when possible and expanded the inclusion to well-
designed trials and cohort studies for less common harms and complications. The search related to the 
impact of health insurance coverage for infertility treatment was limited to studies published from 2012 to 
present because CHBRP had previously conducted thorough literature searches on these topics in 2013 
for AB 460. 
Of the 480 articles found in the literature review, 227 were reviewed for potential inclusion in this report on 
AB 767, and a total of 29 studies were included in the medical effectiveness review for this report, as well 
as 8 studies that were included in the previous review for AB 460. The other articles were eliminated 
                                                     
25 Much of the discussion below is focused on reviews of available literature. However, as noted on page 11 of the 
Medical Effectiveness analysis and research approach document (posted here), in the absence of “fully-applicable to 
the analysis” peer-reviewed literature on well-designed randomized controlled trials (RCTs), CHBRP’s hierarchy of 
evidence allows for the inclusion of other evidence. 
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because they did not focus on mandate coverage including IVF, did not report relevant outcomes, or were 
not reporting findings from clinical research studies. A more thorough description of the methods used to 
conduct the medical effectiveness review and the process used to grade the evidence for each outcome 
measure is presented in Appendix B. 
The conclusions below are based on the best available evidence from peer-reviewed and grey literature. 
Unpublished studies are not reviewed because the results of such studies, if they exist, cannot be 
obtained within the 60-day timeframe for CHBRP reports. 
Key Questions 
1. What is the effectiveness of IVF and planned OC as treatments for infertility?  
2. What are the harms associated with IVF and planned OC? 
3. What is the impact of health insurance coverage for infertility treatments on the use of these 
treatments and associated health outcomes? 
Methodological Considerations 
As mentioned previously, due to the amount of available literature, the medical effectiveness review relied 
on existing systematic reviews reporting the effectiveness of IVF. These reviews typically compared the 
effectiveness of IVF to either intrauterine insemination (IUI) or expectant management (conceiving without 
intervention). CHBRP’s discussion of planned OC is limited to women seeking fertility preservation due to 
age-related reasons. The review only identified retrospective cohort studies examining the effectiveness 
of planned OC and none of these studies included an expectant management comparison; studies either 
compared planned OC among nononcologic vs. oncologic patients, cryopreserved vs. fresh embryos, or 
lacked a comparison group. This review also excludes any discussion of fertility preservation for 
iatrogenic infertility; a complete discussion of cryopreservation for that population is discussed in 
CHBRP’s April 2019 analysis of SB 600.26  
When assessing studies examining the impact of health insurance mandates on treatment utilization and 
outcomes, the medical effectiveness analysis was only interested in studies looking at mandates covering 
IVF; there is literature from AB 460 that discussed mandates broadly or without IVF coverage that 
CHBRP has omitted for this review. This analysis will consider studies published after 2013 in addition to 
CHBRP’s previous findings, as ART is a rapidly developing field with clinical advancements expected to 
have occurred in the last 5 years. 
Outcomes Assessed 
To assess the effectiveness of IVF and planned OC, CHBRP assessed the impact on health outcomes 
including the number of embryos transferred, use of intracytoplasmic sperm injection (ICSI), pregnancy 
rates, live births, and rates of multiple births. The goal health outcome of IVF is pregnancy and then live 
birth. Lower pregnancy and birth rates can also be a marker of fewer embryos transferred. The number of 
embryos transferred is an important outcome because transferring more than one embryo per IVF cycle is 
done to increase the likelihood of pregnancy, however it also increases the risks of a multiple gestation 
pregnancy (twins, triplets, or more), increasing both maternal and fetal risks, including preterm birth.  
                                                     
26 CHBRP’s April 2019 analysis of SB 600 Fertility Preservation is available at: 
http://chbrp.org/completed_analyses/index.php 
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ICSI is an IVF procedure in which a single sperm cell is injected directly into the cytoplasm of an egg to 
fertilize the egg, compared to conventional IVF in which multiple sperm are placed in proximity to an egg 
to fertilize it. ICSI is medically indicated in cases of male-factor infertility when sperm are limited in 
number or motility. ICSI can be used for reasons other than male-factor infertility, such as to increase the 
likelihood of IVF success and when genetic screening of the embryo is performed if preferred by the 
fertility specialist. In studies on IVF use, ICSI rates can be a marker of an unnecessary, higher level 
intervention due to pressures for IVF to be successful. 
To assess the harms of IVF and planned OC, CHBRP assessed the effects on maternal health outcomes, 
including ovarian hyperstimulation syndrome, ectopic pregnancies, cardiovascular complications, post-
pregnancy cancer, and multiple gestation. CHBRP also assessed the effects on neonatal health 
outcomes, such as the rate of preterm or low-birthweight births and the incidence of cancer or 
cardiovascular disease, major/minor malformations, cerebral palsy, and infant death.  
For studies of the impact of coverage for infertility treatments, CHBRP assessed effects on two types of 
outcomes: (1) use of infertility treatments, such as number of embryos transferred; and (2) health 
outcomes of infertility treatments, such as pregnancy rates, live birth rates, and rates of multiple births.  
Study Findings27 
CHBRP identified four systematic reviews comparing the effectiveness of IVF versus other infertility 
treatments and found that IVF is an effective treatment for infertility, resulting in increased pregnancy 
rates and live birth rates. CHBRP identified four retrospective cohort studies assessing the effectiveness 
of planned oocyte preservation that consistently found that planned OC is an effective treatment for 
infertility, resulting in pregnancies and live births.  
CHBRP identified 17 studies (13 systematic reviews and four observational studies) that analyzed the 
potential harms and complications associated with IVF and planned OC. CHBRP found evidence that IVF 
is associated with certain maternal and fetal harms, including ovarian hyperstimulation syndrome and 
thromboembolism. There is also evidence that IVF can lead to multiple gestation and preterm delivery. 
However, it is important to note that multiple gestation is associated with higher numbers of embryos 
transferred per cycle, and that preterm delivery is associated with multiple gestation — these outcomes 
can be mitigated by single embryo transfers. CHRBP found evidence that IVF mandates are associated 
with lower numbers of embryos transferred per cycle. There is also evidence that IVF mandates lead to 
fewer births per cycle (due to the decreased number of embryos transferred per cycle), and a reduction in 
overall harms of IVF (i.e., lower rates of multiple gestation, preterm deliveries and low-birthweight births).  
Effectiveness of IVF 
CHBRP identified four systematic reviews including 55 unique (non-overlapping) studies comparing the 
effectiveness of IVF versus other infertility treatments (Humphries et al., 2016; Pandian et al., 2015; 
Siristatidis et al., 2015; Vitorino et al., 2011). A 2015 Cochrane Review compared the effectiveness of 
                                                     
27 The following figures in this section summarize CHBRP’s findings regarding the strength of the evidence for the 
effects of insurance coverage for, and effectiveness of, IVF and planned OC addressed by AB 767. For test, 
treatments, and services for which CHBRP concludes that there is clear and convincing, preponderance, limited, or 
inconclusive evidence, the placement of the highlighted box indicates the strength of the evidence. If CHBRP 
concludes that evidence is insufficient, a figure that states “Insufficient Evidence” will be presented. 
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various infertility treatments (IVF, expectant management, intrauterine insemination, and IUI plus a type 
of medication [e.g., gonadotropins/clomiphene/letrozole]) on live birth rates for patients with diverse 
causes of infertility including endometriosis and unexplained infertility (Pandian et al., 2015). A total of five 
randomized-controlled trials (RCTs) were included in the review, with 1,622 participants. Among the 
studies, a subset reported a higher live birth rate for women undergoing IVF, compared to women 
completing the expectant management treatment (n = 51; odds ratio [OR]=22.00 [95% CI 2.56-189.37]). 
In addition, the live birth rate was higher among IVF versus IUI patients (n = 156; OR=2.47 [95% CI 1.19-
5.12]). The review also found there was no conclusive evidence between conducting IVF versus IUI + 
gonadotropins and IVF versus IUI + clomiphene. Regarding multiple pregnancies due to ovarian 
stimulation, there was no significant difference among women undergoing IVF verses IUI (OR: 0.63, 95% 
CI, 0.27-1.5). 
As discussed previously, a patient’s race/ethnicity could impact the success of infertility treatments. As 
observed via a systematic review by Humphries et al. (2016) assessing 24 peer-reviewed publications, 
Caucasian women were more likely to achieve a pregnancy after completing IVF treatments as compared 
to both Asian and African American women (36.2% vs. 31.4% and 24.4% respectively). Caucasian 
women were also more likely to achieve higher birth rates than Asian women (30.7% vs. 24%; OR=0.64 
[95% CI, 0.51–0.80]) and African American women (30.7% vs. 16.9%; OR=0.50 [95% CI, 0.33–0.72]) 
(Humphries et al., 2016). 
A 2011 systematic review synthesized 17 studies focusing on HIV serodiscordant couples (couples in 
which one is HIV-positive and the other HIV-negative) striving to achieve conception. A total of 738 IVF 
cycles were completed among 579 serodiscordant couples. The median cumulative pregnancy rate 
among IVF patients was 52.9% (range: 41%–67.35%). Additionally, the median number of transferred 
embryos was 2.9 (range: 2.5–3.5), and the fertilization rate was 71.5% (range: 50.1%–77.1%). Finally, it 
is important to note that no seroconversions were reported among the studies of HIV serodiscordant 
couples and/or any newborn infants (Vitorino et al., 2011). 
A 2015 systematic review analyzed data from 11 studies, which include a total of 268 polycystic ovarian 
disorder (PCOS) patients, and 440 infertile, non-PCOS patients, undergoing IVF treatment. After 
undergoing treatment, women with PCOS were more likely than the non-PCOS patients to achieve 
pregnancy (OR=3.29 [95% CI, 1.42–7.62]). The birth rate and embryo transfer rate trended towards 
higher in the PCOS group but not significantly different between both groups undergoing IVF for infertility 
(Siristatidis et al., 2015). 
Summary of findings regarding IVF effectiveness: There is a preponderance of evidence from four 
systematic reviews that IVF is an effective treatment for infertility, resulting in increased pregnancy rates 
and birth rates.  
Figure 1. Effectiveness of IVF as a Treatment for Infertility  
 
Effectiveness of Planned Oocyte Cryopreservation  
CHBRP identified four retrospective cohort studies assessing the effectiveness of planned OC (Cobo et 
al., 2018; Cobo et al., 2016; Doyle et al., 2016; Garcia-Velasco et al., 2013). One of these studies was 
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conducted in the United Sates (Doyle et al., 2016), while the other three included women from infertility 
clinics in Spain (Cobo et al., 2018; Cobo et al., 2016; Garcia-Velasco et al., 2013).  
Doyle et al. (2016) analyzed a retrospective cohort study of 875 women undergoing planned OC at a 
single center in the United States between August 2009 and January 2015. This cohort was comprised of 
women undergoing medically indicated IVF, with cryopreservation due to unavailability of sperm, to limit 
the number of embryos created, or elective preservation for non-medically indicated fertility preservation. 
The mean age of the women undergoing planned OC was 34.9 years. One-hundred seventeen patients 
returned to use their preserved oocytes (13.4%). The live birth rate per transfer cycle was 38.6% (Doyle 
et al., 2016).  
Cobo et al. (2018)28 examined a multisite, retrospective cohort of 5,289 patients undergoing planned OC 
due to age-related fertility decline between January 2007 and May 2018 at multiple infertility clinics in 
Spain (the cohort also included 1,073 patients undergoing fertility preservation prior to cancer treatment; 
their outcomes are not reported here). The mean patient age at cryopreservation was 37.2 years. In this 
cohort, 641 (12.1%) women returned to retrieve their preserved oocytes after an average of 2.1 years, 
resulting in 115 live births; an additional 47 live births were seen among 159 patients undergoing transfer 
of surplus cryopreserved embryos. The authors analyzed the live birth rate based on patient age at 
cryopreservation, and found that cryopreservation at 35 years or younger resulted in a significantly higher 
cumulative live birth rate per patient (68.8%) compared with women undergoing cryopreservation after 
age 35 (25.5%) (Cobo et al., 2018) 
Cobo et al. (2016)28 also analyzed a group of 1,468 Spanish women undergoing elective OC from 
January 2007 to April 2015. The majority of the women (n=1,382; 94%) were undergoing 
cryopreservation because of age-related fertility decline; the remaining women were undergoing 
cryopreservation due to non-cancer medical reasons (e.g., endometriosis). Mean age at cryopreservation 
was 37.2 years. The majority of women undergoing planned OC due to age-related reasons did so 
between ages 37 and 39 years (63%), whereas women with a non-cancer medical condition started at a 
younger age (33.1% between ages 31 and 35 years and 29.6% between ages 36 and 39 years). In the 
overall cohort, 137 (9.3%) women returned to use their preserved oocytes after an average storage 
period of 2.1 years. Significantly more women who underwent planned OC due to non-cancer medical 
reasons returned to use their preserved oocytes (19.8% vs. 8.7%; p<0.05). In the overall cohort, the 
ongoing pregnancy rate (defined as pregnancy >12 weeks with fetal heart beat) per patient was 27.0%; 
the rate among women who preserved due to age was slightly less than the overall rate (21.6%) and 
significantly lower than the rate among women who preserved due to non-cancer medical reasons 
(64.7%; p<0.05). In the overall cohort, there were 31 live births, including three sets of twins; 24 of these 
births occurred in the age-related cohort and seven in the non-cancer cohort (Cobo et al., 2016).  
Garcia-Velasco et al. (2013)28 also analyzed a Spanish cohort including 560 non-oncologic patients 
undergoing planned OC between March 2007 and June 2012; the majority of these patients were 
undergoing cryopreservation due to age-related reasons (n=505; 90.2%). This study also included 475 
oncological patients; their data is not reported here. The mean age of women undergoing planned OC 
was 36.7 years. Twenty-six patients who preserved oocytes due to non-oncologic reasons returned to 
retrieve their cryopreserved oocytes (4.6%) after an average storage time of 1.7 years. The ongoing 
pregnancy rate per patient was 33.3% after cryotransfer. Five healthy babies have been born (one from a 
cryotransfer) (Garcia-Velasco et al., 2013).  
                                                     
28 Cobo (2018), Cobo (2016), and Garcia-Velsaco (2013) all report on cohorts of women from the same multisite 
settings in Spain over similar recruitment periods. However, the publications do not indicate that these are 
overlapping cohorts and as such, CHBRP has treated them as three separate publications with unique cohorts.  
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Professional societies have differed on the ethics of age-related OC. In 2013, the American Society of 
Reproductive Medicine (ARSM) and the Society of Assisted Reproductive Technology (SART) released 
guidelines around OC, and noted that planned OC “should not be recommended in order to bypass age-
related infertility decline due to the absence of data supporting safety, efficacy, ethics, emotional risks, 
and cost-effectiveness of egg freezing for that indication” (ASRM, 2013). The American College of 
Obstetricians and Gynecologists (ACOG) adopted the ARSM-SART guideline in 2014 (ACOG, 2014a). In 
2018, the ASRM Ethics Committee released an opinion on planned OC for future reproductive potential, 
stating that planned OC is an ethically permissible procedure that serves women’s legitimate interest in 
reproductive autonomy; because this is a newer procedure, the benefits and harms are not fully 
understood and this should be discussed with women (ASRM, 2018).  
Summary of findings regarding planned OC: There is a preponderance of evidence from four studies 
that planned OC results in pregnancy and live births. However, due to the lack of studies with relevant 
comparator groups (e.g., expectant management or fertility treatments without planned OC), there is 
insufficient evidence to assess whether planned OC is more effective than other infertility treatments at 
the time of desired fertility.  
Figure 2. Effectiveness of Planned Oocyte Cryopreservation for Fertility Preservation   
 
 
Harms of Infertility Treatment 
CHBRP identified 17 studies (13 systematic reviews and four observational studies) that analyzed the 
potential harms and complications associated with IVF and planned OC. Maternal harms include the 
incidence of ovarian hyperstimulation syndrome, ectopic pregnancy, cardiovascular complications, post-
pregnancy cancer, and complications stemming from the increased incidence of pregnancy with multiples 
associated with IVF. Harms affecting the offspring of infertility treatment include preterm birth, low 
birthweight, pediatric cancer, congenital malformations, developmental disorders, and infant death.  
Maternal harms 
Ovarian hyperstimulation syndrome  
Ovarian hyperstimulation syndrome (OHSS) occurs when the ovaries are hyperstimulated and enlarged 
due to due fertility treatment. Clinical features of OHSS range be mild (e.g., abdominal distention, 
diarrhea), moderate (same symptoms as mild, along with abdominal fluid build-up visible on ultrasound), 
severe (e.g., severe abdominal pain, rapid weight gain, syncope) or critical (e.g., acute renal failure, 
sepsis, thromboembolism). An older systematic review (including literature published between 1990 and 
2002) found that the incidence of moderate OHSS ranges from 3% to 6% and severe/critical OHSS 
ranges from 0.1% to 2%; the incidence of mild OHSS is higher, ranging from 20% to 33% of IVF cycles 
(Delvigne and Rozenberg, 2002). 
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Ectopic pregnancy  
A 2015 cohort study including 553,577 pregnancies reported to the National ART Surveillance System 
(NASS) between 2001 and 2011 included 9,480 ectopic pregnancies in ART pregnancies; of those 485 
were heterotopic, meaning both extra-uterine (ectopic) and intrauterine pregnancy occurred 
simultaneously. The rate of ectopic pregnancy was higher with fresh, nondonor cycles (2.0%; 95% CI, 
1.9–2.0) than with fresh, donor cycles (1.0%; 95% CI, 0.9–1.1). The rate of ectopic pregnancy increased 
with the number of embryos transferred; 1.7% (95% CI, 1.7–1.8) for one embryo compared to 2.5% (95% 
CI, 2.1–2.3) with four embryos. The authors concluded that the national rate of ectopic pregnancy in ART, 
1.7% for a single embryo transfer, was similar to the general population rate, 2.0% (Perkins et al., 2015).  
Cardiovascular complications  
Three studies have found that IVF is associated with an increased risk of pulmonary and venous 
thromboembolism during pregnancy, and that this risk is highest in the first trimester and in pregnancies 
with multiples. A large cross-sectional study of women undergoing IVF in Sweden (n=24,498) individually 
matched with women with spontaneous pregnancies (n=116,960) found that the risk of venous 
thromboembolism was higher among women undergoing IVF (4.2 per 1,000 women) compared with 
spontaneous conceptions (2.5 per 1,000 women) (hazard ratio [HR]=1.77; 95% CI, 1.41–2.23) 
(Henriksson et al., 2013). 
The study also found that the risk was particularly high during the first trimester, with 1.5 per 1,000 
women undergoing IVF experiencing thromboembolism compared with 0.3 per 1,000 women with 
spontaneous conceptions (HR=4.22; 95% CI, 2.46–7.26). Similarly, the rate of pulmonary embolism was 
higher among women undergoing IVF (3.0 per 10,000 women) compared with spontaneous conception 
(0.40 per 10,000 women) (HR=6.97; 95% CI 2.21–21.96) (Henriksson et al., 2013). A large cohort study, 
also conducted in Sweden (n=964,532 deliveries) also found that the incidence of first-trimester venous 
thromboembolism was higher among IVF pregnancies (1.67 per 1,000 women) compared to non-IVF 
pregnancies (0.17 per 1,000 women) (OR=9.8; 95% CI, 6.7–14.3) (Rova et al., 2012). A cohort study of 
women undergoing IVF in Denmark (n=18,787) compared the incidence of venous thrombosis after IVF 
versus the incidence in spontaneous pregnancies. The incidence rate ratio (IRR) of venous thrombosis 
was higher among during pregnancies among those undergoing IVF (2.2 per 1,000 women) compared to 
a reference population (IRR=3.0; 95% CI, 2.1–4.3). This study also found that the rate of venous 
thrombosis was higher among multiple pregnancies compared to the reference group (0.6 per 1,000 
women; IRR=4.4 [95% CI, 2.4–8.3]), but was not significantly higher compared to singleton IVF 
pregnancies (Hansen et al., 2014).  
In contrast to thromboembolism, a meta-analysis of six observational studies of women who received 
fertility treatment (n=41,190; not limited to IVF) compared with those who did not (n=1,400,202) found no 
difference in the risk of cardiac events among women receiving fertility treatment (Dayan et al., 2017). 
Post-pregnancy cancer 
A 2013 meta-analysis by Li et al included eight cohort studies (n=764,455) and found no significant 
association between IVF treatment and overall cancer risk. The meta-analysis did not identify any 
significant association between IVF and risk for breast, ovarian, or cervical cancer (Li et al., 2013). A 
2015 meta-analysis of six cohort studies (n=776,224) compared the incidence of uterine cancer among 
patients receiving fertility treatment (defined as using IVF with or without ovulation-induction medications). 
This analysis found no significant difference in the incidence of uterine cancer among the fertility 
treatment group (0.14%; 150/103,758) and the non-fertility treatment group (2.22%; 14,918/672,466), 
reporting an odds ratio of 0.78 (95% CI, 0.39–1.57) (Saso et al., 2015).  
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Multiple gestation  
As noted previously, use of infertility treatments is associated with increased risk of multiple births. In 
2016, the CDC estimated that twins accounted for about 3% of all live births in the general population and 
almost 19% of live births among persons undergoing ART; similarly, triplets and higher-order multiples 
accounted for 0.1% of lives births in the general population as compared with 0.6% of live births from 
ART (Martin et al., 2018). Maternal medical complications are more common in multiple gestation 
pregnancies, including hyperemesis gravidarum (severe morning sickness), gestational hypertension, 
pre-eclampsia and gestational diabetes (Finlayson et al., 2016). Infant complications arising from multiple 
gestation include preterm birth, fetal growth restriction, congenital anomalies, and malformations (Mandy, 
2019).  
Offspring harms 
Preterm birth 
Four systematic reviews reported data on preterm births among women undergoing infertility treatment 
(Hoorsan et al., 2017; McGovern et al., 2004; Qin et al., 2016). The total number of studies included in 
each review ranged from 15 to 30. For instance, Qin et al. (2016) reported a preterm birth rate of 
RR=1.08 (95% CI, 1.02-1.13) among twins conceived via ART (N = 5,944) compared to twins 
spontaneously conceived (N = 12,742). Horrsan et al. (2017) reported a preterm labor odds ratio of 1.79 
(95% CI, 1.21–2.63), among 5,470,181 infants (315,402 cases and 5,154,779 controls).   
Low birthweight 
Two systematic reviews reported higher rates of low birthweight in offspring of women treated for infertility 
(Hoorsan et al., 2017; Qin et al., 2016). Horrsan et al. (2017) reported an odds ratio of 1.89 (95% CI, 
1.36–2.62) among 5,470,181 infants (315,402 cases and 5,154,779 controls). Another review included an 
assessment of nine studies focusing on twins conceived via ART versus twins conceived spontaneously 
(Qin et al., 2016). A risk ratio of 1.09 (95% CI, 1.03–1.16) was reported when comparing the likelihood of 
a twin being born with a low birthweight among the two groups (ART group: N = 4,297 and SC group: N = 
7,808).  
Pediatric Cancer 
The associated risk of cancer among children conceived via infertility treatments is under investigation as 
some studies suggest the risk is higher, while others suggest the risks are lower. For example, Wang et 
al. (2018) reviewed 29 studies (N= 327,884) and found that approximately 578 children who were born 
post-fertility treatments were diagnosed with cancer. The overall risk was 1.16 (95% CI, 1.01-1.32) (Wang 
et al., 2018). Another review assessed 11 studies (N = 38,815) and observed a lower cancer incidence 
(n=47) than expected (n=38) (standardized incidence ratio [SIR]=1.23 [95% CI, 0.93-1.37]) (Raimondi et 
al., 2005). 
Congenital Malformations 
Several congenital malformations appear to have higher rates among children conceived with ART. 
Hoorsan et al. (2017) assessed the risk of cardiovascular abnormalities among children conceived via 
ART (IVF or other ART fertility treatment) verses spontaneous conception with a meta-analysis of 30 
articles. As previously described, a total of 5,470,181 infants were assessed (315,402 cases and 
5,154,779 controls). Children born via ART had a higher chance of being diagnosed with a cardiac 
abnormality compared to SC infants (OR=1.43 [95% CI, 1.27 to 1.62]). Additionally, ART infants had a 
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higher chance of being diagnosed with a central nervous system abnormality compared to SC infants 
(OR=1.36 [95% CI, 1.10–1.70]). This meta-analysis also reported urogenital system abnormalities 
(OR=1.58 (95% CI, 1.28–1.94) and musculoskeletal disorders (OR=1.35; 95% CI, 1.12–1.64) were more 
common, but chromosomal abnormalities were not significantly higher among ART infants.  
Qin et al. (2016) reviewed 14 studies that reported data on congenital malformations. Twins conceived via 
ART (N = 6,068) were more likely to be diagnosed with a malformation than twins conceived 
spontaneously (N = 13,220) (OR=1.26; 95% CI, 1.09–1.46;). Additionally, another review identified a 
similar finding across 46 studies (OR=1.37; 95% CI: 1.26–1.48) (Wen et al., 2012).  
Cerebral palsy, autism spectrum disorder, and developmental delay 
One systematic review reported data on cerebral palsy, autism spectrum disorder, and developmental 
delay. Hvidtjørn et al. (2009) conducted a meta-analysis among nine studies (N = 19,462) and observed 
children conceived with IVF were more likely to be diagnosed with cerebral palsy due to preterm delivery 
compared to those conceived spontaneously (OR=2.18 [95%CI, 1.71-2.77]). Among studies on autism 
spectrum disorder and 30 studies on developmental delay, they found inconsistent results (Hvidtjorn et 
al., 2009). 
Infant death 
One systematic review (Qin et al., 2016) observed perinatal mortality among 10 studies (ART group: N = 
4,564; spontaneous conception group: N = 8,178) and determined the rate to be higher for twins 
conceived via ART compared to twins conceived spontaneously (RR=1.60 [95% CI, 1.20–2.13]; p-value: 
0.01).  
Childhood weight 
Guo et al. (2017) examined body mass index among children born post-IVF treatment and found that they 
had a comparable BMI to spontaneously conceived children (-0.04 kg/m2; 95% CI, -0.28, 0.20) (Guo et 
al., 2017). 
 
Summary of findings regarding the harms associated with infertility treatment: There is a 
preponderance of evidence that IVF is associated with certain maternal harms, including ovarian 
hyperstimulation syndrome and thromboembolism. There is also clear and convincing evidence that IVF 
is related to multiple gestation and preterm delivery, and associated harms. However, it is important to 
note that multiple gestation is associated with higher numbers of embryos transferred per cycle, and that 
preterm delivery is associated with multiple gestation. These outcomes can be mitigated by increases in 
single embryo transfers.  
 
Figure 3. Maternal Harms of IVF and Planned Oocyte Cryopreservation 
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Figure 4. Harms of IVF and Planned Oocyte Cryopreservation due to Multiple Gestation and Preterm 
Delivery 
 
Impact of Infertility Treatment Health Insurance Mandates including IVF Coverage 
Bitler and Schmidt (2006, 2012) examined the impact of state-level insurance mandates for infertility 
coverage on the utilization of infertility treatments using pooled data from the 1982, 1988, 1995 and 2002 
NSFG surveys. Their 2006 analysis found no evidence that state-level mandates impact utilization of 
infertility treatments for the overall population of women aged 15–44, or for examined subgroups (college-
educated women, older women, white women). The only significant finding was an interaction between 
the presence of a state-level mandate, high education, and age 30 years or greater (marginal effect, 4.6 
percentage points); the authors posit that expanding infertility treatment access may differentially impact 
highly educated older women (Bitler and Schmidt, 2006).  
The 2012 study also found that any significant impact of state-level mandates on infertility treatment 
utilization was limited to highly educated older women (4.1 percentage point increase in probability of 
using infertility treatment), and that the effects of infertility insurance mandates was only significant for 
use of ovulation-inducing drugs (32% increase in use compared to baseline [without a mandate]) (Bitler 
and Schmidt, 2012). For IVF, the presence of a mandate resulted in a 0.4% decrease in utilization 
compared to baseline. The authors compared utilization in states with “mandates to cover” versus 
“mandates to offer” and found that both mandate types had similar effects on utilization of infertility 
treatments (Bitler and Schmidt, 2012).  
Impact on IVF utilization  
In the 2013 analysis of AB 460, CHBRP concluded that results from six studies (Banks et al., 2010; 
Henne and Bundorf, 2008; Jain et al., 2002; Martin et al., 2011; Navarro et al., 2008; Reynolds et al., 
2003) were consistent in their findings that clinics in states with infertility treatment insurance mandates 
had an increase in the number of IVF cycles, lower numbers of embryos transferred per cycle, lower 
pregnancy rates and fewer births per cycle compared to states without mandates. This effect of infertility 
insurance may be specific to the type of treatment (IVF) where insurance coverage reduces financial 
pressure to achieve a pregnancy in the minimal number of IVF cycles, thus decreasing the pressure to 
transfer more embryos per cycle, which in turn reduces birth rates and multiple birth rates (Martin et al., 
2011).  
CHBRP identified three studies published since the AB 460 review examining the impact of state 
mandates including IVF treatment on IVF utilization (Boulet et al., 2015; Crawford et al., 2016; Dieke et 
al., 2018). With the exception of Crawford (2016), these studies were consistent in their findings that 
states with infertility treatment insurance mandates covering IVF had lower numbers of embryos 
transferred per cycle, more single embryo transfers, fewer cycles with >3 embryos transferred and less 
use of ICSI.   
Dieke (2018) analyzed 2000–2015 data from the National ART Surveillance System (NASS), comparing 
states with an infertility mandate to cover IVF (n=8; AR, CT, HI, IL, MA, MD, NJ and RI) versus those that 
do not have a mandate, with an emphasis on the use of ICSI in mandate versus nonmandate states. This 
analysis found that IVF cycles in mandated states were more likely to involve <10 oocytes retrieved 
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(p<0.05) and more likely to be single embryo transfers (29.3% in mandate states vs. 22.3%; p<0.05). ICSI 
use was more common in nonmandate states than states with mandates (79.4% vs. 70.8%; p<0.05). For 
cycles without male-factor infertility, the increase in ICSI use was greater among nonmandate states 
(34.6% in 2000 to 73.9% in 2015) versus mandated states (39.5% to 63.5%); the percentage increase 
was approximately 7% for male-factor infertility in both mandate and nonmandate states.  
Crawford (2016) analyzed 1996-2013 NASS data comparing IVF utilization premandate and postmandate 
implementation in two states (Connecticut and New Jersey) compared to four states without a mandate 
(Maine, New Hampshire, Pennsylvania, and Vermont). The New Jersey mandate was enacted in 2001, 
and Connecticut in 2005; the study generated a two-year pre- and post-implementation period for each 
state and compared IVF utilization between each state and the nonmandate states. This study found that 
IVF use in the mandated states was greater in the post-implementation period than in the nonmandate 
states. After mandate implementation in both New Jersey and Connecticut, there was a significant 
increase in the number of IVF cycles per 1,000 females aged 15-44 compared with the nonmandate 
states (interaction p<0.001). This analysis found that changes in IVF practice (ICSI use, mean number of 
embryos transferred, transfers of >2 embryos) across mandate periods were not significantly different for 
the states with mandates compared to those without. The authors posit that these IVF practice changes 
suggest changes in care patterns across the ART community, versus changes attributable only to the 
mandate. 
Boulet (2015) linked 2007-2009 NASS data with vital records from Massachusetts (which has an infertility 
mandate including IVF), Michigan and Florida (neither of which had a mandate). This study found that 
more deliveries conceived by IVF occurred in the mandate state versus nonmandate states (2.9% of all 
deliveries vs. 0.8%). The analysis found lower average numbers of embryos transferred per cycle in the 
mandate state versus nonmandate states (mean, 2.2 versus 2.4; p<0.001), more elective single embryo 
transfers (8.6% of all transfers in the mandate state vs. 2.5%; p<0.001), fewer cycles involving >3 
embryos transferred (23.1% vs. 33.6%; p<0.001), and a higher percentage of transfers resulting in a term, 
normal birthweight singleton (64.6% vs. 56.3%; p<0.001). The analysis also found less use of ICSI in 
mandate states versus nonmandate states (39.2% vs. 64.1%).  
Interaction of Health Insurance Mandates for IVF and Age 
CHBRP identified three studies examining the interaction of health insurance mandates covering IVF and 
age; two were discussed in AB 460 (Banks et al., 2010; Martin et al., 2011) and one study was identified 
as part of this review (Boulet et al., 2015). Banks (2010) found that although there was a consistent 
relationship between mandates and number of embryos transferred across all age groups, the impact of 
mandates on the number of births per transfer was only seen among the youngest (<35 years; p=0.01) 
and oldest (41-42 years; p=0.02) age groups (Banks et al., 2010). Martin (2011) found that younger age 
groups (<35 years) in mandate states were significantly more likely to have fewer embryos transferred 
compared to older age groups (Martin et al., 2011).  
Boulet (2015) found that women younger than 35 years living in a nonmandate state were more likely to 
transfer >3 embryos per cycle compared to those living in a mandate state (adjusted RR 4.18 [95% CI, 
2.74-6.36]), and correspondingly, deliveries resulting from the transfer of >3 embryos in the nonmandate 
state were higher (26.9% vs. 7.0% in mandate states). Women 35 years and older living in a mandate 
state were also more likely to transfer >3 embryos than those living in nonmandate states (RR, 1.46 [95% 
CI, 1.17-1.81]), but the difference in proportion of live births resulting from these transfers between 
mandate vs. nonmandate states was less pronounced (33.6% vs. 39.7% in nonmandate states) (Boulet et 
al., 2015). 
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Impact on IVF-Related Birth Outcomes  
In the 2013 analysis of AB 460, CHBRP concluded that results from four studies were consistent in their 
findings that states with infertility treatment insurance mandates covering IVF had lower pregnancy rates, 
fewer births per cycle, lower rates of multiple births, and fewer adverse birth outcomes compared to 
states without mandates (Henne and Bundorf, 2008; Jain et al., 2002; Martin et al., 2011; Navarro et al., 
2008).  
CHBRP identified two studies published since the AB 460 review examining the impact of state mandates 
including IVF treatment on birth outcomes (Boulet et al., 2015; Crawford et al., 2016); these studies also 
found that IVF in states without mandates were more likely to result in more live births, multiple births, 
preterm deliveries and low-birthweight births.  
Crawford (2016) found that there was no significant difference between Connecticut (mandate state) and 
the nonmandate states between premandate and postmandate implementation in the percentage of 
transfers resulting in live births, multiple births, preterm births or low-birthweight births. Compared with 
New Jersey (mandate state), the nonmandate states saw significantly larger increases in percentage of 
transfers resulting in live births (interaction p=0.049) as well as multiple births (interaction p=0.005) likely 
due to the higher (but not significantly different) rates of transfers involving >2 embryos in the 
nonmandate states; changes in preterm and low-birthweight births were not significant.  
Boulet (2015) found that, compared to mandated states, IVF deliveries in nonmandate states were more 
likely to be twins (adjusted RR, 1.2 [95% CI, 1.12-1.29]) or higher order multiples (adjusted RR, 2.4 [95% 
CI, 1.81–3.28]), and were more likely to result in preterm deliveries (adjusted RR, 1.3 [95% CI, 1.20–1.42] 
or low-birthweight births (adjusted RR, 1.3 [95% CI, 1.17–1.40]. 
As mentioned previously, Martin and colleagues (2011) note that insurance coverage for IVF may reduce 
the financial pressure to achieve a pregnancy in the minimal number of IVF cycles, thus decreasing the 
pressure to transfer more embryos per cycle, which in turn reduces birth rates and multiple birth rates. 
Multiple births are considered an adverse outcome of IVF, leading to more complications and worse 
health outcomes, such as preterm birth or low birthweight.  
Summary of findings regarding the impact of health insurance mandates including IVF coverage 
on utilization and related birth outcomes: There is a preponderance of evidence that infertility 
treatment health insurance mandates are associated with an increase in utilization of infertility treatments 
in general, as well as a preponderance of evidence that IVF insurance mandates are associated with a 
decrease in the number of embryos transferred per IVF cycle and a decrease in the proportion of cycles 
transferring >2 embryos, and that these decreases are more pronounced among younger women. There 
is also a preponderance of evidence that IVF mandates are associated with lower pregnancy rates (due 
to a decrease in embryos transferred), and a lower likelihood of other adverse birth outcomes, including 
rates of multiple births.   
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BENEFIT COVERAGE, UTILIZATION, AND COST IMPACTS 
As discussed in the Policy Context section, AB 767 would require DMHC-regulated group health plans 
and CDI-regulated group policies to provide coverage for infertility treatments, including in vitro 
fertilization (IVF), and mature oocyte cryopreservation (OC). Individual plans and Medi-Cal are excluded 
from AB 767. 
This section reports the potential incremental impacts of AB 767 on estimated baseline benefit coverage, 
utilization, and overall cost.  
Approach and Assumptions 
CHBRP’s overarching approach to the cost analysis of AB 767 and accompanying key assumptions are 
described below. 
Infertility Services 
• CHBRP examined 2016 MarketScan® database and Milliman’s proprietary 2016 Consolidated 
Health Cost Guidelines™ Sources Database (CHSD) for infertility services among enrollees with 
an infertility diagnosis in California as well as New Jersey, a state where an infertility mandate is 
already in place. Using estimates from the peer-reviewed literature on differences in utilization 
rates for infertility services in states with infertility coverage mandates in place versus those 
without coverage mandates, CHBRP estimated baseline utilization rates for enrollees in California 
in 2020.29 New Jersey utilization rates were used to model postmandate utilization for California.30 
More detail on this is included in Appendix C. 
• The claims data for diagnostic and treatment services for females aged 15–44 years with infertility 
diagnoses were categorized into the following broad groups for female enrollees:  
o Diagnostic Services 
o Medications (i.e., infertility treatment using only medication) 
o IUI 
o IVF 
o ICSI 
o As explained in the Policy Context section, GIFT and ZIFT were not included in this analysis.  
• The claims data for male enrollees aged 18–60 years were grouped as the following: 
o Diagnostic Services 
o Treatment  
 Postmandate utilization rates and distribution of services (e.g., percent receiving medication, IUI, 
IVF, ICSI) is assumed to shift in proportion to that observed in New Jersey plus an additional 
increase due to pent-up demand for these services. Pent-up demand is assumed to occur given 
the financial burden currently cited by couples hoping to use infertility services but are unable to 
                                                     
29 Per content expert input, infertility diagnoses in claims data are reflective of the inability to become pregnant after 
12 months or more of regular unprotected intercourse without conceiving, at which point a diagnostic evaluation is 
indicated, as defined by the American Society of Reproductive Medicine. Milliman’s 2016 Consolidated Health Cost 
Guidelines (CHSD) were also used in the analysis of utilization. 
30 As discussed in Medical Effectiveness, utilization of infertility services is higher in states where an infertility 
mandate is in place compared to states without a mandate (Boulet et al., 2019; Crawford et al., 2016; Dieke et al., 
2018). 
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because of cost barriers. It is assumed that utilization in the first and second year would be 10% 
greater than the NJ utilization rates as awareness around the infertility mandate would increase. 
Per literature on mandates in other states and internationally (Chambers et al., 2014), pent-up 
demand for infertility services dissipates over time and utilization reaches a steady state after a 
few years postmandate (Machado and Sanz-de-Galdeano, 2015). 
 With CHBRP’s content expert input, CHBRP assumes there is an acceptable number of infertility 
service providers and facilities in California to accommodate the increase in utilization of services 
postmandate as described above, thus CHBRP assumes no supply-side deficiencies that would 
hinder utilization increases.31 
Planned Oocyte Cryopreservation 
 AB 767 includes the coverage of mature OC; as described in the Policy Context section, CHBRP 
examines this as specifically mature OC for planned OC, as opposed to OC for iatrogenic 
infertility. No utilization data are available for planned OC in MarketScan claims data. There are 
no studies that estimate utilization of OC for non-iatrogenic or planned use, thus the approach to 
CHBRP’s estimation of utilization change postmandate due to AB 767’s coverage of mature OC 
included an estimate of potential increase in utilization per CHBRP’s content expert. Table 1 
estimates of utilization change do not include planned fertility preservation, however CHBRP 
offers an estimate of potential cost increase if a modest proportion of females of reproductive age 
opt to use the service in the Baseline and Utilization subsection below.  
Pregnancy and Related Outcomes 
 Rates of pregnancies, percent resulting in live birth, percent resulting in single birth, percent 
resulting in twin birth and percent resulting in higher order multiples as a result of the use of 
infertility services for the broad categories of IVF, IUI, medications, were obtained from the peer 
reviewed literature. The Medical Effectiveness section provides details on the pregnancy 
outcomes related to IVF. For the non-IVF infertility services, additional literature was sourced to 
obtain these estimates (Diamond et al., 2015; Hill et al., 2013; van der Poel et al., 2010). 
 To capture the full cost of coverage of infertility services for each year, CHBRP included the cost 
of pregnancies and births resulting from infertility services in year 1 into year 1 cost estimates. 
Similarly, for the infertility services used in year 2, costs from resulting pregnancies and births are 
included in year 2 estimates.  
 Literature based estimates of cost per pregnancy and live birth for singleton, twin, and multiple 
births take into account additional neonatal care costs associated with each type of birthweight, 
such as use of neonatal intensive care unit (NICU) services (Lemos et al., 2013). 
                                                     
31 In 2015, there were 65 infertility clinics in California with 7,802 live birth deliveries; assisted reproductive technology 
procedures per 1 million women aged 15-44 years in California = 2,869. There are recent reports regarding 
California’s role as a leading destination for infertility tourism and many clinics in the state handle a high volume of 
patients each year (Dunn J. How California became the world’s fertility treatment destination. Vogue. March 13, 2019. 
Available at: https://www.vogue.com/article/california-worlds-fertility-treatment-destination). 
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Benefit Coverage and Unit Cost 
 Infertility service coverage provided by carriers with regards to cost-sharing, number of cycles 
covered, and other limits to treatment at baseline is assumed to stay the same postmandate 
since AB 767 does not place limitations on how infertility services is to be covered by carriers.32 
 Unit cost estimates are from 2016 MarketScan and 2016 CHSD for California. Medical costs are 
trended at an annual rate of 2% per the medical component of the Consumer Price Index and 
pharmacy costs are trended at an annual rate of 7.5% per Milliman’s Health Cost Guidelines. 
For further details on the underlying data sources and methods used in this analysis, please see 
Appendix C. 
Baseline and Postmandate Benefit Coverage 
Currently, 4.3% of enrollees with health insurance that would be subject to AB 767 in DMHC-regulated 
group plans or CDI-regulated group policies have coverage for infertility treatments, including IVF (see 
Table 1). All enrollees have coverage for female surgical treatments under major medical coverage so 
surgical treatments were not modeled in this analysis. No enrollees currently have coverage for mature 
OC as defined by AB 767. AB 767 does not apply to individual market or Medi-Cal enrollees.  
Current coverage of infertility treatments and mature OC was determined by a survey of the largest (by 
enrollment) providers of health insurance in California. Responses to this survey represent 68% of 
enrollees with private market health insurance that can be subject to state mandates.  
Benefit coverage for relevant infertility services among enrollees in DMHC-regulated plans or CDI-
regulated policies would increase to 100% based on the CHBRP assumption that all noncompliant plans 
and policies at baseline would become compliant postmandate.  
Plans vary with regards to how infertility services are covered, such as imposing cost-sharing, age 
restrictions, restrictions on number of treatment cycles, or a cap on the dollar amount covered for 
services. Based on responses to the carrier survey, a portion of enrollees who currently have coverage 
for infertility services have cost sharing for infertility services that is the same as major medical services. 
For enrollees who have infertility coverage but do not have the same cost share as major medical 
services, CHBRP found in its carrier survey that coverage includes a 50% co-insurance for these 
services, including IVF, without an out of pocket maximum. Because the bill does not specify any limits on 
enrollee cost-sharing, for example specifying that fertility related out of pocket expenses not exceed a 
certain amount as for all other conditions, CHBRP assumes postmandate carriers would cover infertility 
services with the same restrictions in baseline.33  CHBRP assumed the baseline percentage of enrollees 
with infertility coverage the same as major medical services would remain unchanged postmandate. 
Enrollee cost sharing for pregnancies and births as a result of infertility services were assumed to have 
coverage the same as major medical services in the baseline and postmandate scenarios.  
                                                     
32 AB 767 does not mandate the same copayments, deductibles, and limits are applied to infertility benefits as to 
other medical or surgical benefits. A separate copayment, coinsurance, deductible, dollar maximum, visit maximum or 
procedure maximum can thus be imposed on any infertility treatment as can limiting infertility coverage to a certain 
number of egg retrievals per lifetime for the covered person. 
33 Ibid 
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Baseline and Postmandate Utilization 
CHBRP examined claims data for baseline estimates of utilization of infertility services among enrollees in 
California. There are approximately 53,000 users of female diagnostic tests at baseline and 14,000 users 
of medications for infertility (i.e., only medications and no other service). IUI baseline utilization is about 
9,000 users annually. IVF services alone (i.e. without ICSI) is estimated to have about 2,000 users and 
ICSI, which is done with IVF, is about 2,000 users annually. For males, at baseline there are 25,000 users 
of diagnostic tests and 11,000 users of any male treatment. At baseline there are an estimated 7,000 
pregnancies due to the use of infertility services and 6,000 live births from these pregnancies.  
To estimate the degree to which utilization of infertility services might shift postmandate, CHBRP 
examined the literature to obtain estimates of utilization change in states where infertility mandates have 
already been implemented. As described in the Medical Effectiveness section, studies have noted 
significant increase in utilization of IVF in mandate states compared to nonmandate states, having used 
National ART Surveillance System (NASS) data to examine increase in IVF cycles (Boulet et al., 2019; 
Crawford et al., 2016; Dieke et al., 2018). However, these studies are limited to IVF treatment and do not 
include an examination of the change in other infertility services, such as diagnostic tests and IUI. Thus, 
CHBRP obtained utilization data on all infertility services from MarketScan for a state with an existing 
mandate to be able to obtain estimates of potential postmandate change for all infertility services as 
categorized above.  
To identify the most appropriate mandate state to use in this analysis, CHBRP examined infertility 
legislation from the states whereby the state mandates included all types of infertility services (including 
explicit mention of ICSI), no specific cap on the dollar amount covered, and no cap on the number of 
cycles to determine which other states had mandates most close to the bill language laid out in AB 767. 
See Table in Appendix C for the full list of states with infertility mandates to cover IVF and limits placed by 
those mandates. Massachusetts and New Jersey were the two states identified in this process. While 
Delaware’s infertility mandate is also flagged as similar to that of California’s, it was enacted in 2018 and 
CHBRP’s claims data are for 2016, therefore postmandate utilization could not be estimated with data 
from Delaware. CHBRP determined New Jersey’s infertility mandate limits on age and egg retrievals are 
likely to be close to the types of limits carriers may issue if AB 767 were to pass since the bill does not 
specify any restrictions to placing such limits. Thus, claims data from New Jersey were used to generate 
utilization rates and these rates were applied to the California enrollee population to estimate 
postmandate utilization in California.  
An additional increase due to pent-up demand for these services was considered. Pent-up demand is 
assumed to occur given the financial burden currently cited by couples hoping to use infertility services 
but are unable to because of cost barriers (Eisenberg et al., 2010). It is assumed that utilization in the first 
and second year would be 10% greater than the NJ utilization rates. Pent-up demand for infertility 
services likely dissipates over time and utilization reaches a steady state after a few years postmandate 
(Chambers et al., 2014; Machado and Sanz-de-Galdeano, 2015). 
CHBRP did not find any source of data on baseline utilization for planned OC or likely changes 
postmandate. CHBRP estimates34 that if 2% of women aged 25–37 years used planned OC services, the 
total expenditures would increase by $319,683,000 (premium increases for private employers for group 
insurance increase 0.79% and CalPERS HMO 0.82%). If a higher share of women aged 25–37 used 
planned OC (5%), total expenditures would increase by $799,197,000 (premium increases for private 
employers for group insurance increase 1.24% and CalPERS HMO 1.31%). This assumes the average 
cost for OC is $10,078. 
                                                     
34 A utilization range of 2% to 5% was discussed and agreed upon between CHBRP and the content expert.  
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Baseline and Postmandate Per-Unit Cost 
CHBRP estimated unit cost of infertility services for females and males using 2016 MarketScan and 2016 
CHSD data (Table 1) for commercial lines of business in the state of California. Diagnostic services were 
estimated as an average cost per person receiving one or more diagnostic services. Male treatment cost 
per person was calculated similarly. Female infertility service costs were determined by assigning each 
woman with an infertility diagnosis to one of the four treatment categories (ICSI, IVF, IUI or medication 
only) or the no treatment category. All relevant costs associated with treatment for the calendar year were 
included in the average cost per user calculation. Mature OC was calculated as a case rate assuming 
95% of women had a single cycle and 5% of women had 2 cycles. For additional detail regarding the 
specific services included in each of the rates, please see Appendix C.  
CHBRP assumed literature based estimates of cost per pregnancy and live birth for singleton, twin, and 
multiple births that take into account additional neonatal care costs associated with each type of 
birthweight, such as use of neonatal intensive care unit (NICU) services (Lemos et al., 2013). The per unit 
cost of pregnancies that do not result in a live birth was developed from the 2019 Milliman Health Cost 
Guidelines and includes inpatient services for complications and pregnancies that do not result in a 
delivery due to miscarriage or abortion, maternity professional and maternity anesthesia charges. All 
medical services were trended to 2020 using 2% medical trend and 7.5% pharmacy trend. 
CHBRP considered changes in per unit cost for infertility treatments. A recent study using claims data 
from 2011 examined the magnitude by which infertility treatment expenditures incurred by health carriers 
is higher in states with infertility mandates compared to states without mandates (Boulet et al., 2019). 
Authors found that infertility treatment – IUI, medications, and IVF – expenditures per enrollee were 
higher for women living in states with an infertility mandate compared to women in nonmandate states. 
Per correspondence with the author of the study, it is unclear if any unit cost change in the services might 
have occurred postmandate. Increases in expenditures by may be driven by increased number of 
infertility treatment visits and additional services for women in mandate states. Per CHBRP’s content 
expert, it is unlikely that unit cost of infertility services would change in the short term postmandate (e.g. 
year 1 or year 2) and unclear how costs might change over the longer term. Thus, CHBRP estimates no 
unit cost change to infertility services in year 1 or 2 postmandate.  
Baseline and Postmandate Expenditures 
Table 5 and Table 6 present baseline and postmandate expenditures by market segment for DMHC-
regulated plans and CDI-regulated policies. The tables present per member per month (PMPM) 
premiums, enrollee expenses for both covered and noncovered benefits, and total expenditures 
(premiums as well as enrollee expenses). AB 767 would increase total net annual expenditures by 
$627,288,000 or 0.39% for enrollees with DMHC-regulated plans and CDI-regulated policies. This 
includes estimates for infertility services and associated pregnancies. It does not include additional 
expenditures as a result of fertility preservation services. 
Premiums 
Overall, premiums increase $537,778,000 postmandate as a result of AB 767. Changes in premiums 
would vary by market segment (see Table 5 and Table 6), with health insurance that would be subject to 
AB 767. The largest increases are among small group plans in both DMHC-regulated plans (0.68%) and 
CDI-regulated policies (0.53%). Among publicly funded DMHC-regulated CalPERS HMOs, the premium 
increase is 0.47%.  
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Enrollee Expenses 
AB 767-related changes in enrollee expenses for covered benefits (deductibles, copays, etc.) and 
enrollee expenses for noncovered benefits would vary by market segment. Note that such changes are 
related to the number of enrollees (see Table 5 and Table 6) with health insurance that would be subject 
to AB 767 expected to use infertility services during the year after enactment. CHBRP projects no change 
to copayments or coinsurance rates at baseline vs postmandate as AB 767 does not specify any 
limitations to how plans can apply coinsurance to infertility services. Because the increase in utilization of 
infertility services there would be an increase in enrollee cost sharing. The largest increases are for the 
small group plans for both DMHC-regulated and CDI-regulated plans and policies.  
Out-of-Pocket Spending for Covered and Noncovered Expenses 
CHBRP estimates the marginal impact of the bill on out-of-pocket spending for covered and noncovered 
expenses, defined as uncovered medical expenses paid by the enrollee as well as out-of-pocket 
expenses (e.g., deductibles, copayments, and coinsurance). CHBRP estimates that enrollees with 
uncovered expenses at baseline would receive on the whole a $133,897,000 reduction in their out-of-
pocket spending for covered and noncovered expenses associated with AB 767’s coverage of infertility 
services (Table 1). 
Potential Cost Offsets or Savings in the First 12 Months After Enactment 
If infertility services are covered and the financial pressure of trying to have a child with the fewest 
number of cycles is alleviated, infertility mandates can have the effect of encouraging patients to use a 
greater number of single embryo transfers. As discussed in the Medical Effectiveness section, the peer 
reviewed literature suggests that while infertility mandates increase the utilization of infertility treatments 
overall, thus increasing the potential for multiple births associated with infertility treatments, this potential 
for more costly multiple births is actually offset by a decline in the use of multiple embryo transfers (and 
increase in single embryo transfers) as seen in states with infertility mandates (Banks et al., 2010; Boulet 
et al., 2019; Crawford et al., 2016; Dieke et al., 2018; Henne and Bundorf, 2008; Jain et al., 2002; Martin 
et al., 2011; Navarro et al., 2008; Reynolds et al., 2003). This suggests that while states with infertility 
treatment insurance mandates have an increase in the number of IVF cycles, there is an offset 
associated with the reduction in financial pressure to achieve a pregnancy in the minimal number of IVF 
cycles, thus decreasing the pressure to transfer more embryos per cycle, which thus reduces birth rates 
and multiple birth rates (Martin et al., 2011). The cost model is not able to directly calculate the potential 
cost savings stemming from fewer multiple births or fewer preterm deliveries. Note that in comparing 
pregnancy and birth outcomes (namely, percent twin and percent multiple births) at baseline from 2016 
National ART Surveillance System data in California versus New Jersey, there are only small differences 
in the twin and multiple birth rates: in California, 41.2% of all IVF procedures result in pregnancy, 67.5% 
of which result in live birth, 12.4% are twin live birth, and 1.6% are multiple births. In New Jersey 
(mandate state), 41.7% of all IVF procedures result in pregnancy, 69.2% of which result in live birth, 
11.4% are twin live birth, and 1.2% are higher multiple births.  
Postmandate Administrative Expenses and Other Expenses 
CHBRP estimates that the increase in administrative costs of DMHC-regulated plans and/or CDI-
regulated policies would remain proportional to the increase in premiums. CHBRP assumes that if health 
care costs increase as a result of increased utilization or changes in unit costs, there is a corresponding 
proportional increase in administrative costs. CHBRP assumes that the administrative cost portion of 
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premiums is unchanged. All health plans and insurers include a component for administration and profit in 
their premiums. 
Other Considerations for Policymakers 
In addition to the impacts a bill may have on benefit coverage, utilization, and cost, related considerations 
for policymakers are discussed below. 
Potential Cost of Exceeding Essential Health Benefits 
As explained in the Policy Context section, infertility services required to be covered by AB 767 are not 
included in California’s EHB package. The state is required to defray the additional cost incurred by 
enrollees in qualified health plans (QHPs) for any state benefit mandate that exceeds the state’s definition 
of essential health benefits (EHBs). Coverage for infertility services, as would be required if AB 767 were 
enacted, could trigger this requirement for the state to defray related costs. 
CHBRP has considered means of projecting the potential cost to the state of enacting a benefit mandate 
that would exceed EHBs. As federal regulations are not yet final, CHBRP presents several scenarios 
regarding the cost to the state, should AB 767 be judged to exceed EHBs. Impacts would vary by market 
segment (and by market segment enrollment) (Table 4).  
Table 4. Estimated State Responsibility for Portion of Mandate that Is in Excess of EHBs, California, 2020 
    DMHC-Regulated   CDI-Regulated   
    
Small Group Individual   
Small 
Group 
Individual TOTAL 
Enrollee counts             
  
Total enrollees in 
plans/policies subject to state 
mandates 3,099,000 --   108,000 -- 3,207,000 
  
Number of enrollees in 
QHPs(a) 658,000 --   12,000 -- 670,000 
Premium cost of mandated benefit             
  
Estimated premium cost of 
mandated benefit (b) 
$6.43 -- 
  
$7.10 -- $6.45 
  
Marginal premium impact with 
offsets (c) 
$6.43 -- 
  
$7.10 -- $6.45 
  
Marginal premium impact 
considering baseline coverage 
(d) 
$3.78 -- 
  
$3.53 -- $3.77 
Estimated annual state 
responsibility for portion of 
mandate that is in excess of EHB             
  
Scenario 1 - Full estimated 
cost (e) = (a) x (b) x 12 
$50,801,000 -- 
  
$1,023,000 -- $51,823,000 
  
Scenario 2 - With cost offsets 
(f) = (a) x (c) x 12 
$50,801,000 -- 
  
$1,023,000 -- $51,823,000 
  
Scenario 3 - With baseline 
coverage offset (g) = (a) x (d) 
x 12 
$29,830,000 -- 
  
$509,000 -- $30,339,000 
Source: California Health Benefits Review Program, 2019. 
Notes: (a) States are required to defray the costs of state-mandated benefits that are in excess of the EHB for QHPs. QHPs are a 
subset of the plans offered in the individual and small group markets. AB 767 only applies to small-group QHPs.  
(b) Estimated full cost of the mandated benefit without offsets for reduction in costs for related benefits that are EHBs.   
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(c) Estimated marginal premium impact considering some of the increase in costs associated with a given benefit mandate may be 
offset by reductions in costs for related benefits that are EHBs. 
(d) Estimated marginal premium impact of the proposed mandated benefit considering some QHPs may already cover the 
mandated benefit.  It is yet to be determined whether the State is responsible for defraying the full cost of the mandated benefit in 
this circumstance. 
Key: CDI=California Department of Insurance; DMHC=Department of Managed Health Care 
Postmandate Changes in the Number of Uninsured Persons35 
Because the change in average premiums does not exceed 1% for any market segment (Table 1, Table 
5, and Table 6) for coverage of infertility treatments, CHBRP would expect no measurable change in the 
number of uninsured persons due to the enactment of AB 767. 
However, should 5% of female enrollees aged 25–37 use mature OC services as a form of fertility 
preservation, premiums would increase by more than 1% for enrollees in group and CalPERS HMO plans 
(premium increases for private employers for group insurance increase 1.24% and CalPERS HMO 
1.31%). It is unclear how the increase in premiums translates into uninsurance since not all of the 
increase is transferred to the enrollee. 
Changes in Public Program Enrollment 
CHBRP estimates that the mandate would produce no measurable impact on enrollment in publicly 
funded insurance programs due to the enactment of AB 767. 
How Lack of Benefit Coverage Results in Cost Shifts to Other Payers 
IVF generally is self-funded when there is no coverage and there may be some opportunity for enrollees 
without coverage to seek help via grant or loan programs through private organizations. There are no 
state-funded programs providing direct financial assistance to enrollees in California. In California, 
unreimbursed medical expenses are income tax deductible, following the federal deductibility threshold. 
CHBRP is unable to provide a quantifiable estimate of shifts from private grant and loan funding to health 
plans and programs postmandate.  
                                                     
35 See also CHBRP’s Uninsured: Criteria and Methods for Estimating the Impact of Mandates on the Number of 
Individuals Who Become Uninsured in Response to Premium Increases (December 2015), available at 
http://chbrp.com/analysis_methodology/cost_impact_analysis.php.  
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Table 5. Baseline Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2020 
  DMHC-Regulated  CDI-Regulated    
  Privately Funded Plans 
(by Market) (a) 
 Publicly Funded Plans  Privately Funded Plans 
(by Market) (a) 
  
 
  Large 
Group 
Small 
Group 
Individual  CalPERS 
HMOs (b) 
MCMC 
(Under 65) 
(c) 
MCMC 
(65+) (c) 
 Large 
Group 
Small 
Group 
Individual   
Total 
Enrollee counts               
 
Total enrollees in 
plans/policies 
subject to state 
mandates (d) 10,565,000 3,099,000 2,184,000 
 
523,000 6,796,000 795,000 
 
318,000 108,000 102,000 
  
24,490,000 
 
Total enrollees in 
plans/policies 
subject to AB 767 10,565,000 3,099,000 0 
 
523,000 0 0 
 
318,000 108,000 0 
  
16,899,000 
Premiums                        
 
Average portion 
of premium paid 
by employer $555.35 $341.99 $0.00  $493.71 $268.13 $694.55  $710.92 $462.84 $0.00   $118,029,198,000 
 
Average portion 
of premium paid 
by employee $39.66 $205.44 $437.39  $94.04 $0.00 $0.00  $250.37 $202.64 $475.67   $26,521,718,000 
 Total premium $595.01 $547.43 $437.39  $587.76 $268.13 $694.55  $961.29 $665.48 $475.67   $144,550,916,000 
Enrollee expenses                        
 
For covered 
benefits 
(deductibles, 
copays, etc.) $46.18 $121.03 $115.38  $48.33 $0.00 $0.00  $162.44 $186.84 $168.51   $14,750,880,000 
 
For noncovered 
benefits (e) $0.61 $1.31 $0.00  $0.47 $0.00 $0.00  $0.98 $1.24 $0.00   $133,897,000 
 
Total 
expenditures $641.80 $669.77 $552.77  $636.55 $268.13 $694.55  $1,124.71 $853.56 $644.18   $159,435,692,000 
Source: California Health Benefits Review Program, 2019. 
Notes: (a) Includes enrollees with grandfathered and nongrandfathered health insurance acquired outside or through Covered California (the state’s health insurance marketplace). 
(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents.  
(c) Medi-Cal Managed Care Plan expenditures for members over 65 include those who are also Medicare beneficiaries. This population does not include enrollees in COHS. 
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(d) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in employer-sponsored health insurance. This group includes 
commercial enrollees (including those associated with Covered California or CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.36  
(e) Includes only those expenses that are paid directly by enrollees or other sources to providers for services related to the mandated benefit that are not currently covered by 
insurance. This only includes those expenses that would be newly covered, postmandate. Other components of expenditures in this table include all health care services covered by 
insurance. 
Key: CalPERS HMOs = California Public Employees’ Retirement System Health Maintenance Organizations; CDI = California Department of Insurance; COHS = County Organized 
Health Systems; DMHC = Department of Managed Health Care; MCMC = Medi-Cal Managed Care. 
 
                                                     
36 For more detail, see Estimates of Sources of Health Insurance in California, available at  http://chbrp.com/analysis_methodology/cost_impact_analysis.php.   
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Table 6. Postmandate Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2020 
  DMHC-Regulated  CDI-Regulated   
  Privately Funded Plans 
(by Market) (a) 
 Publicly Funded Plans  Privately Funded Plans 
(by Market) (a) 
  
  Large 
Group 
Small 
Group 
Individual  CalPERS 
HMOs (b) 
MCMC 
(Under  
65) (c) 
MCMC 
(65+) (c) 
 Large 
Group 
Small 
Group 
Individual  Total 
Enrollee counts              
 
Total enrollees in 
plans/policies 
subject to state 
mandates (d) 10,565,000 3,099,000 2,184,000 
 
523,000 6,796,000 795,000 
 
318,000 108,000 102,000 
 
24,490,000 
 
Total enrollees in 
plans/policies 
subject to AB 767 10,565,000 3,099,000 2,184,000 
 
523,000 0 0 
 
318,000 108,000 0 
 
14,613,000 
Premiums                       
 
Average portion of 
premium paid by 
employer $2.6831 $2.3264 $0.00  $2.3166 $0.00 $0.00  $2.5089 $2.4591 $0.00  $453,977,000 
 
Average portion of 
premium paid by 
employee $0.1916 $1.3976 $0.000  $0.4413 $0.00 $0.00  $0.8836 $1.0766 $0.00  $83,801,000 
 Total premium $2.8747 $3.7240 $0.00  $2.7578 $0.00 $0.00  $3.3925 $3.5357 $0.00  $537,778,000 
Enrollee expenses              
 
For covered 
benefits 
(deductibles, 
copays, etc.) $1.0990 $1.8821 $0.00  $1.0896 $0.00 $0.00  $1.2635 $1.8763 $0.00  $223,409,000 
 
For noncovered 
benefits (e) -$0.6071 -$1.3082 $0.00  -$0.4650 $0.00 $0.00  -$0.9816 -$1.2411 $0.00  -$133,897,000 
 
Total 
expenditures $3.3665 $4.2979 $0.00  $3.3824 $0.00 $0.00  $3.6744 $4.1710 $0.00  $627,290,000 
Percent change              
 Premiums 0.4831% 0.6803% 0 %  0.4692% 0 % 0 %  0.3529% 0.5313% 0%  0.3720% 
 
Total 
expenditures 0.5245% 0.6417% 0 %  0.5314% 0 % 0 %  0.3267% 0.4887% 0%  0.3934% 
Source: California Health Benefits Review Program, 2019. 
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Notes: (a) Includes enrollees with grandfathered and nongrandfathered health insurance acquired outside or through Covered California (the state’s health insurance marketplace). 
(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents.  
(c) Medi-Cal Managed Care Plan expenditures for members over 65 include those who are also Medicare beneficiaries. This population does not include enrollees in COHS. 
(d) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in employer-sponsored health insurance. This group includes 
commercial enrollees (including those associated with Covered California or CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.37  
(e) Includes only those expenses that are paid directly by enrollees or other sources to providers for services related to the mandated benefit that are not currently covered by 
insurance. This only includes those expenses that would be newly covered, postmandate. Other components of expenditures in this table include all health care services covered by 
insurance. 
Key: CalPERS HMOs = California Public Employees’ Retirement System Health Maintenance Organizations; CDI = California Department of Insurance; COHS = County Organized 
Health Systems; DMHC = Department of Managed Health Care; MCMC = Medi-Cal Managed Care. 
 
                                                     
37 For more detail, see Estimates of Sources of Health Insurance in California, available at  http://chbrp.com/analysis_methodology/cost_impact_analysis.php.   
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PUBLIC HEALTH IMPACTS 
As discussed in the Policy Context section, AB 767 would modify the current infertility mandate, which 
requires health plans and policies to offer coverage for infertility services, excluding in vitro fertilization 
(IVF) coverage. In contrast, AB 767 would require group health plans and policies, excluding the 
individual market and Medi-Cal, to provide coverage for infertility treatments, including IVF, and mature 
oocyte cryopreservation (planned oocyte preservation). 
The public health impact analysis includes estimated impacts in the short term (within 12 months of 
implementation) and in the long term (beyond the first 12 months postmandate). This section estimates 
the short-term impact38 of AB 767 on infertility treatment-relevant public health impacts (i.e., fertility 
outcomes, mental health outcomes, and quality of life), potential harms of treatment use, and potential 
impacts on disparities with respect to treatment use and outcomes. See Long-Term Impacts for a 
discussion of public health impacts regarding planned oocyte cryopreservation (OC), premature death, 
and economic loss. 
Estimated Public Health Outcomes 
Measurable public health outcomes relevant to AB 767 include mental health and quality of life, multiple 
gestation outcomes, and impact on barriers to infertility treatments.  
As presented in the Medical Effectiveness section, there is a preponderance of evidence that state health 
insurance mandates for infertility treatments are associated with an increase in utilization of those 
treatments, including IVF. There is also a preponderance of evidence that IVF is an effective treatment for 
infertility and planned oocyte preservation is an effective step to preserve infertility and as a treatment for 
future infertility in conjunction with IVF.  
As presented in the Benefit Coverage, Utilization, and Cost Impacts section, 4.3% of enrollees with health 
insurance subject to AB 767 have coverage for infertility treatments, including IVF, and no enrollees have 
coverage for planned OC at baseline. If enacted, CHBRP estimates that the proportion of enrollees with 
insurance coverage for infertility treatment, including IVF and planned OC, would increase to 100% 
postmandate. In addition, the number using diagnostic infertility services would increase from 78,000 to 
85,000 and the number using infertility treatment services would increase from 38,000 enrollees to 55,000 
enrollees in the first year postmandate. The additional 17,000 persons (1,000 males and 16,000 females) 
would newly use all forms of infertility treatment and demonstrate the greatest increases for IVF with ICSI 
use among females (350% increase) and general treatment for males (9% increase). 
As presented in Table 1, CHBRP estimates that the number of pregnancies resulting from infertility 
treatments in the first year postmandate will increase the number of pregnancies by 6,000 (from 7,000 to 
13,000) and the number of live births by 5,000 (from 6,000 to 11,000).These estimates are supported by 
a preponderance of evidence that infertility treatments, including IVF and planned oocyte preservation, 
are medically effective and that health insurance benefit mandates are effective in increasing utilization of 
treatments for infertility, including IVF.    
                                                     
38 CHBRP defines short-term impacts as changes occurring within 12 months of bill implementation. 
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Mental Health and Quality of Life Outcomes 
Receiving an infertility diagnosis can be a cause of stress, distress, anxiety, and depression among both 
female and male partners (Greil et al., 2010; Zurlo et al., 2018) The stress attributable to infertility in 
females has been compared to that experienced by female cancer patients (Roudsari et al., 2007). In one 
study of heterosexual couples seeking infertility treatments, nearly one-third of females reported 
depression, with 13% reporting severe depressive symptoms (Nelson et al., 2008). Higher levels of 
psychological distress and diminished quality of life have been found among females who view their 
future happiness as contingent on becoming a parent (Greil et al., 2010), among Asian women in the 
United States (Greil et al., 2016), and among couples experiencing infertility for three years or longer 
(Zurlo et al., 2018). 
CHBRP also reviewed literature regarding the psychosocial impacts of undergoing treatment for infertility. 
Milazzo et al. (2016) conducted a recent systematic review and meta-analysis of 21 studies including 
7,258 women and 5,653 that evaluated depression and anxiety outcomes associated with ART failures 
(i.e., a pregnancy did not result after embryo transfer occurred). Results of the meta-analysis showed that 
infertility-associated depression and anxiety significantly increased for both men and women in the period 
directly following a failed ART treatment. Although both depression and anxiety slightly decreased in the 6 
months following a failed ART cycle, higher levels of both conditions were observed compared to before 
the participants engaged in ART. Following a treatment failure, men and women both reported more 
adverse emotional adjustment outcomes, such as anger and low self-esteem, as compared with baseline 
and compared to persons who experienced treatment success. Overall women with treatment failures 
experienced a higher level of negative emotional outcomes as compared with men, including more guilt, 
anger, frustration, and powerlessness, as well as less happiness and confidence (Milazzo et al., 2016). 
According to one study, the average number of ART cycles needed before a pregnancy success was 3.4 
(Katz et al., 2011), therefore it is likely that the incidence of psychosocial distress would increase among 
the women and men who would newly use ART as a result of this bill. 
Although experiencing infertility and undergoing infertility treatments is associated with significant mental 
health and quality of life deficits, CHBRP identified evidence showing that achievement of a successful 
pregnancy through infertility treatment may alleviate the psychosocial burden of these experiences. One 
study measuring life satisfaction among women with infertility participating in the National Survey of 
Fertility Barriers found that women who successfully conceived a pregnancy with medical intervention 
reported significantly higher life satisfaction levels than women who did not have a successful treatment 
experience or who never sought treatment for their infertility (McCarthy and Chiu, 2011). In addition, 
results of a recent systematic review and meta-analysis evaluating depression and anxiety associated 
with ART outcomes among a cumulative 7,258 women and 5,653 men demonstrated that a successful 
ART treatment was associated with a statistically significant decrease in depression as compared with 
patient-reported depression levels prior to treatment. Moreover, persons who experienced treatment 
success exhibited lower levels of emotional distress and isolation and reported healthier marital 
relationships as compared with persons who experienced treatment failure with ART (Milazzo et al., 2016)  
Although CHBRP found evidence that engaging in infertility treatments may result in short-term 
psychosocial harms, evidence-based literature also indicates that the inability to have wanted children is 
itself associated with stress, anxiety, depression, and quality of life deficits that are likely to decrease 
upon the achievement of a successful pregnancy through treatment. Therefore, it stands to reason that 
mental health and quality of life would improve for the additional 5,000 persons and couples who would 
have a live birth resulting from infertility treatments postmandate. 
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Although persons experiencing infertility and engaging in unsuccessful treatment may experience mental 
health and quality of life deficits, it is important to consider that the alternative to treatment is having no 
children or pursuing adoption which may not be acceptable or feasible for many enrollees with infertility. 
Potential Harms from Multiple Births with Infertility Treatment 
When data are available, CHBRP estimates the marginal change in relevant harms associated with 
interventions affected by the proposed mandate. In the case of AB 767 there is evidence to suggest that 
an increase in the use of infertility treatments could result in harm. Potential harms associated with the 
use of infertility treatments, include increased risk of adverse maternal and perinatal outcomes associated 
with multiple births. 
As described in the Medical Effectiveness section some treatments for infertility, particularly IVF and 
ovulation stimulating medications, increase the risk of having multiple gestation pregnancies, which are 
associated with an increased risk of maternal and perinatal complications, including preeclampsia, 
preterm birth, and low birthweight (2017; Martin et al., 2018). Although these risks are not greater than 
those experienced by women with multiple gestation pregnancies conceived without ART, the incidence 
of twins and higher-order multiples is disproportionately greater among persons undergoing ART than 
among the general population (twins: 19% vs. 3%; triplets or more: 0.6% vs. 0.1%) (Martin et al., 2018).  
CHBRP’s literature search identified several studies suggesting that the high rate of multiple births with 
ART may be, in part, attributable to the high financial burden of uncovered treatment costs posed to the 
individual39 (Banks et al., 2010; Kulkarni et al., 2017; Martin et al., 2011; Smith et al., 2011). Among a 
cohort of couples receiving care at infertility clinics in San Francisco, Smith et al. (2011) observed that 
higher income couples were significantly more likely to use more cycles of IVF over an 18-month period 
as compared with lower-income women, but did not experience significantly different live birth outcomes, 
suggesting that lower-income women may have been incentivized by high costs to transfer multiple 
embryos in order to increase the chance of conception with fewer cycles. Moreover, Martin et al. (2011) 
and Kulkarni et al. (2017) found that rates of multiple births and multiple embryo transfers were 
significantly lower among persons undergoing ART in states with insurance benefit mandates for ART; 
however, rates of multiple gestation pregnancies with ART in mandated states remained higher than the 
general population. This effect appears to be more pronounced among older women and may further vary 
based on the fertility beliefs and cultural attitudes towards infertility treatment of the recipients (Banks et 
al., 2010). 
Comparing pregnancy and birth outcomes (namely, percent twin and percent multiple births) at baseline 
from 2016 National ART Surveillance System data, in California, 41.2% of all IVF procedures result in 
pregnancy, 67.5% of which result in live birth, 12.4% are twin live birth, and 1.6% are multiple births. In 
New Jersey (mandate state), 41.7% of all IVF procedures result in pregnancy, 69.2% of which result in 
live birth, 11.4% are twin live birth, and 1.2% are higher-order multiple births.  
CHBRP estimates that, postmandate, AB 767 would increase utilization of IVF and ovulation-stimulating 
medications among enrollees with state-regulated insurance, which could result in an increase in the rate 
of multiple births and associated adverse maternal and fetal outcomes among the enrollees who would 
contribute to the additional 7,000 pregnancies projected to occur with infertility treatment in the first year 
postmandate. However, to the extent that insurance benefit mandates promote single embryo transfers 
during individual cycles of IVF by alleviating uncovered out-of-pocket costs, some of the potential risk for 
multiple births with IVF in California could be attenuated. 
                                                     
39 The median cost of one cycle of IVF, including medications, in the United States is $19,234 (Wu et al., 2014). 
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Impact on Disparities40 
Insurance benefit mandates that bring more state-regulated plans and policies to parity may change an 
existing disparity. As described in the Background section, disparities in infertility and infertility treatment 
use exist by race/ethnicity and gender identity/sexual orientation. Within the first year postmandate, 
CHBRP estimates AB 767 could create or exacerbate disparities in gender identity and sexual orientation 
and would have no impact on racial/ethnic disparities. (For discussion of potential impacts beyond the first 
12 months of implementation see the Long-Term Impacts section.) 
Impact on Racial or Ethnic Disparities 
As presented in the Background section, infertility rates are highest among racial and ethnic minorities, 
yet utilization of infertility treatments is highest among non-Hispanic whites (Chandra et al., 2013; Craig et 
al., 2019; Janitz et al., 2018). Furthermore, studies have shown that black and Hispanic women wait 
longer to seek care for an infertility diagnosis as compared with white women (Chin et al., 2015). In 
addition, CHBRP found evidence suggesting that, as compared with white women, racial and ethnic 
minority groups experience less infertility treatment success, with respect to pregnancies and births, and 
are also more likely to experience multiple gestation pregnancies, which have been associated with 
increased risk of adverse maternal and perinatal outcomes (Humphries et al., 2016; McQueen et al., 
2015; Quinn and Fujimoto, 2016). 
The medical effectiveness review found a preponderance of evidence that insurance benefit mandates 
increase utilization of infertility treatments in general and for IVF, specifically. However, CHBRP’s 
literature review found evidence suggesting that insurance benefit mandates may not impact the 
differential use and treatment outcomes observed among racial and ethnic minorities as compared with 
whites. In Massachusetts, a state with an insurance benefit mandate for infertility care, Jain et al. (2005) 
compared the racial and ethnic distribution of patients at a large infertility treatment clinic to the statewide 
distribution and found that Hispanics were disproportionately underrepresented, accounting for 6.8% of 
the state population but only 3.9% of infertility patients. Differential use by Hispanic populations was also 
observed in an equal-access military health setting, with Hispanics accounting for 9% of the Department 
of Defense, but only 4% of persons seeking infertility care in a military healthcare setting (Feinberg et al., 
2007). More recently, Dieke et al. (2017) analyzed use of ART by all racial and ethnic groups reported in 
the 2014 National ART Surveillance System (NASS) database and stratified use rates by state insurance 
mandate status. Although ART utilization rates were significantly higher among all racial and ethnic 
groups in states with insurance benefit mandates, as compared with nonmandate states, the differences 
in rates by racial and ethnic groups persisted, with the lowest rates observed for Hispanic and non-
Hispanic black women regardless of mandate status.  
CHBRP identified two studies that describe the impact of insurance benefit mandates on racial and ethnic 
differences in treatment outcomes, such as multiple gestation pregnancies and miscarriages. In the first, 
Feinberg et al. (2006) compared treatment outcomes in a military population with insurance for infertility 
treatment and found that African American patients experienced a significantly higher miscarriage rate 
and lower live birth rate with ART as compared with non-Hispanic white patients. This result is consistent 
with the previously-described racial and ethnic disparities in ART outcomes among the general population 
(Humphries et al., 2016; McQueen et al., 2015). In the second study, Luke et al. (2016) observed that the 
rate of multiple gestation pregnancy and preterm births among singleton pregnancies did not differ for 
                                                     
40 For details about CHBRP’s methodological approach to analyzing disparities, see the Benefit Mandate Structure 
and Unequal Racial/Ethnic Health Impacts document here: 
http://chbrp.com/analysis_methodology/public_health_impact_analysis.php. 
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Hispanic and non-Hispanic black populations using ART in states with insurance benefit mandates (i.e., 
Massachusetts) as compared with nonmandate states (i.e., Florida and Michigan).  
These findings suggest that economic barriers are not the primary mediators of who does and does not 
access infertility care with respect to racial and ethnic groups. Rather, as described in the Background 
section, cultural and social factors, such as ethical reservations about medical intervention for conception 
or intercommunity stigma regarding infertility, may play a larger role. 
Racial and ethnic disparities in the prevalence of infertility have been consistently documented; 
furthermore, disparities in use and outcomes of infertility treatments have also been described for racial 
and ethnic minorities. However, CHBRP found literature indicating that racial and ethnic disparities in 
infertility treatment use and outcomes persist in states with insurance benefit mandates for infertility care. 
Therefore, CHBRP estimates that AB 767 would have no impact on racial and ethnic disparities in 
infertility prevalence, treatment use, or outcomes.   
Impact on Disparities by Marital Status or Sexual Orientation 
As described in the Background section, an increasing number of single persons and same-sex couples 
are pursuing biological reproduction through infertility treatments; however, these populations face 
disproportionate barriers to infertility treatment as compared with opposite-sex couples.  
Advocacy and professional groups have described access barriers to single persons and same-sex 
couples on the basis of definitional discrimination wherein infertility is often defined only among persons 
who have attempted to become pregnant through 12 months of regular intercourse with an opposite-sex 
partner. By definition, same-sex couples and single persons cannot meet this standard. CHBRP did not 
find any literature addressing the differential impact of more- or less-inclusive infertility definitions for 
coverage of infertility on disparities in marital status or sexual orientation. However, if passed, AB 767 
would amend the current infertility treatment benefit mandate in California by removing the definitional 
clause defining infertility by the aforementioned clinical standard and would solely define infertility as “the 
presence of a demonstrated condition recognized by a licensed physician and surgeon as a cause of 
infertility.” This definition relies on the interpretation of a physician or surgeon, who would be free to 
recognize the lack of a biologically compatible partner as a cause of infertility. Moreover, this definition 
does not arbitrarily impose time-related barriers, which are often not meaningful to same-sex couples. If 
enacted, AB 767 would also preserve the current nondiscrimination clause that prohibits the denial of 
coverage for infertility treatments on the basis of marital status or sexual orientation. 
Although AB 767 would mandate coverage for all infertility treatments, including IVF, it does not mandate 
coverage for the donor materials (i.e., sperm, embryos, gestational carriers) that all single persons and 
same-sex couples need in order to have a baby. This may create a financial-related disparity wherein 
same-sex couples retain higher out-of-pocket costs as compared with opposite-sex couples who may not 
need to utilize donor materials to conceive. For example, one study conducted among almost 400 women 
at eight reproductive endocrinology clinics in California found that the median cost for one cycle of 
standard IVF was $24,373 whereas the median cost of one cycle of IVF with donor eggs was $38,015, 
which, if AB 767 were enacted, would account for nearly an additional $14,000 in uncovered expenses 
(Katz et al., 2011). Analysis of the same cohort found that the median out-of-pocket cost for one round of 
artificial insemination with partner sperm was $2,623 which is about half of what the National LGBT 
Health Education Center estimates artificial insemination with donor sperm would cost ($5,000) (National 
LGBT Health Education Center, 2019; Wu et al., 2014). Estimates for infertility treatment using a 
gestational carrier range from range from $80,000 to $140,000 depending on medical and legal 
arrangements (National LGBT Health Education Center, 2019). 
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In a similar manner, lack of coverage for donor materials could potentially create a financial disparity 
between male and female same-sex couples and singles who are attempting to conceive as males need 
to utilize IVF with donor eggs and gestational carriers in order to conceive, which, as described above, is 
a more expensive process as compared to artificial insemination with donor sperm needed for female 
same-sex or single conception. Additionally, CHBRP assumes that, whereas most infertility treatments 
would have minimal cost-sharing burdens postmandate, IVF would likely be subject to the 50% cost-
sharing policies observed in other states with health insurance benefit mandates. Subsequently, this 
differential financial burden could potentially lead to a disparity in utilization of infertility treatments.  
AB 767 would remove language from current law that defines infertility between opposite-sex couples and 
expand the definition of infertility to any condition recognized by a physician or surgeon as a cause of 
infertility, thereby potentially removing one barrier to care. However, CHBRP did not identify any 
evidence-based literature regarding the potential impact of insurance mandates on infertility-related 
disparities among same-sex couples, nor did CHBRP find literature assessing the impact of definitional 
changes in law that may impact the way that same-sex couples access infertility care. Therefore, the 
impact on gender identity and sexual orientation disparities is unknown.  
It should be noted that, in not mandating coverage for donor materials and gestational carriers, the 
implementation of AB 767 could exacerbate or create disparities between same-sex couples/single 
persons and opposite sex couples, or create a disparity between male and female same-sex couples or 
singles. However, the potential magnitude of this effect is unknown.  
Impact on Socioeconomic Disparities 
As described in the Background section, cost is one of the most significant barriers to treatment for 
infertility and is experienced as both high out-of-pocket spending and loss of wages from missed work 
due to treatment administration. Consequently, persons with high income demonstrate disproportionately 
greater use of treatments for infertility, are more likely to use higher-intensity (and higher cost) treatments, 
and seek treatment for infertility earlier as compared with persons who have low income.   
If enacted, AB 767 would expand the definition of infertility and mandate coverage for all non-
experimental infertility treatments, including IVF, for all state-regulated commercial group and CalPERS 
plans in California. These provisions, as described in the Medical Effectiveness and Cost sections, would 
result in a reduction of $133,897,000 in previously uncovered expenses associated with these treatments 
and a corresponding increase in utilization for all infertility diagnostics and treatments, primarily among 
persons with no or insufficient coverage at baseline. In this manner, cost-related treatment barriers may 
be attenuated thereby reducing income-associated disparities in infertility treatment use postmandate 
among enrollees impacted by AB 767. However, AB 767 does not limit the extent of cost-sharing for 
infertility treatments, which may temper the magnitude significantly if high co-insurance structures are 
applied as observed in other mandated states, like New Jersey (see the Benefit Coverage, Cost, and 
Utilization section for more information).  
Although documented income-related disparities in infertility treatment use may be alleviated among 
enrollees with commercial group and CalPERS coverage, it should be noted that AB 767 does not apply 
to Medi-Cal and the individual market. By definition, Medi-Cal enrollees are low-income, as are a 
significant portion of enrollees in the individual market. Excluding these groups may result in the 
persistence of high out-of-pocket expense burdens on those with comparably small disposable incomes, 
thereby exacerbating infertility treatment use and outcome disparities between high- and low-income 
enrollees. 
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If enacted, AB 767 would reduce out-of-pocket spending by $133,897,000 among enrollees in commercial 
group and CalPERS plans without coverage for infertility treatments at baseline and, as a result, increase 
utilization of treatments among these enrollees in the first year postmandate. To the extent that the 
mandated coverage would attenuate cost-related barriers to infertility treatment access and use, 
disparities by income level would be reduced; however, it is unknown how the increase in utilization and 
would be distributed across income-levels, therefore the magnitude of this effect is unknown.  
It should be noted that, in excluding Medi-Cal and commercial plans sold on the individual market, a 
significant portion of low-income persons in California would continue to face high out-of-pocket and 
uncovered costs for infertility treatment, which could potentially exacerbate income-related disparities in 
treatment use and infertility outcomes.   
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LONG-TERM IMPACTS 
In this section, CHBRP estimates the long-term impact41 of AB 767, which CHBRP defines as impacts 
occurring beyond the first 12 months after implementation. These estimates are qualitative and based on 
the existing evidence available in the literature. CHBRP does not provide quantitative estimates of long-
term impacts because of unknown improvements in clinical care, changes in prices, implementation of 
other complementary or conflicting policies, and other unexpected factors. 
Long-Term Utilization and Cost Impacts 
Utilization Impacts  
As discussed above, in the short-term, the aggregate pregnancy and birth rate is expected to increase 
postmandate due to increased utilization of infertility services. In the longer term, it is possible that the 
coverage of infertility services results in encouraging couples to undergo infertility treatment earlier than 
they would normally and where pregnancy might be achieved naturally (Machado and Sanz-de-
Galdeano, 2015). It is also possible that in the longer-term the coverage of infertility services might 
encourage delays in child bearing, thus shifting utilization to females on the upper end of the age 
spectrum where infertility services are still clinically appropriate.  
Cost Impacts 
A recent study using claims data from 2011 examined the magnitude by which infertility treatment 
expenditures incurred by health carriers is higher in states with infertility mandates compared to states 
without mandates (Boulet et al., 2019). Authors found that infertility treatment — IUI, medications, and 
IVF — expenditures per enrollee were higher for women living in states with an infertility mandate 
compared to women in nonmandate states. This could be driven by the increased number in infertility 
treatment visits and medication claims for these women in mandate states. Per correspondence with the 
author of the study, it is unclear if any unit cost change in the services might have occurred postmandate. 
It is unclear if costs of infertility services change when mandates are introduced. Per CHBRP’s content 
expert, it is possible that over time as infertility services are covered, there may be pressure to clinics to 
accept lower reimbursement for services. It is also possible that clinics decide to move out of network with 
carriers if contract rates are not high enough. There are no studies examining market changes when 
infertility mandates have been introduced in other states.  
Long-Term Public Health Impacts 
Some interventions in proposed mandates provide immediate measurable impacts (e.g., maternity service 
coverage or acute care treatments) while other interventions may take years to make a measurable 
impact (e.g., coverage for tobacco cessation or vaccinations). When possible, CHBRP estimates the long-
term effects (beyond 12-months postmandate) to the public’s health that would be attributable to the 
mandate, including impacts on long-term health outcomes, disparities, the social determinants of health, 
premature death, and economic loss. In the case of AB 767, long-term health outcomes are presented for 
IVF, planned oocyte cryopreservation (OC), as well as impacts on premature death and economic loss.  
                                                     
41 See also CHBRP’s Criteria and Guidelines for the Analysis of Long-Term Impacts on Healthcare Costs and Public 
Health, available at http://www.chbrp.org/analysis_methodology/cost_impact_analysis.php.  
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Long-Term Health Outcomes for Planned Oocyte Cryopreservation 
CHBRP found one study reporting on live birth outcomes for women using planned OC. Cobo et al. 
(2018) report that over a 10-year period, 12.1% percent of women using planned OC retrieved frozen 
oocytes and 18% of these women had live births. In the case of AB 767, CHBRP estimates that an 
additional 31,700 females (2% of female enrollees aged 25–37) would utilize planned OC annually as a 
result of AB 767, and an estimated 3,806 females newly covered for planned OC in a given year would 
eventually retrieve the frozen eggs. Given that the live birth rate reported in the Cobo analysis is 18%, 
about 685 live births would occur in the original cohort of 1,586,000 newly covered females using planned 
fertility preservation.42 Note that more than one ART cycle may be required to achieve the live birth. 
For each cohort of females electing to undergo mature OC for the prevention of age-related infertility in a 
given year, CHBRP estimates the long-term marginal impact of AB 767 would yield about 685 more live 
births among these women over time.  
Although AB 767 would decrease the financial burden of planned OC services in the short term, AB 767 
would not cover future storage costs, which can range from $100 to $1,500 per year (average $300/year) 
(Mesen et al., 2015). These additional uncovered costs may have an impact on the demand for these 
services, but the magnitude of this effect is unknown.  
Potential Harms Associated with Planned Oocyte Cryopreservation and IVF  
Those who elect to undergo planned OC, and who later experience infertility, must use assisted 
reproductive technology (ART) to utilize the frozen oocytes and become pregnant.  
CHBRP identified a single study assessing perinatal outcomes for children born from frozen oocytes. 
Cobo et al. (2014) reported that 1,027 babies were born from cryopreserved oocytes in 2014 with no 
observed increase in the rate of obstetric problems (e.g., gestational diabetes, preeclampsia, preterm 
birth) or perinatal deficits (e.g., low birthweight, congenital abnormalities, gestational age at birth) 
compared to babies born from ART procedures using fresh oocytes.  
The American Society of Reproductive Medicine’s Ethics Committee opinion on oocyte preservation 
states that uncertainties remain around the efficacy of planned oocyte preservation in reducing future 
infertility, and women must be informed that the benefits and harms are not fully understood. Planned OC 
does not guarantee future successful fertilization or pregnancy (2018). Moreover, whereas planned OC 
may allow women to successfully utilize IVF at older ages, it is possible that the burden of adverse 
maternal and perinatal adverse outcomes associated with advanced maternal age pregnancies would 
increase. 
As in the medical effectiveness discussion of harms related to IVF, in the case of multiple embryo transfer 
and multiple gestation, which is more common after IVF than occurs spontaneously (19% vs 3% for twins 
and 0.6% vs 0.1% for higher order multiples), there is an increased risk of pre-term birth compared to 
singleton gestations and compared to non-IVF multiple gestations. Children born pre-term have a higher 
risk of developmental issues such as cerebral palsy that can lead to long-term health, education, and 
social support needs (Martin et al., 2018).   
                                                     
42 Should 5% of female enrollees ages 25-37 used planned OC (79,300 enrollees), an estimated 9,516 women would 
retrieve the frozen oocytes, and an estimated 1,713 additional live births would occur in the original cohort of 
1,586,000 newly covered females using planned fertility preservation.  
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Evidence-based literature indicates that fertility preservation poses no higher risk to the health outcomes 
of children conceived with cryopreserved transfers as compared with ART-conceived children from fresh 
transfers. Additionally, literature indicates that, although there are harms to utilizing ART for conception 
and pregnancy with or without planned oocyte preservation, these are small and the alternative is lack of 
fertility. 
Impacts on Premature Death and Economic Loss 
Premature death 
Premature death is often defined as death occurring before the age of 75 years (Cox, 2006).43 In 
California, it is estimated that there are nearly 102,000 premature deaths each year, accounting for about 
1.9 million years of potential life lost (YPLL) (CDPH, 2011).  
Females 
A recent study examining long-term health outcomes in 78,000 women enrolled in the Prostate, Lung, 
Colorectal, and Ovarian (PLCO) cancer screening trial, found that women who reported an infertility 
diagnosis had a 10% increased risk of all-cause mortality and a 20% increased risk of cancer-related 
mortality after 13 years of follow-up as compared with women who never experienced infertility. The 
authors stated that it was not possible to ascertain whether the excess mortality among women with 
infertility was driven by the experience of infertility itself or whether it was the underlying conditions that 
caused infertility in individuals that contributed to premature death (Stentz et al., 2017). Therefore, it is 
unknown if treatment for infertility would reduce premature death.  
Males 
CHBRP identified one study that evaluated the risk of premature death associated with infertility in males. 
Among almost 12,000 men (average age evaluated for infertility at infertility clinics in California and 
Texas, Eisenberg et al. (2014) observed that men diagnosed with male-factor infertility due to two or more 
sperm defects (i.e., motility, concentration, volume, count) had 2.3 times the risk of early death compared 
to men with normal sperm over an average 7.7 years of follow-up. The average age at death observed 
among men in the California cohort was 44 years. As with women, the authors noted that infertility alone 
may be an indicator of underlying disease or diminished fitness that could lead to worse health outcomes 
later in life (Eisenberg et al., 2014). Therefore, it is unknown if treatment for infertility would reduce 
premature death. 
Infertility is associated with increased risk of death in both females and males as compared with the fertile 
population, although it is unclear to what extent excess mortality risk is attributable to infertility itself or to 
the underlying health conditions that cause infertility; therefore, the impact of AB 767 on premature death 
among enrollees who are subject to the bill is unknown.  
Economic loss 
Economic loss associated with disease is generally presented in the literature as an estimation of the 
value of the YPLL in dollar amounts (i.e., valuation of a population’s lost years of work over a lifetime). In 
                                                     
43 The overall impact of premature death due to a particular disease can be measured in years of potential life lost 
prior to age 75 and summed for the population (generally referred to as “YPLL”) (Cox, 2006). For more information 
about CHBRP’s public health methodology, see 
http://chbrp.com/analysis_methodology/public_health_impact_analysis.php.  
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addition, morbidity associated with the disease or condition of interest can also result in lost productivity 
by causing a worker to miss days of work due to illness or acting as a caregiver for someone else who is 
ill. 
CHBRP identified one study that estimated productivity loss among women and men undergoing 
treatment for infertility. Among a cohort of 318 couples seeking infertility care at eight US infertility 
practices who recorded diaries of the time spent pursuing infertility care over an 18-month period, the 
average amount of time spent on fertility care was 125 hours, which is equivalent to 15.6 work days. 
Overall, IVF was the most time-costly treatment, requiring an average of 162 hours to complete one cycle, 
followed by IUI (70 hours) and ovulation medications (25.7 hours). Among couples pursuing the 
treatments mandated by AB 767, provider visits accounted for the greatest time loss. Although health 
insurance coverage status for infertility treatment was recorded, it was not found to be significantly 
associated with any treatment-related time differences (Wu et al., 2013).  
Among the 37,500 women who utilize mature oocyte preservation as a preventive therapy for infertility as 
mandated by AB 767, some of the time-cost of IVF would be offset if they choose to utilize their already 
frozen eggs. Although women who elect to freeze their eggs still need to undergo IVF to fertilize and 
implant the eggs, they would not duplicate the time investment required to retrieve oocytes during the 
infertility treatment process. Additionally, given that the previously harvested oocytes may be more likely 
to be viable due to the early age at which they were retrieved, women utilizing IVF after planned oocyte 
preservation may require fewer cycles, and therefore fewer productive hours missed, to achieve a 
successful pregnancy. It is possible that some of the women who engaged in planned oocyte 
preservation would have other underlying causes of infertility at the time of retrieval, but for those who 
can make use of their preserved oocytes, the time-cost associated with egg retrieval on the back end 
could be substantially reduced. 
Infertility treatments are costly in terms of time to search for and undergo treatments. Although CHBRP 
estimates that AB 767 would decrease financial burden and increase utilization associated with these 
treatments, CHBRP concludes that AB 767 would not impact economic loss since the mandate does not 
alter the procedures or time-investment required to undergo infertility treatment. For the 31,700 (2%) to 
79,300 (5%) women who would undergo planned OC, the time-cost of this treatment would be distributed 
over two time periods but would amount to the same cumulative burden.  
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APPENDIX A  TEXT OF BILL ANALYZED 
On February 20, 2019, the California Assembly Committee on Health requested that CHBRP analyze AB 
767.  
Below is the bill language, as it was introduced on February 19, 2019. Immediately following is the bill 
language as amended on April 9, 2019. CHBRP incorporated these amendments into the analysis.  
 
ASSEMBLY BILL No. 767 
 
 
Introduced by Assembly Member Wicks 
(Principal coauthors: Assembly Members Burke and Low) 
(Principal coauthor: Senator Stern) 
 
February 19, 2019 
 
An act to amend Sections 1248 and 1374.55 of the Health and Safety Code, and to amend 
Section 10119.6 of the Insurance Code, relating to healthcare coverage. 
 
LEGISLATIVE COUNSEL'S DIGEST 
 
AB 767, as introduced, Wicks. Healthcare coverage: infertility. 
 
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure 
and regulation of health care service plans by the Department of Managed Health Care and makes 
a willful violation of the act a crime. Existing law provides for the regulation of health insurers by 
the Department of Insurance. Existing law imposes various requirements and restrictions on health 
care service plans and health insurers, including, among other things, a requirement that every 
group health care service plan contract or health insurance policy that is issued, amended, or 
renewed on or after January 1, 1990, offers coverage for the treatment of infertility, except in vitro 
fertilization, under those terms and conditions as may be agreed upon between the group subscriber 
or the group policyholder and the health care service plans or the health insurers. Existing law 
provides that any employer that is a religious organization or health care service plans and health 
insurers which are a subsidiary of an entity whose owner or corporate member is a religious 
organization shall not be required to offer coverage for forms of treatment of infertility in a manner 
inconsistent with the religious organization’s religious and ethical principles, as specified. 
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This bill would require every health care service plan contract or health insurance policy that is 
issued, amended, or renewed on or after January 1, 2020, to provide coverage for in vitro 
fertilization, as a treatment of infertility, and mature oocyte cryopreservation. The bill would delete 
the exemption for religiously affiliated employers, health care service plans, and health insurance 
policies, from the requirements relating to coverage for the treatment of infertility, thereby 
imposing these requirements on these employers, plans, and policies. The bill would also delete 
the requirement that a health care service plan contract and health insurance policy provide 
infertility treatment under agreed upon terms that are communicated to all group contractholders 
and prospective group contractholders. By expanding the duties of health care service plans, the 
bill would expand the scope of an existing crime, thereby imposing a state-mandated local 
program. 
 
The California Constitution requires the state to reimburse local agencies and school districts for 
certain costs mandated by the state. Statutory provisions establish procedures for making that 
reimbursement. 
 
This bill would provide that no reimbursement is required by this act for a specified reason. 
 
DIGEST KEY 
Vote: majority   Appropriation: no   Fiscal Committee: yes   Local Program: yes   
 
BILL TEXT 
 
THE PEOPLE OF THE STATE OF CALIFORNIA DO ENACT AS FOLLOWS: 
 
SECTION 1. Section 1248 of the Health and Safety Code is amended to read: 
 
1248. For purposes of this chapter, the following definitions shall apply: 
 
(a) “Division” means the Medical Board of California. All references in this chapter to the division, 
the Division of Licensing of the Medical Board of California, or the Division of Medical Quality 
shall be deemed to refer to the Medical Board of California pursuant to Section 2002 of the 
Business and Professions Code. 
 
(b) (1) “Outpatient setting” means any facility, clinic, unlicensed clinic, center, office, or other 
setting that is not part of a general acute care facility, as defined in Section 1250, and where 
anesthesia, except local anesthesia or peripheral nerve blocks, or both, is used in compliance with 
the community standard of practice, in doses that, when administered have the probability of 
placing a patient at risk for loss of the patient’s life-preserving protective reflexes. 
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(2) “Outpatient setting” also means facilities that offer in vitro fertilization, as defined 
in paragraph (2) of subdivision (b) (e) of Section 1374.55. 
 
(3) “Outpatient setting” does not include, among other settings, any setting where anxiolytics and 
analgesics are administered, when done so in compliance with the community standard of practice, 
in doses that do not have the probability of placing the patient at risk for loss of the patient’s life-
preserving protective reflexes. 
 
(c) “Accreditation agency” means a public or private organization that is approved to issue 
certificates of accreditation to outpatient settings by the board pursuant to Sections 1248.15 and 
1248.4. 
 
SEC. 2. Section 1374.55 of the Health and Safety Code is amended to read: 
 
1374.55 (a) On and after January 1, 1990, 2020, every health care service plan contract that is 
issued, amended, or renewed that covers hospital, medical, or surgical expenses on a group basis, 
where the plan is not a health maintenance organization as defined in Section 1373.10, 
shall offer provide coverage for the treatment of infertility, except including in vitro 
fertilization, under those terms and conditions as may be agreed upon between the group subscriber 
and the plan. Every plan shall communicate the availability of that coverage to all group 
contractholders and to all prospective group contractholders with whom they are negotiating. and 
mature oocyte cryopreservation. 
 
(b)For purposes of this section, “infertility” means either (1) the presence of a demonstrated 
condition recognized by a licensed physician and surgeon as a cause of infertility, or (2) the 
inability to conceive a pregnancy or to carry a pregnancy to a live birth after a year or more of 
regular sexual relations without contraception. “Treatment for infertility” means procedures 
consistent with established medical practices in the treatment of infertility by licensed physicians 
and surgeons including, but not limited to, diagnosis, diagnostic tests, medication, surgery, and 
gamete intrafallopian transfer. “In vitro fertilization” means the laboratory medical procedures 
involving the actual in vitro fertilization process. 
 
(c) 
 
(b) On and after January 1, 1990, 2020, every health care service plan that is a health maintenance 
organization, as defined in Section 1373.10, and that issues, renews, or amends a health care 
service plan contract that provides group coverage for hospital, medical, or surgical expenses shall 
offer the coverage specified in subdivision (a), according to the terms and conditions that may be 
agreed upon between the group subscriber and the plan to group contractholders with at least 20 
employees to whom the plan is offered. The plan shall communicate the availability of the 
coverage to those group contractholders and prospective group contractholders with whom the 
plan is negotiating. 
 
(d) 
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(c) This section shall not be construed to deny or restrict in any way any existing right or benefit 
to coverage and treatment of infertility under an existing law, plan, or policy. 
(e)This section shall not be construed to require any employer that is a religious organization to 
offer coverage for forms of treatment of infertility in a manner inconsistent with the religious 
organization’s religious and ethical principles. 
 
(f)(1)This section shall not be construed to require any plan, which is a subsidiary of an entity 
whose owner or corporate member is a religious organization, to offer coverage for treatment of 
infertility in a manner inconsistent with that religious organization’s religious and ethical 
principles. 
 
(2)For purposes of this subdivision, “subsidiary” of a specified corporation means a corporation 
more than 45 percent of the voting power of which is owned directly, or indirectly through one 
or more subsidiaries, by the specified corporation. 
 
(g) 
 
(d) Consistent with Section 1365.5, coverage for the treatment of infertility shall be offered and, 
if purchased, provided without discrimination on the basis of age, ancestry, color, disability, 
domestic partner status, gender, gender expression, gender identity, genetic information, marital 
status, national origin, race, religion, sex, or sexual orientation. Nothing in this subdivision shall 
be construed to interfere with the clinical judgment of a physician and surgeon. 
 
(e) The following definitions shall apply for purposes of this section: 
 
(1) “Infertility” means the presence of a demonstrated condition recognized by a licensed 
physician and surgeon as a cause of infertility. 
 
(2) “In vitro fertilization” means the laboratory medical procedures involving the in vitro 
fertilization process. 
 
(3) “Mature oocyte cryopreservation” means the procedures consistent with established medical 
practices, including laboratory medical procedures, involving ovulation induction, egg retrieval, 
and freezing of the egg. 
 
(4) “Preventative fertility care treatment” means procedures consistent with established medical 
practices in the treatment of fertility care, which is rendered by a licensed physician and surgeon, 
to prevent the inability to conceive a child. 
 
(5) “Treatment for infertility” means procedures consistent with established medical practices in 
the treatment of infertility by a licensed physician and surgeon, including, but not limited to, 
diagnosis, diagnostic tests, medication, surgery, gamete intrafallopian transfer, and in vitro 
fertilization. 
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SEC. 3. Section 10119.6 of the Insurance Code is amended to read: 
 
10119.6 (a) On and after January 1, 1990, 2020, every insurer issuing, renewing, or amending a 
policy of disability insurance that covers hospital, medical, or surgical expenses on a group basis 
shall offer provide coverage of infertility treatment, except including in vitro fertilization, under 
those terms and conditions as may be agreed upon between the group policyholder and the insurer. 
Every insurer shall communicate the availability of that coverage to all group policyholders and 
to all prospective group policyholders with whom they are negotiating. and mature oocyte 
cryopreservation. 
 
(b)For purposes of this section, “infertility” means either (1) the presence of a demonstrated 
condition recognized by a licensed physician and surgeon as a cause of infertility, or (2) the 
inability to conceive a pregnancy or to carry a pregnancy to a live birth after a year or more of 
regular sexual relations without contraception. “Treatment for infertility” means procedures 
consistent with established medical practices in the treatment of infertility by licensed physicians 
and surgeons, including, but not limited to, diagnosis, diagnostic tests, medication, surgery, and 
gamete intrafallopian transfer. “In vitro fertilization” means the laboratory medical procedures 
involving the actual in vitro fertilization process. 
 
(c) 
 
(b) This section shall not be construed to deny or restrict in any way any existing right or benefit 
to coverage and treatment of infertility under an existing law, plan, or policy. 
 
(d)This section shall not be construed to require any employer that is a religious organization to  
offer coverage for forms of treatment of infertility in a manner inconsistent with the religious 
organization’s religious and ethical principles. 
 
(e)(1)This section shall not be construed to require any insurer, which is a subsidiary of an entity 
whose owner or corporate member is a religious organization, to offer coverage for treatment of 
infertility in a manner inconsistent with that religious organization’s religious and ethical 
principles. 
 
(2)For purposes of this subdivision, “subsidiary” of a specified corporation means a corporation 
more than 45 percent of the voting power of which is owned directly, or indirectly through one 
or more subsidiaries, by the specified corporation. 
 
(f) 
 
(c) This section applies to every disability insurance policy that is issued, amended, or renewed to 
residents of this state regardless of the situs of the contract. 
 
(g) 
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(d) Consistent with Section 10140, coverage for the treatment of infertility shall be offered and, if 
purchased, provided without discrimination on the basis of age, ancestry, color, disability, 
domestic partner status, gender, gender expression, gender identity, genetic information, marital 
status, national origin, race, religion, sex, or sexual orientation. Nothing in this subdivision shall 
be construed to interfere with the clinical judgment of a physician and surgeon. 
 
(e) The following definitions shall apply for purposes of this section: 
 
(1) “Infertility” means the presence of a demonstrated condition recognized by a licensed 
physician and surgeon as a cause of infertility. 
 
(2) “In vitro fertilization” means the laboratory medical procedures involving the in vitro 
fertilization process. 
 
(3) “Mature oocyte cryopreservation” means the procedures consistent with established medical 
practices, including laboratory medical procedures, involving ovulation induction, egg retrieval, 
and freezing of the egg. 
 
(4) “Preventative fertility care treatment” means procedures consistent with established medical 
practices in the treatment of fertility care, which is rendered by a licensed physician and surgeon, 
to prevent the inability to conceive a child. 
 
(5) “Treatment for infertility” means procedures consistent with established medical practices in 
the treatment of infertility by a licensed physician and surgeon, including, but not limited to, 
diagnosis, diagnostic tests, medication, surgery, gamete intrafallopian transfer, and in vitro 
fertilization. 
 
SEC. 4. No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the 
California Constitution because the only costs that may be incurred by a local agency or school 
district will be incurred because this act creates a new crime or infraction, eliminates a crime or 
infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 
of the Government Code, or changes the definition of a crime within the meaning of Section 6 of 
Article XIII B of the California Constitution. 
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AMENDED  IN  ASSEMBLY  APRIL 09, 2019 
CALIFORNIA LEGISLATURE— 2019–2020 REGULAR SESSION 
 
 
ASSEMBLY BILL No. 767 
 
Introduced by Assembly Member Wicks 
(Principal coauthors: Assembly Members Burke and Low) 
(Principal coauthor: Senator Stern) 
 
February 19, 2019 
 
 
An act to amend Sections 1248 and Section 1374.55 of the Health and Safety Code, and to amend Section 
10119.6 of the Insurance Code, relating to healthcare health care coverage. 
LEGISLATIVE COUNSEL'S DIGEST 
 
AB 767, as amended, Wicks. Healthcare Health care coverage: infertility. 
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, 1975 (Knox-Keene Act), provides for 
the licensure and regulation of health care service plans by the Department of Managed Health Care and 
makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by 
the Department of Insurance. Existing law imposes various requirements and restrictions on health care 
service plans and health insurers, including, among other things, a requirement that every group health care 
service plan contract or health insurance policy that is issued, amended, or renewed on or after January 1, 
1990, offers coverage for the treatment of infertility, except in vitro fertilization, under those terms and 
conditions as may be agreed upon between the group subscriber or the group policyholder and the health 
care service plans or the health insurers. The Knox-Keene Act specifies that a health care service plan that 
is a health maintenance organization (HMO) is required to provide this coverage to a group contractholder 
with at least 20 employees. Existing law provides that any employer that is a religious organization or health 
care service plans and health insurers which are a subsidiary of an entity whose owner or corporate member 
is a religious organization shall not be required to offer coverage for forms of treatment of infertility in a 
manner inconsistent with the religious organization’s religious and ethical principles, as specified. 
This bill would require every all health care service plan contract contracts, including every HMO 
contract, or health insurance policy that is issued, amended, or renewed on or after January 1, 2020, to 
provide coverage for in vitro fertilization, as a treatment of infertility, and mature oocyte cryopreservation. 
The bill would delete the exemption for religiously affiliated employers, health care service plans, and 
health insurance policies, from the requirements relating to coverage for the treatment of infertility, thereby 
imposing these requirements on these employers, plans, and policies. The bill would also delete the 
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requirement that a health care service plan contract and health insurance policy provide infertility treatment 
under agreed upon terms that are communicated to all group contractholders and prospective group 
contractholders. By expanding the duties of health care service plans, the bill would expand the scope of an 
existing crime, thereby imposing a state-mandated local program. 
The California Constitution requires the state to reimburse local agencies and school districts for certain 
costs mandated by the state. Statutory provisions establish procedures for making that reimbursement. 
This bill would provide that no reimbursement is required by this act for a specified reason. 
DIGEST KEY 
Vote: majority   Appropriation: no   Fiscal Committee: yes   Local Program: yes   
 
BILL TEXT 
THE PEOPLE OF THE STATE OF CALIFORNIA DO ENACT AS FOLLOWS: 
 
SECTION 1.Section 1248 of the Health and Safety Code is amended to read: 
1248. 
For purposes of this chapter, the following definitions shall apply: 
(a)“Division” means the Medical Board of California. All references in this chapter to the division, the 
Division of Licensing of the Medical Board of California, or the Division of Medical Quality shall be 
deemed to refer to the Medical Board of California pursuant to Section 2002 of the Business and 
Professions Code. 
(b)(1)“Outpatient setting” means any facility, clinic, unlicensed clinic, center, office, or other setting that 
is not part of a general acute care facility, as defined in Section 1250, and where anesthesia, except local 
anesthesia or peripheral nerve blocks, or both, is used in compliance with the community standard of 
practice, in doses that, when administered have the probability of placing a patient at risk for loss of the 
patient’s life-preserving protective reflexes. 
(2)“Outpatient setting” also means facilities that offer in vitro fertilization, as defined in paragraph (2) of 
subdivision (e) of Section 1374.55. 
(3)“Outpatient setting” does not include, among other settings, any setting where anxiolytics and 
analgesics are administered, when done so in compliance with the community standard of practice, in 
doses that do not have the probability of placing the patient at risk for loss of the patient’s life-preserving 
protective reflexes. 
(c)“Accreditation agency” means a public or private organization that is approved to issue certificates of 
accreditation to outpatient settings by the board pursuant to Sections 1248.15 and 1248.4. 
SEC. 2.SECTION 1. 
 Section 1374.55 of the Health and Safety Code is amended to read: 
1374.55. 
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 (a) On and after January 1, 2020, every health care service plan contract that is issued, amended, or renewed 
that covers hospital, medical, or surgical expenses on a group basis, where the plan is not a health 
maintenance organization as defined in Section 1373.10, basis shall provide coverage for the treatment of 
infertility, including in vitro fertilization, and mature oocyte cryopreservation. 
(b)On and after January 1, 2020, every health care service plan that is a health maintenance organization, 
as defined in Section 1373.10, and that issues, renews, or amends a health care service plan contract that 
provides group coverage for hospital, medical, or surgical expenses shall offer the coverage specified in 
subdivision (a), according to the terms and conditions that may be agreed upon between the group 
subscriber and the plan to group contractholders with at least 20 employees to whom the plan is offered. 
The plan shall communicate the availability of the coverage to those group contractholders and 
prospective group contractholders with whom the plan is negotiating. 
(c) 
(b) This section shall not be construed to deny or restrict in any way any existing right or benefit to coverage 
and treatment of infertility under an existing law, plan, or policy. 
(d) 
(c) Consistent with Section 1365.5, coverage for the treatment of infertility shall be offered and, if 
purchased, provided without discrimination on the basis of age, ancestry, color, disability, domestic partner 
status, gender, gender expression, gender identity, genetic information, marital status, national origin, race, 
religion, sex, or sexual orientation. Nothing in this subdivision shall be construed to interfere with the 
clinical judgment of a physician and surgeon. 
(e) 
(d) The following definitions shall apply for purposes of this section: 
(1) “Infertility” means the presence of a demonstrated condition recognized by a licensed physician and 
surgeon as a cause of infertility. 
(2) “In vitro fertilization” means the laboratory medical procedures involving the in vitro fertilization 
process. 
(3) “Mature oocyte cryopreservation” means the procedures consistent with established medical practices, 
including laboratory medical procedures, involving ovulation induction, egg retrieval, and freezing of the 
egg. 
(4)“Preventative fertility care treatment” means procedures consistent with established medical practices 
in the treatment of fertility care, which is rendered by a licensed physician and surgeon, to prevent the 
inability to conceive a child. 
(5) 
(4) “Treatment for of infertility” means procedures consistent with established medical practices in the 
treatment of infertility by a licensed physician and surgeon, including, but not limited to, diagnosis, 
diagnostic tests, medication, surgery, gamete intrafallopian transfer, and in vitro fertilization. 
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SEC. 3.SEC. 2. 
 Section 10119.6 of the Insurance Code is amended to read: 
10119.6. 
 (a) On and after January 1, 2020, every insurer issuing, renewing, or amending a policy of disability 
insurance that covers hospital, medical, or surgical expenses on a group basis shall provide coverage of 
infertility treatment, including in vitro fertilization, and mature oocyte cryopreservation. 
(b) This section shall not be construed to deny or restrict in any way any existing right or benefit to coverage 
and treatment of infertility under an existing law, plan, or policy. 
(c) This section applies to every disability insurance policy that is issued, amended, or renewed to residents 
of this state regardless of the situs of the contract. 
(d) Consistent with Section 10140, coverage for the treatment of infertility treatment shall be offered and, 
if purchased, provided without discrimination on the basis of age, ancestry, color, disability, domestic 
partner status, gender, gender expression, gender identity, genetic information, marital status, national 
origin, race, religion, sex, or sexual orientation. Nothing in this subdivision shall be construed to interfere 
with the clinical judgment of a physician and surgeon. 
(e) The following definitions shall apply for purposes of this section: 
(1) “Infertility” means the presence of a demonstrated condition recognized by a licensed physician and 
surgeon as a cause of infertility. 
(2) “In vitro fertilization” means the laboratory medical procedures involving the in vitro fertilization 
process. 
(3) “Mature oocyte cryopreservation” means the procedures consistent with established medical practices, 
including laboratory medical procedures, involving ovulation induction, egg retrieval, and freezing of the 
egg. 
(4)“Preventative fertility care treatment” means procedures consistent with established medical practices 
in the treatment of fertility care, which is rendered by a licensed physician and surgeon, to prevent the 
inability to conceive a child. 
(5)“Treatment for infertility” 
(4) “Coverage of infertility treatment” means procedures consistent with established medical practices in 
the treatment of infertility by a licensed physician and surgeon, including, but not limited to, diagnosis, 
diagnostic tests, medication, surgery, gamete intrafallopian transfer, and in vitro fertilization. 
SEC. 4.SEC. 3. 
 No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the California 
Constitution because the only costs that may be incurred by a local agency or school district will be incurred 
because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty 
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for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the 
definition of a crime within the meaning of Section 6 of Article XIII B of the California Constitution. 
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APPENDIX B  LITERATURE REVIEW METHODS 
This appendix describes methods used in the medical effectiveness literature review conducted for this 
report. A discussion of CHBRP’s system for grading evidence, as well as lists of MeSH Terms, publication 
types, and keywords, follows. 
As presented in the Background section, infertility diagnosis and treatment encompasses a wide range of 
tests, treatments, and medications. It is not feasible for CHBRP to review the literature on the 
effectiveness of the numerous diagnostic and treatment options for all causes of infertility to which AB 
767 applies within the 60-day timeframe allotted for this analysis. In light of the wide range of conditions 
that cause infertility and the types of treatments to which AB 767 would apply, and the fact that AB 767 
addresses the provision of coverage of infertility benefits, the medical effectiveness review summarizes 
these findings from evidence:44 (1) the impact of health insurance coverage (specifically mandates to 
cover) for infertility treatments and (2) the medical effectiveness of the two treatments newly mandated 
under the bill language (i.e., IVF and mature OC).  
Studies of infertility treatments and impacts of infertility insurance coverage were identified through 
searches of PubMed, the Cochrane Library, Web of Science, EconLit, Business Source Complete, the 
Cumulative Index of Nursing and Allied Health Literature, and PsycINFO. Websites maintained by the 
following organizations that produce and/or index meta-analyses and systematic reviews were also 
searched: the Agency for Healthcare Research and Quality (AHRQ), the International Network of 
Agencies for Health Technology Assessment (INAHTA), the National Health Service (NHS) Centre for 
Reviews and Dissemination, the National Institute for Health and Clinical Excellence (NICE), and the 
Scottish Intercollegiate Guideline Network. The search was limited to abstracts of studies published in 
English.  
The search related to the effectiveness and harms of IVF and planned OC (“planned oocyte 
cryopreservation”) was limited to studies published from 2000 to present. Due to the amount of literature 
published related to IVF, CHBRP focused on previously published systematic reviews to inform the 
medical effectiveness analysis. In assessing harms related to IVF and planned OC, CHBRP relied 
primarily on previously published systematic reviews when possible and expanded the inclusion to well-
designed trials and cohort studies for less common harms and complications. The search related to the 
impact of health insurance coverage for infertility treatment was limited to studies published from 2012 to 
present because CHBRP had previously conducted thorough literature searches on these topics in 2013 
for AB 460. 
Of the 480 articles found in the literature review, 227 were reviewed for potential inclusion in this report on 
AB 767, and a total of 29 studies were included in the medical effectiveness review for this report, as well 
as eight studies that were included in the previous review for AB 460. The other articles were eliminated 
because they did not focus on mandate coverage including IVF, did not report relevant outcomes, or were 
not reporting findings from clinical research studies. 
                                                     
44 Much of the discussion below is focused on reviews of available literature.  However, as noted on page 11 of the 
Medical Effectiveness analysis and research approach document (posted here), in the absence of “fully-applicable to 
the analysis” peer-reviewed literature on well-designed randomized controlled trials (RCTs), CHBRP’s hierarchy of 
evidence allows for the inclusion of other evidence. 
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Evidence Grading System 
In making a “call” for each outcome measure, the medical effectiveness lead and the content expert 
consider the number of studies as well the strength of the evidence. Further information about the criteria 
CHBRP uses to evaluate evidence of medical effectiveness can be found in CHBRP’s Medical 
Effectiveness Analysis Research Approach.45 To grade the evidence for each outcome measured, the 
team uses a grading system that has the following categories: 
• Research design; 
• Statistical significance; 
• Direction of effect;  
• Size of effect; and 
• Generalizability of findings.  
The grading system also contains an overall conclusion that encompasses findings in these five domains. 
The conclusion is a statement that captures the strength and consistency of the evidence of an 
intervention’s effect on an outcome. The following terms are used to characterize the body of evidence 
regarding an outcome: 
• Clear and convincing evidence; 
• Preponderance of evidence; 
• Limited evidence; 
• Inconclusive evidence; and  
• Insufficient evidence. 
A grade of clear and convincing evidence indicates that there are multiple studies of a treatment and that 
the large majority of studies are of high quality and consistently find that the treatment is either effective 
or not effective.  
A grade of preponderance of evidence indicates that the majority of the studies reviewed are consistent in 
their findings that treatment is either effective or not effective.  
A grade of limited evidence indicates that the studies had limited generalizability to the population of 
interest and/or the studies had a fatal flaw in research design or implementation. 
A grade of inconclusive evidence indicates that although some studies included in the medical 
effectiveness review find that a treatment is effective, a similar number of studies of equal quality suggest 
the treatment is not effective. 
A grade of insufficient evidence indicates that there is not enough evidence available to know whether or 
not a treatment is effective, either because there are too few studies of the treatment or because the 
available studies are not of high quality. It does not indicate that a treatment is not effective. 
                                                     
45 Available at: http://chbrp.com/analysis_methodology/medical_effectiveness_analysis.php.  
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Search Terms (* indicates truncation of word stem) 
The following Medical Subject Headings (MeSH) were used to search PubMed and Cochrane:  
 
• Age Factors 
• Autism Spectrum Disorder 
• Autistic Disorder 
• Birth Rate 
• Cardiovascular Diseases 
• Cerebral Palsy 
• Cleft Palate 
• Cost Benefit Analysis 
• Cost of Illness 
• Cost Savings 
• Cryopreservation 
• Depression 
• Depressive Disorder 
• Developmental Disabilities 
• Down Syndrome 
• Educational Status 
• Ethnic Groups 
• Embryo Transfer 
• Fertilization in Vitro 
• Fertilization in Vitro/adverse effects 
• Fertility Preservation 
• Gender Identity 
• Health Care Costs 
• Health Impact Assessment 
• Health Services Accessibility 
• Health Services Needs and Demand 
• Health Status Disparities 
• Healthcare Disparities 
• Homosexuality, Female 
• Homosexuality, Male 
• Incidence 
• Infant, Low Birth Weight 
• Infertility/Therapy 
• Insemination, Artificial 
• Insurance, Health  
• Insurance Coverage 
• Live Birth 
• Minority Health 
• Neoplasms 
• Oocytes 
• Pregnancy Complications 
• Pregnancy Outcome 
• Pregnancy Rate 
• Premature Birth 
• Prevalence 
• Quality of Life 
• Race Factors 
• Reproductive Medicine/Legislation and 
jurisprudence 
• Reproductive Techniques, Assisted 
• Risk Assessment 
• Risk Factors 
• Sexuality 
• Social Determinants of Health 
• Sperm Injections, 
Intracytoplasmic/adverse effects 
• Stress, Psychological 
• Transgendered Persons 
• Treatment Outcome 
 
The following keywords were used to search PubMed, Cochrane, Web of Science, EMBASE, Business 
Source Complete and Web sites:  
 
• Access 
• Age 
• Anxiet* 
• Artificial insemination 
• Assisted reproductive technology 
• Assistive reproductive technology 
• Autism 
• Autistic 
• Barrier* 
• Behavioral disorder* 
• Birth 
• Birth outcomes 
• Birth rates 
• Cancer* 
• Cardiovascular disease* 
• Cerebral palsy 
• Childhood tumors 
• Cleft palate 
• Complications 
• Cost* 
• Cost offset 
• Cost savings 
• Cost effective* 
• Cost utility 
• Cryopreservation 
• Death 
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• Depression 
• Demand 
• Demographic* 
• Developmental disabilit* 
• Discrimination* 
• Disparit* 
• Down’s syndrome 
• Economic loss 
• Education  
• Educational attainment 
• Educational status 
• Effects of insurance mandates 
• Effective* 
• Embryo transfer 
• Ethnic* 
• Ethnic disparities 
• Fertilization in vitro 
• Fertility preservation 
• Financial burden 
• Gender 
• Harms 
• Homosexual* 
• Impact*  
• In-vitro fertilization 
• Income 
• infertility 
• Infertility insurance mandates 
• Infertility therapy 
• Infertility treatments 
• Insurance coverage 
• Insurance mandates 
• Intracytoplasmic sperm injection 
• Health outcomes 
• Lesbian* 
• Live birth rates 
• Long term impact* 
• Malformations 
• Market 
• Maternal fertility status 
• Mature oocyte cryopreservation 
• Mental retardation 
• Miscarriage 
• Morbidity 
• Mortality 
• Multiple birth rates 
• Oocytes 
• Out of pocket 
• Outcome* 
• Pregnancy 
• Pregnancy complication* 
• Pregnancy outcome* 
• Pregnancy rate* 
• Premature death 
• Premium* 
• Preventive fertility care treatment* 
• Price elasticity 
• Productivit* 
• Psychological 
• Quality of life 
• Race 
• Racial disparities 
• Religion 
• Religious 
• Reproductive Medicine 
• Reproductive technique* 
• Risk* 
• Risk factors 
• Safety 
• Same sex couples 
• Sex differences 
• Sexual orientation 
• Social determinants 
• Stigma 
• Stress 
• Transgender* 
• Treatment outcomes 
• Treatment utilization 
• Uncovered cost* 
• Utilisation 
• Utilization 
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APPENDIX C  COST IMPACT ANALYSIS: DATA 
SOURCES, CAVEATS, AND ASSUMPTIONS 
The cost analysis in this report was prepared by the members of the cost team, which consists of CHBRP 
task force members and contributors from the University of California, Los Angeles, and the University of 
California, Davis, as well as the contracted actuarial firm, Milliman, Inc.46  
Information on the generally used data sources and estimation methods, as well as caveats and 
assumptions generally applicable to CHBRP’s cost impacts analyses are available at CHBRP’s website.47 
This appendix describes analysis-specific data sources, estimation methods, caveats, and assumptions 
used in preparing this cost impact analysis. 
Analysis-Specific Caveats and Assumptions 
As explained in the Policy Context section, GIFT and ZIFT were not included in this analysis.  
Identification of Infertility Cases 
• CHBRP examined 2016 MarketScan® database and Milliman’s proprietary 2016 Consolidated 
Health Cost Guidelines™ Sources Database (CHSD) for infertility services among enrollees with 
an infertility diagnosis in California as well as New Jersey, a state where an infertility mandate is 
already in place.  
• The analysis of California’s 2016 MarketScan and 2016 CHSD claims data for infertility services 
required categorizing claims to estimate annual utilization rates and cost per services. Only 
enrollees with 11 or more months of enrollment who had drug coverage were included in the 
analysis. The female reproductive age range is 15-44 years. The male reproductive age range is 
18-60 years.  
• Content expert input and guidance from recent research on the impact of state-level infertility 
mandates on health plan expenditures that also used MarketScan data (Boulet et al., 2019) were 
the basis for CHBRP’s methodology on how to group claims codes into treatment categories.  
• Infertility Diagnosis — For all diagnostic and treatment categories, the claims were first subset to 
only include claims for members with the following infertility ICD 10 diagnosis codes: N468, N469, 
N970, N971, N972, N978, N979, Z3141, Z3162, Z3181, Z3183, Z3184, and Z3189. 
• Diagnostic Procedures - For the claims with the infertility diagnosis codes, the following 
Healthcare Common Procedure Coding System (HCPCS) codes were used to identify diagnostic 
services: 54500, 54505, 54800, 55200, 55300, 55550, 58340, 58345, 58350, 58540, 58560, 
58700, 58740, 58752, 58770, 58920, 74740, 76831, 83001, 83002, 89300, 89310, 89320, 89321, 
89322, 89330, 89331, G0027, S3655.  
                                                     
46 CHBRP’s authorizing statute, available at http://chbrp.com/CHBRP%20authorizing%20statute_2018_FINAL.pdf, 
requires that CHBRP use a certified actuary or “other person with relevant knowledge and expertise” to determine 
financial impact.  
47 See method documents posted here, http://chbrp.com/analysis_methodology/cost_impact_analysis.php; in 
particular, see 2019 Cost Analyses: Data Sources, Caveats, and Assumptions. 
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• Male treatments were identified as claims with an infertility diagnosis code and the following 
HCPCS codes: 0357T, 58323, 58970, 58974, 58976, 89250, 89251, 89253, 89254, 89255, 
89257, 89258, 89259, 89260, 89261, 89264, 89268, 89272, 89280, 89281, 89290, 89291, 89325, 
89329, 89335, 89337, 89342, 89343, 89344, 89346, 89352, 89353, 89354, 89356, S4011, 
S4015, S4016, S4017, S4018, S4020, S4021, S4022, S4023, S4025, S4026, S4027, S4028, 
S4030, S4031, S4035, S4037, S4040, S4042, 76948, 55400, 55870 
• To categorize female enrollees into the four treatment categories, ICSI, IVF, IUI and OI, CHBRP 
completed the following steps: 
o Step 1: Using the claims with the infertility diagnosis codes, assign female enrollees to a 
treatment category by the following hierarchy: 
 ICSI – Assisted oocyte fertilization HCPCS 89280 or 89281 
 IVF – Follicle puncture for oocyte retrieval HCPCS 58970 or Embryo transfer HCPCS 
58974 
 IUI – Artificial insemination HCPCS 58321 or 58322, Sperm washing HCPCS 58323, 
Sperm isolation 89260, or IUI case rate S4035   
o Step 2: For members identified in one of the three groups in Step 1, all claims associated with 
that member that have an infertility diagnosis code are included in the enrollee’s treatment 
costs. 
o Step 3: For the enrollees identified in step 1, the following prescription drugs were included: 
Anastrozole, Cetrorelix acetate, Chorionic gonadotropin, Chorionic gonadotropin alfa, 
recombinant, Clomiphene citrate, Follicle stimulating hormone/luteinizing hormone, Follitropin 
beta, Follitropin beta/ganirelix acetate, Follitropin alfa, Ganirelix acetate, Gonadorelin acetate, 
Gonadorelin hydrochloride, Histrelin acetate, Hydroxyprogesterone caproate, Letrozole, 
Lutropin alfa, Medroxyprogesterone acetate, Metformin hydrochloride, Norethindrone, 
Norethindrone acetate, Progesterone, Progesterone, micronized, Urofollitropin, Bravelle, 
Bromocriptine mesylate, Cabergoline, Cetrotide, Chorionic gonadotropin, Clomid, 
Clomiphene citrate, Dexamethasone, Femara, Follistim aq, Ganirelix acetate, Glucophage, 
Gonal-f, Gonal-f rff, Gonal-f rff pen, Menopur, Metformin hcl, Novarel, Ovidrel, Pregnyl 
w/diluent benzyl, Repronex, Synarel, Estrace, Testosterone gel, Testosterone patch, 
Omnitrope. 
o Step 4: For enrollees not categorized into one of the three treatment categories listed in step 
1, they were included in the medication only treatment category if they had one of the 
following drugs: Cetrorelix acetate, Chorionic gonadotropin, Chorionic gonadotropin alfa, 
recombinant, Clomiphene citrate, Follicle stimulating hormone/luteinizing hormone, Follitropin 
beta, Follitropin beta/ganirelix acetate, Follitropin alfa, Ganirelix acetate, Gonadorelin acetate, 
Gonadorelin hydrochloride, Histrelin acetate, Letrozole, Progesterone, micronized, 
Urofollitropin, Bravelle, Clomid, Clomiphene citrate, Femara, Follistim aq, Ganirelix acetate, 
Gonal-f, Gonal-f rff, Gonal-f rff pen, Menopur, Novarel, Ovidrel, Pregnyl w/diluent benzyl, 
Repronex, Synarel. Women with progesterone only also needed to have estradiol to be 
included in the medication only treatment category.  
o Step 5: The enrollees as a percentage of the total reproductive population in each category 
were calculated and used as the baseline with coverage utilization assumptions. The CA cost 
per enrollee was used as the cost per user. 
Analysis of California Assembly Bill 767 
Current as of April 18, 2019 www.chbrp.org C-3 
Baseline utilization – Infertility Services 
• Percent (%) of people with infertility – Using the New Jersey data grouped by gender, the count of 
enrollees with a diagnostic code listed above as a percent of the total New Jersey enrollees in 
reproductive age range was assumed to be the utilization of diagnostic services for the baseline 
with coverage population.  
• Percent (%) of reproductive people with infertility using services – The New Jersey utilization data 
grouped into the infertility treatment categories listed above was used as the baseline with 
coverage utilization assumption.  
• MarketScan and CHSD data in California provides a snapshot of utilization of infertility services 
among those with some coverage of these services. Because infertility is largely not covered by 
insurance, a significant portion of utilization at baseline is driven by individuals who use services 
without coverage. Per CHBRP’s content expert, approximately 80% of patients presenting at 
infertility clinic have coverage for diagnostic tests and about 40% have coverage for infertility 
treatment. To estimate the utilization stemming from enrollees who obtain services without 
coverage in California at baseline, CHBRP used estimates from the peer-reviewed literature 
applied to 2016 MarketScan data from New Jersey, where infertility treatment is covered via a 
state mandate. Evidence from the peer-reviewed literature that suggests utilization of IVF 
services in mandate states vs nonmandate states is 1:4 ratio (Chambers et al., 2014). CHBRP 
applied this ratio for IVF and ICSI to the New Jersey data to estimate utilization in California. A 
study from couples in Northern California, where the population is likely more affluent than the 
rest of the state, suggests that 58% of couples who are diagnosed with infertility but do not 
pursue treatment cite financial difficulty as the reason for not pursuing treatment (Eisenberg et al., 
2010). Given non-IVF services are less costly to enrollees, IUI and medication utilization in 
California is assumed to be 20% less than that of New Jersey; and diagnostic testing for females 
and treatment for males is assumed to be 5% less than New Jersey. Because male diagnostic 
tests are inexpensive, utilization rates among enrollees represented in the claims database in 
New Jersey are assumed to be the same as that in California. 
• To estimate the degree to which utilization of infertility services might shift postmandate, CHBRP 
identified various data sources. Examining utilization rates claims for states with an existing 
infertility mandate was determined to be a sound means of obtaining potential postmandate rates. 
Thus, CHBRP first examined infertility legislation from the states whereby the state mandates 
included all types of infertility services (including explicit mention of ICSI), no specific cap on the 
dollar amount covered, and no cap on the number of cycles to determine which other states had 
mandates most close to the bill language laid out in AB 767. See Table 7 below for the full list of 
states with infertility mandates to cover IVF and limits placed by those mandates. Massachusetts 
and New Jersey were the two states identified in this process. While Delaware’s infertility 
mandate is also flagged as similar to that of California’s, it was enacted in 2018 and CHBRP’s 
claims data are for 2016, thus postmandate utilization could not be estimated with data from 
Delaware. CHBRP determined New Jersey’s infertility mandate limits on age and egg retrievals 
are likely to be close to the types of limits carriers may issue if AB 767 were to pass since the bill 
does not specify any restrictions to placing such limits. Thus, 2016 MarketScan claims data from 
New Jersey were used to estimate postmandate utilization. 
 
Analysis of California Assembly Bill 767 
Current as of April 18, 2019 www.chbrp.org C-4 
Table 7. States with Infertility Mandates to Cover IVF and Limits Placed by those Mandates 
 
Limit 
State Mandate Age $ amount covered # of IVF cycles Egg retrieval 
Arkansas - $15,000 lifetime max - - 
Connecticut - - 2 cycles max - 
Delaware 
<45 years at 
time of 
female egg 
retrieval 
- - 6 egg retrievals max 
Hawaii - - 1 cycle max - 
Illinois - - 
Note, ISCI not 
included in mandate 
4 egg retrievals; 2 
more if live birth 
successful 
Maryland - $100,000 max - - 
Massachusetts - - - - 
New Jersey <45 years - - 4 egg retrievals max 
Rhode Island 25-42 years $100,000 max - - 
Source: (NCSL, 2018) 
 
Postmandate utilization – Infertility 
• Percent (%) of people with infertility – Same as the baseline population. 
• Percent (%) of reproductive people with infertility using services – The baseline with coverage 
utilization rates adjusted for 10% pent-up demand in both years 1 and 2. 
Baseline Cost – Infertility Services 
 Using the treatment categories outlined in the Identification of Infertility Cases section, the 
California average cost per identified user was calculated.  
 Medical claims were trended using a 2.0% medical trend, the medical component of CPI, and a 
7.5% pharmacy trend rate, from the 2019 Milliman Health Cost Guidelines. 
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Postmandate Cost – Infertility Services 
 Postmandate costs of infertility services are assumed to be the same as baseline infertility service 
costs.  
Pregnancies 
 For each of the treatment categories, the % of users of the infertility services resulting in a 
pregnancy, the % of pregnancies resulting in a non-live birth, single birth, twins, or three or more 
babies was assumed as follows: 
Table 8. Pregnancy related outcomes of infertility treatment, by treatment category 
Type of Pregnancy/Birth % Resulting in Pregnancy % Not Live % Live Single % Twins % Multi 
Baseline       
Medication Only 25.4% 17.1% 75.0% 7.8% 0.1% 
IVF 41.2% 18.4% 67.5% 13.8% 0.4% 
ICSI 41.2% 18.4% 67.5% 13.8% 0.4% 
IUI 15.2% 16.0% 81.1% 2.8% 0.1% 
        
Postmandate       
Medication Only 25.4% 17.1% 75.0% 7.8% 0.1% 
IVF 41.7% 18.2% 69.2% 12.2% 0.4% 
ICSI 41.7% 18.2% 69.2% 12.2% 0.4% 
IUI 15.2% 16.0% 81.1% 2.8% 0.1% 
Source: California Health Benefits Review Program, 2019. 
 The Medication only source was a blend of outcomes from the use of clomiphene and letrozole 
(Diamond et al., 2015).  
 The IVF and ICSI source for the baseline population is California observed pregnancy rates and 
for the postmandate is New Jersey observed pregnancy rates from the National ART 
Surveillance, US, 2015. The postmandate rate has slightly more live births, more single births and 
fewer multi-births than the baseline population due to women getting more cycles with fewer 
embryos transferred as a result of cost.   
 The IUI pregnancy rates are the 2017 national average for all pregnancies as provided by the 
CDC. Because these rates were only reported for live births, the values were adjusted for the 
percentage of non-life births from stillbirths and miscarriages, reported by the CDC and March of 
Dimes respectively.48 
                                                     
48 CDC estimates 1% of pregnancies result in stillbirth (Macdorman et al., 2015) and March of Dimes estimates up to 
15% of pregnancies result in miscarriage (https://www.marchofdimes.org/miscarriage.aspx) 
Analysis of California Assembly Bill 767 
Current as of April 18, 2019 www.chbrp.org C-6 
 CHBRP assumed literature based estimates of cost per pregnancy and live birth for singleton, 
twin, and multiple births that take into account additional neonatal care costs associated with 
each type of birthweight, such as use of neonatal intensive care unit (NICU) services (Lemos et 
al., 2013). The per unit cost of pregnancies that do not result in a live birth was developed from 
the 2019 Milliman Health Cost Guidelines and includes inpatient services for complications and 
pregnancies that do not result in a delivery due to miscarriage or abortion, maternity professional 
and maternity anesthesia charges. All medical services were trended to 2020 using 2% medical 
trend and 7.5% pharmacy trend. The baseline and postmandate costs are assumed to be the 
same. 
Fertility Preservation 
 The case rate used for the cost of fertility preservation of mature oocytes is from the 2019 
CHBRP analysis of SB 600. CHBRP’s analysis of SB 600 is available at www.chbrp.org.  
Determining Public Demand for the Proposed Mandate 
This subsection discusses public demand for the benefits AB 767 would mandate. Considering the criteria 
specified by CHBRP’s authorizing statute, CHBRP reviews public demand for benefits relevant to a 
proposed mandate in two ways. CHBRP:  
• Considers the bargaining history of organized labor; and 
• Compares the benefits provided by self-insured health plans or policies (which are not regulated 
by the DMHC or CDI and therefore not subject to state-level mandates) with the benefits that are 
provided by plans or policies that would be subject to the mandate. 
On the basis of conversations with the largest collective bargaining agents in California, CHBRP 
concluded that unions currently do not include cost-sharing arrangements for description treatment or 
service. In general, unions negotiate for broader contract provisions such as coverage for dependents, 
premiums, deductibles, and broad coinsurance levels. 
Among publicly funded self-insured health insurance policies, the preferred provider organization (PPO) 
plans offered by CalPERS currently have the largest number of enrollees. The CalPERS PPOs currently 
provide benefit coverage similar to what is available through group health insurance plans and policies 
that would be subject to the mandate.  
To further investigate public demand, CHBRP used the bill-specific coverage survey to ask carriers who 
act as third-party administrators for (non-CalPERS) self-insured group health insurance programs 
whether the relevant benefit coverage differed from what is offered in group market plans or policies that 
would be subject to the mandate. The responses indicated that there were no substantive differences.  
However, CHBRP is aware of some large employers (i.e., Google and Facebook) that do provide 
coverage for the full range of infertility treatments in addition to planned oocyte cryopreservation (OC), 
suggesting there is a public demand for these services.  
Second Year Impacts on Benefit Coverage, Utilization, and Cost 
In order to develop Table 9, CHBRP has considered whether continued implementation during the 
second year of the benefit coverage requirements of AB 767 would have a substantially different impact 
on utilization of either the tests, treatments, or services for which coverage was directly addressed, the 
utilization of any indirectly affected utilization, or both. To generate this table, CHBRP reviewed the 
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literature and consulted content experts about the possibility of varied second year impacts and applied 
what was learned to a projection of a second year of implementation.   
 
Table 9. AB 767 Impacts on Benefit Coverage, Utilization, and Cost, 2021 
  Baseline Postmandate Increase/ 
Decrease 
Percentage 
Change 
Benefit coverage 
 Total enrollees with 
health insurance subject 
to state benefit 
mandates (a) 24,395,000 24,395,000 0 0% 
 Total enrollees with 
health insurance subject 
to AB 767 14,630,000 14,630,000 0 0% 
 Percentage of enrollees 
with coverage for 
infertility services, 
including IVF  4.3% 100% 96% 2247% 
 Number of enrollees with 
coverage for infertility 
services, including IVF  623,297 14,630,000 96% 2247% 
 Percentage of enrollees 
with coverage for mature 
oocyte cryopreservation 
as defined by AB 767 0% 100% 100% 100% 
 Number of enrollees with 
coverage for mature 
oocyte cryopreservation 
as defined by AB 767 0 14,630,000 100% 100% 
Utilization and unit cost 
 Female  - Number of enrollees using:  
   Diagnostic tests  52,000  58,000 5,000 12% 
   Medications only 14,000 17,000 3,000 21% 
   IVF 2,000 7,000 5,000 250% 
   ICSI-IVF 2,000 9,000 7,000 350% 
   IUI 9,000 10,000 1,000 11% 
 Male  - Number of enrollees using: 
   Diagnostic tests 24,000 27,000 3,000 13% 
   Treatment 11,000 12,000 1,000 9% 
 Average per unit cost 
   Diagnostic tests  $467 $467 $0 0% 
   Medications only $5,756 $5,756 $0 0% 
   IVF $16,012 $16,012 $0 0% 
   ICSI-IVF $30,027 $30,027 $0 0% 
   IUI $6,900 $6,900 $0 0% 
   Male diagnostic tests $83 $83 $0 0% 
   Male treatment $652 $652 $0 0% 
 Pregnancy      
 # of pregnancies due to 
infertility services (all 
types)  7,000   13,000  6,000 86% 
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 # of live birth deliveries 
due to infertility services 
(single, twin, multiples)  6,000   11,000  5,000 83% 
 Average annual cost of 
pregnancy and delivery 
from infertility services 
(single, twin, multiples) $37,000 $39,000 1,000 5% 
Expenditures 
Premiums by payer 
 Private employers for 
group insurance 
$90,700,422,000 $91,148,774,000 $448,352,000 0.49% 
 CalPERS HMO 
employer expenditures 
(b) (c) 
$3,234,903,000 $3,249,963,000 $15,060,000 0.47% 
 Medi-Cal Managed Care 
Plan expenditures 
$29,186,401,000 $29,186,401,000 $0 0% 
 Enrollees with 
individually purchased 
insurance 
$13,111,153,000 $13,111,153,000 $0 0% 
 Enrollees with group 
insurance, CalPERS 
HMOs, Covered 
California, and Medi-Cal 
Managed Care (c) 
$15,255,718,000 $15,339,320,000 $83,602,000 0.55% 
Enrollee expenses 
 For covered benefits 
(deductibles, 
copayments, etc.) (d) 
$15,636,259,000 $15,864,108,000 $227,849,000 1.46% 
 For noncovered benefits 
(e) 
$136,793,000 $0 $136,793,000 -100% 
Total expenditures $167,261,649,000 $167,899,719,000 $638,070,000 0.38% 
Source: California Health Benefits Review Program, 2019. 
Notes: For estimates of the impact of mature oocyte cryopreservation coverage, refer to the Benefit, Cost, and Utilization section.  
(a) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in employer-
sponsored health insurance. This group includes commercial enrollees (including those associated with Covered California or 
CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.49  
(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents.  
(c) Enrollee premium expenditures include contributions by employees to employer-sponsored health insurance, health insurance 
purchased through Covered California, and contributions to Medi-Cal Managed Care. 
(d) Enrollee out-of-pocket expenses for covered benefits for IVF & ICSI services (not including associated pregnancies) is 
$44,110,547 at baseline and $172,904,155 postmandate, resulting in an increase of 292%; for all other infertility services, out-of-
pocket expenses at baseline is $15,592,148,453 and $15,691,203,845 postmandate, a 0.64% increase. 
(e) Includes only expenses paid directly by enrollees (or other sources) to providers for services related to the mandated benefit that 
are not currently covered by insurance. This only includes those expenses that would be newly covered postmandate. Other 
components of expenditures in this table include all health care services covered by insurance.  
Key: CalPERS  = California Public Employees’ Retirement System; CDI = California Department of Insurance; DMHC = Department 
of Managed Health Care; HMO = Health Maintenance Organizations; ICSI = intracytoplasmic sperm injection; IUI = intrauterine 
insemination; IVF = in vitro fertilization 
                                                     
49 For more detail, see Estimates of Sources of Health Insurance in California, available at  
http://chbrp.com/analysis_methodology/cost_impact_analysis.php.   
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